





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 99/54333
C07D 487/04, A61K 31/505, C07D 401/12			(43) International Publication Date:	28 October 1999 (28.10.99)
(21) International Application Number:	PCT/IB99/00519		(74) Agents:	SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).
(22) International Filing Date:	25 March 1999 (25.03.99)			
(30) Priority Data:			(81) Designated States:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (for all designated States except GB US):	PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).			
(71) Applicant (for GB only):	PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).			
(72) Inventors; and			Published	With international search report.
(75) Inventors/Applicants (for US only):	BUNNAGE, Mark, Edward [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). MATHIAS, John, Paul [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). STREET, Stephen, Derek, Albert [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). WOOD, Anthony [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).			

(54) Title: PYRAZOLOPYRIMIDINONE CGMP PDES INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION



(IA)



(IB)

(57) Abstract

Compounds of formulae (IA) and (IB) wherein R¹ is C₁ to C₃ alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substituents selected from C₁ to C₄ alkoxy; halo; CN; CF₃; OCF₃ or C₁ to C₄ alkyl wherein said C₁ to C₄ alkyl group is optionally substituted by C₁ to C₄ haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R² is C₁ to C₆ alkyl and R¹³ is OR³ or NR⁵R⁶, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE
TREATMENT OF SEXUAL DYSFUNCTION

5

This invention relates to a series of pyrazolo[4,3-d]pyrimidin-7-ones, which inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably, the compounds of the invention are potent and selective inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase 10 (cGMP PDE5) and have utility therefore in a variety of therapeutic areas.

15

In particular, the compounds are of value in the treatment of male erectile dysfunction (MED) and female sexual dysfunction (FSD) but, clearly, will be useful also for treating other medical conditions for which a potent and selective cGMP PDE5 inhibitor is indicated. Such conditions include premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, conditions of reduced blood vessel patency, e.g. post-20 percutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, stroke, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma and diseases characterised by disorders of gut motility, e.g. irritable bowel syndrome (IBS).

25


Other conditions which may be mentioned include pre-eclampsia, Kawasaki's syndrome, nitrate tolerance, multiple sclerosis, peripheral diabetic neuropathy, stroke, Alzheimer's disease, acute respiratory failure, psoriasis, skin necrosis, cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and hypoxic vasoconstriction.

30


Particularly preferred conditions include MED and FSD.

-2-

Thus the invention provides compounds of formulae (IA) and (IB):



(IA)



(IB)

or a pharmaceutically or veterinarily acceptable salt thereof, or a
 5 pharmaceutically or veterinarily acceptable solvate of either entity,
 wherein R¹ is C₁ to C₃ alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substituents selected from C₁ to C₄ alkoxy; halo; CN; CF₃; OCF₃ or C₁ to C₄ alkyl wherein said C₁ to C₄ alkyl group is optionally substituted by C₁ to C₄ haloalkyl or C₁ to C₄ haloalkoxy either of which is substituted by one or more halo atoms;
 10 R² is C₁ to C₆ alkyl;
 R¹³ is OR³ or NR⁵R⁶;
 15 R³ is C₁ to C₆ alkyl optionally substituted with one or two substituents selected from C₃ to C₅ cycloalkyl, OH, C₁ to C₄ alkoxy, benzyloxy, NR⁵R⁶, phenyl, furanyl and pyridinyl; C₃ to C₆ cycloalkyl; 1-(C₁ to C₄ alkyl)piperidinyl; tetrahydrofuranyl or tetrahydropyranyl; and wherein the C₁ to C₆ alkyl and C₁ to C₄ alkoxy groups may optionally be terminated by a haloalkyl group such as CF₃;
 20 R⁴ is SO₂NR⁷R⁸;
 R⁵ and R⁶ are each independently selected from H and C₁ to C₄ alkyl optionally substituted with C₃ to C₅ cycloalkyl or C₁ to C₄ alkoxy, or, together with the nitrogen atom to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl group;
 25

-3-

R⁷ and R⁸, together with the nitrogen atom to which they are attached, form a 4-R¹⁰-piperazinyl group optionally substituted with one or two C₁ to C₄ alkyl groups and optionally in the form of its 4-N-oxide;

R¹⁰ is H; C₁ to C₄ alkyl optionally substituted with one or two substituents selected from OH, NR⁵R⁶, CONR⁵R⁶, phenyl optionally substituted with C₁ to C₄ alkoxy, benzodioxolyl and benzodioxanyl; C₃ to C₆ alkenyl; pyridinyl or pyrimidinyl;

10

and Het is a C-linked 6-membered heterocyclic group containing one or two nitrogen atoms, optionally in the form of its mono-N-oxide, or a C-linked 5-membered heterocyclic group containing two or three nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkoxy or NHR¹⁵ 15 wherein R¹⁵ is H, C₁ to C₄ alkyl or C₁ to C₄ alkanoyl.

In the above definition, unless otherwise indicated, alkyl, alkoxy and alkenyl groups having three or more carbon atoms, and alkanoyl groups having 20 four or more carbon atoms, may be straight chain or branched chain. The term halo atom includes, Cl, Br, F, and I. Haloalkyl and haloalkoxy are preferably CF₃ and OCF₃ respectively.

The compounds of formulae (IA) and (IB) may contain one or more chiral 25 centres and therefore can exist as stereoisomers, i.e. as enantiomers or diastereoisomers, as well as mixtures thereof. The invention includes both the individual stereoisomers of the compounds of formulae (IA) and (IB) and any mixture thereof. Separation of diastereoisomers may be achieved by conventional techniques, e.g. by fractional crystallisation or chromatography 30 (including HPLC) of a diastereoisomeric mixture of a compound of formula (IA) or (IB) or a suitable salt or derivative thereof. An individual enantiomer of a compound of formula (IA) or (IB) may be prepared from a corresponding optically pure intermediate or by resolution, either by HPLC of the racemate

-4-

using a suitable chiral support or, where appropriate, by fractional crystallisation of the diastereoisomeric salts formed by reaction of the racemate with a suitable optically active acid or base.

5

The compounds of formulae (IA) and (IB) may also exist in tautomeric forms and the invention includes both mixtures thereof and the individual tautomers.

Also included in the invention are radiolabelled derivatives of compounds 10 of formulae (IA) and (IB) which are suitable for biological studies.

The pharmaceutically or veterinarilly acceptable salts of the compounds of formulae (IA) and (IB) which contain a basic centre are, for example, non-toxic acid addition salts formed with inorganic acids such as hydrochloric, hydrobromic, sulphuric and phosphoric acid, with carboxylic acids or with 15 organo-sulphonic acids. Compounds of formulae (IA) and (IB) can also provide pharmaceutically or veterinarilly acceptable metal salts, in particular non-toxic alkali metal salts, with bases. Examples include the sodium and potassium salts.

20 A preferred group of compounds of formulae (IA) and (IB) is that wherein R¹ is C₁ to C₂ alkyl optionally substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R² is C₂ to C₄ alkyl; R¹³ is OR³ or NR⁵R⁶; R³ is C₁ to C₄ alkyl optionally substituted with one or two substituents selected from cyclopropyl, cyclobutyl, OH, methoxy, ethoxy, benzyloxy, NR⁵R⁶, phenyl, furan-3-yl, pyridin-2-yl and 25 pyridin-3-yl; cyclobutyl; 1-methylpiperidin-4-yl; tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R⁵ and R⁶ are each independently selected from H and C₁ to C₂ alkyl optionally substituted with cyclopropyl or methoxy, or, together with the nitrogen atom to which they are attached, form a azetidinyl, pyrrolidinyl or morpholinyl group; R⁷ and R⁸, together with the nitrogen atom to which they are 30 attached, form a 4-R¹⁰-piperazinyl group optionally substituted with one or two methyl groups and optionally in the form of its 4-N-oxide; R¹⁰ is H, C₁ to C₃ alkyl optionally substituted with one or two substituents

-5-

selected from OH, NR⁵R⁶, CONR⁵R⁶, phenyl optionally substituted with methoxy, benzodioxol-5-yl and benzodioxan-2-yl; allyl; pyridin-2-yl; pyridin-4-yl or pyrimidin-2-yl; and Het is selected from pyridin-2-yl; 1-oxidopyridin-2-yl; 6-methylpyridin-2-yl; 6-methoxypyridin-2-yl; pyridazin-3-yl; pyrimidin-2-yl and 1-methylimidazol-2-yl.

A more preferred group of compounds of formulae (IA) and (IB) is that wherein R¹ is C₁ to C₂ alkyl optionally substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R² is C₂ to C₄ alkyl; R¹³ is OR³; R³ is C₁ to C₄ alkyl optionally monosubstituted with cyclopropyl, cyclobutyl, OH, methoxy, ethoxy, phenyl, furan-3-yl or pyridin-2-yl; cyclobutyl; tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R⁷ and R⁸, together with the nitrogen atom to which they are attached, form a 4-R¹⁰-piperazinyl group optionally in the form of its 4-N-oxide; R¹⁰ is C₁ to C₃ alkyl optionally monosubstituted with OH; and Het is selected from pyridin-2-yl; 1-oxidopyridin-2-yl; 6-methylpyridin-2-yl; 6-methoxypyridin-2-yl; pyridazin-3-yl; pyrimidin-2-yl and 1-methylimidazol-2-yl.

Particularly preferred individual compounds of the invention include 3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; 5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

-6-

3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-(6-methylpyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(6-methoxypyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

10 5-[2-i-butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2,3-diethyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and

5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

According to a further aspect of the present invention there are provided compounds of the formula (IA) and (IB) as defined hereinbefore but wherein R¹ is not unsubstituted C₁ alkyl; the optional substituent on the C₁ alkyl group of R¹ is not a substituted phenyl group or a N-linked heterocyclic group; the optional substituent on the C₂ or C₃ alkyl group of R¹ is not phenyl or Het; or wherein R¹³ is not NR⁵R⁶; or wherein the alkyl group of R³ is not C₅ or C₆; or wherein the optional substituent on R³ is not C₃ to C₅ cycloalkyl; or wherein neither the alkyl or the optional alkoxy substituents on R³ are terminated by a haloalkyl group; or wherein the C₁ to C₄ alkyl groups of R⁵ and R⁶ are not substituted by C₃ to C₅ cycloalkyl or C₁ to C₄ alkoxy; or wherein the C₁ to C₄ alkyl groups of R⁵ and R⁶ do not, together with the nitrogen group to which they are attached form an azetidinyl group; or wherein Het is not a C₁ to C₄ alkoxy or an HNR¹⁵ group.

25 In a further aspect, the present invention provides processes for the preparation of compounds of formulae (IA) and (IB), their pharmaceutically and veterinarily acceptable salts, and pharmaceutically and veterinarily acceptable solvates of either entity, as illustrated below.

It will be appreciated by persons skilled in the art that, within certain of the processes described, the order of the synthetic steps employed may be varied and will depend inter alia on factors such as the nature of other functional groups present in a particular substrate, the availability of key intermediates and the protecting group strategy (if any) to be adopted. Clearly,

-7-

such factors will also influence the choice of reagent for use in the said synthetic steps.


5 Illustrative of a protecting group strategy is the route to the 2¹-(2-hydroxyethoxy) analogue (Example 33), the precursor to which (Example 32) contains benzyl as the alcohol-protecting group.

10 It will also be appreciated that various standard substituent or functional group interconversions and transformations within certain compounds of formulae (IA) and (IB) will provide other compounds of formulae (IA) and (IB). Examples include alkoxide exchange at the 2-position of the 5-(pyridin-3-yl) substituent (see conversions of Example 1 to Examples 4B, 9, 11, 13, 23, 24, 32 and 64, Example 2 to Example 14, Example 20 to Example 21, Example 26 to Examples 29, 65, 66, 67 and 68, Example 35 to Example 36, Example 38 to Examples 39 and 40, and Example 45 to Example 46), amine exchange at the 2-position of the 5-(pyridin-3-yl) substituent (see conversions of Example 78 to Examples 148 and 154) and piperazine and/or pyridine N-oxidation (see conversions of Example 1 to Example 70, Example 28 to Example 71, and Example 4 to Examples 72 and 73).


20 The following processes are illustrative of the general synthetic procedures which may be adopted in order to obtain the compounds of the invention.

1. A compound of formula (IA) or (IB) may be prepared from a compound of formula (IIA) or (IIB) respectively:

25



(IIA)




(IIB)

-8-

wherein Y is halo, preferably chloro, and R¹, R² and R¹³ are as previously defined for formulae (IA) and (IB), by reaction with a compound of formula (III):

5




wherein R⁷ and R⁸ are as previously defined for formulae (IA) and (IB).

The reaction is generally conducted at from about 0°C to about room temperature, preferably in the presence of an appropriate solvent such as a C₁ to C₃ alkanol or dichloromethane, using an excess of (III) or other suitable base 10 such as triethylamine to scavenge the acid by-product (HY).


Conveniently, this reaction lends itself to "high-speed analogue synthesis" (HSAS), as illustrated by Examples 203 to 212 in which a particular 15 compound of formula (IIB) is coupled with a range of readily accessible amines of formula (III).

A compound of formula (IIA) or (IIB) may be prepared from a compound of formula (IVA) or (IVB) respectively:

20



(IVA)



(IVB)

wherein R¹, R² and R¹³ are as previously defined for formulae (IIA) and (IIB), by the application of known methods for converting amino to a SO₂Y group wherein Y is also as previously defined for formulae (IIA) and (IIB). For example, when Y is chloro, by the action of about a two-fold excess of sodium


25

-9-

nitrite in a mixture of concentrated hydrochloric acid and glacial acetic acid at from about -25°C to about 0°C, followed by treatment with excess liquid sulphur 5 dioxide and a solution of about a three-fold excess of cupric chloride in aqueous acetic acid at from about -15°C to about room temperature. When R¹³ contains a primary or secondary amino group, protection of the said amino group with an acid stable group such as acetyl or benzyl will generally be advantageous.

10



A compound of formula (IVA) or (IVB) may be prepared by cyclisation of a compound of formula (VA) or (VB) respectively:



wherein R¹, R² and R¹³ are as previously defined for formulae (IVA) and (IVB). 15 Preferably, the cyclisation is base-mediated, using an alkali metal salt of a sterically hindered alcohol or amine. For example, the required cyclisation may be effected using about a 1.5 to 5, preferably a 3- to 5-fold excess of potassium t-butoxide or potassium bis(trimethylsilyl)amide, optionally in the presence of molecular sieves, in a suitable solvent at the reflux temperature of the reaction 20 mixture, or, optionally in a sealed vessel at about 100°C. When R¹³ is OR³ and an alcohol is selected as solvent, the appropriate alcohol of formula R³OH should be employed in order to obviate potential problems associated with alkoxide exchange at the 2-position of the pyridine ring.

-10-



A compound of formula (VA) or (VB) may be prepared by reduction of a compound of formula (VIA) or (VIB) respectively:



5 wherein R¹, R² and R¹³ are as previously defined for formulae (VA) and (VB), by conventional catalytic or catalytic transfer hydrogenation procedures. Typically, the hydrogenation is achieved using a Raney nickel catalyst or a palladium catalyst such as 10% Pd on charcoal, in a suitable solvent such as ethanol at a hydrogen pressure of from about 345 kPa (50 psi) to about 414 10 kPa (60 psi) at from about room temperature to about 60°C, preferably from about 40°C to about 50°C.

A compound of formula (VIA) or (VIB) may be prepared by reaction of a compound of formula (VIIA) or (VIIIB) respectively:

15




20

wherein R¹ and R² are as previously defined for formulae (VIA) and (VIB), with a compound of formula (VIII):

25

-11-



(VIII)

wherein R¹³ is also as previously defined for formulae (VIA) and (VIB). Again, as for (IVA) and (IVB), a conventional amine protecting group strategy is preferred for (VIII) when R¹³ contains a primary or secondary amino group.

The coupling reaction may be achieved using conventional amide bond-forming techniques, e.g. via the acyl chloride derivative of (VIII) in the presence of up to about a five-fold excess of a tertiary amine such as triethylamine or pyridine to act as scavenger for the acid by-product (HY), optionally in the presence of a catalyst such as 4-dimethylaminopyridine, in a suitable solvent such as dichloromethane, at from about 0°C to about room temperature. For convenience pyridine may also be used as the solvent.

In particular, any one of a host of amino acid coupling variations may be used. For example, the acid of formula (VIII) or a suitable salt (e.g. sodium salt) thereof may be activated using a carbodiimide such as 1,3-dicyclohexylcarbodiimide or 1-ethyl-3-(3-dimethylaminoprop-1-yl)carbodiimide optionally in the presence of 1-hydroxybenzotriazole hydrate and/or a catalyst such as 4-dimethylaminopyridine, or by using a halotrisaminophosphonium salt such as bromotris(pyrrolidino)phosphonium hexafluorophosphate or by using a suitable pyridinium salt such as 2-chloro-1-methylpyridinium iodide. Either type of coupling is conducted in a suitable solvent such as dichloromethane or tetrahydrofuran, optionally in the presence of a tertiary amine such as N-methylmorpholine or N-ethyldiisopropylamine (for example when either the compound of formula (VIIA) or (VIIIB), or the activating reagent, is presented in the form of an acid addition salt), at from about 0°C to about room temperature. Preferably, from 1 to 2 molecular equivalents of the activating reagent and from 1 to 3 molecular equivalents of any tertiary amine present are employed.


-12-

In a further variation, the carboxylic acid function of (VIII) may first of all be activated using up to about a 5% excess of a reagent such as N,N-carbonyldiimidazole in a suitable solvent, e.g. ethyl acetate or butan-2-one, at 5 from about room temperature to about 80°C, followed by reaction of the intermediate imidazolide with either (VIIA) or (VIIIB) at from about 20°C to about 90°C.

2. An alternative, generally applicable, synthetic route to compounds of 10 formulae (IA) and (IB) involves the incorporation of the R⁴ substituent at an earlier stage of the synthesis.

Thus a compound of formula (IA) or (IB) may be prepared by cyclisation of a compound of formula (IXA) or (IXB) respectively:

15



wherein R¹, R², R¹³ and R⁴ are as previously defined for formulae (IA) and (IB), by analogy with the previously described cyclisation of the compounds of formulae (VA) and (VB).


20 Alternative reaction conditions are to conduct the reaction with about 1.2 to 4 molecular equivalents of sterically hindered base in a sealed vessel at from about 100°C to about 120°C or, rather than an alcohol of formula R³OH, to use a sterically hindered alcohol, e.g. 3-methylpentan-3-ol, as solvent with about 1.5

-13-

to 4.5 molecular equivalents of sterically hindered base, such as potassium t-butoxide or KHMDS, and optionally in a sealed vessel at from about 120°C to about 150°C.

5

A compound of formula (IXA) or (IXB) may be prepared by reaction of a compound of formula (VIIA) or (VIIB) respectively, wherein R¹ and R² are as previously defined for formulae (IXA) and (IXB) with a compound of formula (X):



10

(X)

wherein R¹³ and R⁴ are also as previously defined for formulae (IXA) and (IXB), by analogy with the reactions of (VIIA) or (VIIB) with the nicotinic acid derivatives of formula (VIII) already described. Compounds having the general formula (X) may be prepared directly from compounds having the general formula (VIII) by reduction and subsequent conversion to R⁴ as detailed previously herein.

3. As mentioned earlier, certain compounds of formulae (IA) and (IB) can
20 be interconverted by inducing alkoxide exchange or displacement at the 2-position of the 5-(pyridin-3-yl) substituent.

25

(i) When R¹³ is OR³, this may be achieved, by treating the appropriate alcohol with an alkali metal salt of a sterically hindered alcohol or amine in order to generate the required alkoxide anion which then reacts with the substrate. Typically, in a two-step procedure, a mixture of from about 5 to about 8 molecular equivalents of potassium bis(trimethylsilyl)amide and the required alcohol as solvent is heated at from about 80°C to

-14-

about 100°C for about 0.5 to 1 hour, followed by addition of the compound of formula (IA) or (IB) and heating of the reaction mixture at from about 100°C to about 120°C. Alternatively, in a one-step procedure, the substrate may be treated directly, in the required alcohol as solvent, with from about 1.2 to about 6, preferably from about 4 to about 6 molecular equivalents of, for example, potassium bis(trimethylsilyl)amide or potassium t-butoxide at from about 80°C to about 130°C. A further variation employs the required alcohol as solvent, saturated with ammonia, at about 100°C in a sealed vessel.

(ii) When R^{13} is NR^5R^6 , the substrate may be treated with an excess of R^5R^6NH , or a suitable acid addition salt thereof, in the presence of an excess of a sterically hindered amine in a suitable solvent. Typically, R^5R^6NH is used as the free base with about a 3-fold excess (over the substrate) of potassium bis(trimethylsilyl)amide (KHMDS) in dimethylformamide (DMF) as solvent at about 100°C. Alternatively, an excess of R^5R^6NH may be used as the solvent and the reaction conducted in the presence of about a 50% excess of copper(II) sulphate at up to the reflux temperature of the reaction medium. Where the desired amino substituent on the compound of the formula (IA) or (IB) is $-NR^5R^6$ and one of either R^5 or R^6 is H, then the exchange reaction may be carried out by refluxing with the appropriate amine, and copper(II)sulphate penta- or hepta-hydrate or KHDMS in DMF. Typically, to exchange the OR^3 group for alternative amines of the formula NHR^5R^6 , such as compounds wherein R^5 or R^6 are selected from aliphatic or cyclic amines, optionally including oxygen, then the reaction is preferably carried out by treating with the appropriate amine and about 3 equivalents of potassium bis(trimethylsilyl)amide in DMF for about 18 hours at 100°C.

-15-

4. Clearly, for certain compounds of formulae (IA) and (IB) wherein R^{13} is OR^3 , by exploiting the cyclisation and alkoxide exchange methodology described hereinbefore, it may be particularly advantageous to generate a 5 compound of formula (IA) or (IB) from a compound of formula (IXA) or (IXB) respectively, wherein the 2-alkoxy group of the 5-(pyridin-3-yl) substituent in the former is different from that in the latter, directly in a "one-pot reaction".

When the alcohol which is to provide the new 2-alkoxy group is too scarce or expensive to be employed as the reaction solvent, then it will be 10 expedient to use a suitable alternative such as 1,4-dioxan.

5. A further, generally applicable, synthetic route to compounds of formula (IA) and (IB) involves incorporation of the R^1 substituent in the final step of the synthesis.

15

Thus a compound of formula (IA) or (IB) may be prepared by alkylation of a compound of formula (IA) or (IB) wherein R^1 is hydrogen and R^2 , R^{13} and R^4 are as previously defined for formulae (IA) and (IB), using one or more of a plethora of well-known methods, such as:

20 (i) reaction with a compound of formula $R^1 X$, wherein R^1 is as previously defined for formulae (IA) and (IB), and X is a suitable leaving group, e.g. halo (preferably chloro, bromo or iodo), C_1 - C_4 alkanesulphonyloxy, trifluoromethanesulphonyloxy or arylsulphonyloxy (such as benzenesulphonyloxy or p-toluenesulphonyloxy), in the presence of an appropriate base, optionally in the presence of sodium iodide or potassium iodide, at from about $-70^\circ C$ to about $100^\circ C$. Preferably the alkylation is conducted at from about room temperature to about $80^\circ C$. Suitable base-solvent combinations may be selected from

25

(a) sodium, potassium or caesium carbonate, sodium or potassium bicarbonate, or a tertiary amine such as triethylamine or pyridine, together with a C_1 to C_4 alkanol, 1,2-

-16-

dimethoxyethane, tetrahydrofuran, 1,4-dioxan, acetonitrile, pyridine, dimethylformamide or N,N-dimethylacetamide;

5

(a) sodium or potassium hydroxide, or a sodium or potassium C₁ to C₄ alkoxide, together with a C₁ to C₄ alkanol, water or mixtures thereof;

10

(b) lithium, sodium or potassium hydride, lithium, sodium or potassium bis(trimethylsilyl)amide, lithium diisopropylamide or butyllithium, together with toluene, ether, 1,2-dimethoxyethane, tetrahydrofuran or 1,4-dioxan; or

15

(d) under phase transfer catalysis conditions, a tetraalkylammonium halide or hydroxide, together with a mixture of an aqueous solution of sodium or potassium hydroxide and dichloromethane, 1,2-dichloroethane or chloroform;

20

(i) reaction with a compound of formula R¹OH, wherein R¹ is as previously defined for formulae (IA) and (IB), using classical Mitsunobu methodology. Typical reaction conditions involve treating the substrate with the alkanol in the presence of a triarylphosphine and a di(C₁ to C₄)alkyl azodicarboxylate, in a suitable solvent such as tetrahydrofuran or 1,4-dioxan, at from about -5°C to about room temperature.

25

30

Typically, about a 10% excess of sodium hydride is added to a solution of the substrate in a suitable solvent, e.g. anhydrous tetrahydrofuran, and the resulting anion treated with about a 10% excess of the required R¹X.

-17-

A compound of formula (IA) or (IB) wherein R¹ is hydrogen and R², R¹³
5 and R⁴ are as previously defined for formulae (IA) and (IB) may be obtained
from a compound of formula (IXA) or (IXB) respectively wherein R¹ is hydrogen
and R², R¹³ and R⁴ are as previously defined for formulae (IXA) and (IXB),
under the same conditions as those used for the conversion of a compound of
formula (IXA) or (IXB) to a compound of formula (IA) or (IB) respectively when
10 R¹ is other than hydrogen, followed by acidification of the reaction mixture to a
pH of about 6.

The amines of formula (III), the 4-aminopyrazole-5-carboxamides of
formulae (VIIA) and (VIIIB), the carboxylic acids of formulae (VIII) and (X), the
15 nitriles of formula (XIII) and the esters of formula (XVI), when neither
commercially available nor subsequently described, can be obtained either by
analogy with the processes described in the Preparations section or by
conventional synthetic procedures, in accordance with standard textbooks on
organic chemistry or literature precedent, from readily accessible starting
20 materials using appropriate reagents and reaction conditions.

Moreover, persons skilled in the art will be aware of variations of, and
alternatives to, those processes described hereinafter in the Examples and
Preparations sections which allow the compounds defined by formulae (IA) and
25 (IB) to be obtained.

The pharmaceutically acceptable acid addition salts of the compounds of
formulae (IA) and (IB) which contain a basic centre may also be prepared in a
conventional manner. For example a solution of the free base is treated with
30 the appropriate acid, either neat or in a suitable solvent, and the resulting salt
isolated either by filtration or by evaporation under vacuum of the reaction
solvent.

5 Pharmaceutically acceptable base addition salts can be obtained in an analogous manner by treating a solution of a compound of formula (IA) or (IB) with the appropriate base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.

10 The biological activities of the compounds of the present invention were determined by the following test methods.

15 10 Phosphodiesterase (PDE) inhibitory activity

In vitro PDE inhibitory activities against cyclic guanosine 3',5'-monophosphate (cGMP) and cyclic adenosine 3',5'-monophosphate (cAMP) phosphodiesterases were determined by measurement of their IC₅₀ values (the concentration of compound required for 50% inhibition of enzyme activity).

20 The required PDE enzymes were isolated from a variety of sources, including human corpus cavernosum, human and rabbit platelets, human cardiac ventricle, human skeletal muscle and bovine retina, essentially by the method of W.J. Thompson and M.M. Appleman (Biochem., 1971, 10, 311). In particular, the cGMP-specific PDE (PDE5) and the cGMP-inhibited cAMP PDE (PDE3) were obtained from human corpus cavernosum tissue, human platelets or rabbit platelets; the cGMP-stimulated PDE (PDE2) was obtained from human corpus cavernosum; the calcium/calmodulin (Ca/CAM)-dependent PDE (PDE1) from human cardiac ventricle; the cAMP-specific PDE (PDE4) from human skeletal muscle; and the photoreceptor PDE (PDE6) from bovine retina.

25 Assays were performed using a modification of the "batch" method of W.J. Thompson et al. (Biochem., 1979, 18, 5228). Results from these tests show that the compounds of the present invention are potent and selective inhibitors of cGMP-specific PDE5.

Functional activity

30 This was assessed in vitro by determining the capacity of a compound of the invention to enhance sodium nitroprusside-induced relaxation of pre-contracted rabbit corpus cavernosum tissue strips, as described by S.A. Ballard et al. (Brit. J. Pharmacol., 1996, 118 (suppl.), abstract 153P).

In vivo activity

Compounds were screened in anaesthetised dogs to determine their capacity, after i.v. administration, to enhance the pressure rises in the corpora cavernosa of the penis induced by intracavernosal injection of sodium nitroprusside, using a method based on that described by Trigo-Rocha *et al.* (Neurourol. and Urodyn., 1994, 13, 71).

In human therapy, the compounds of formulae (IA) and (IB), their pharmaceutically acceptable salts, and pharmaceutically acceptable solvates of either entity, can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. Preferably, they are administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents. They can also be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration they may be administered in the form of tablets or lozenges which can be formulated in a conventional manner. The compounds may also be administered intranasally or formulated for dermal application.

For oral, parenteral, buccal and sublingual administration to patients, the daily dosage level of the compounds of formulae (IA) and (IB) and their pharmaceutically acceptable salts and solvates may be from 10 to 500 mg (in single or divided doses). Thus, for example, tablets or capsules may contain from 5 to 250 mg of active compound for administration singly, or two or more at a time, as appropriate. The physician in any event will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case; there can, of course, be individual instances

-20-

where higher or lower dosage ranges are merited and such are within the scope of this invention. The skilled person will also appreciate that, in the treatment of certain conditions (including MED and FSD), compounds of the 5 invention may be taken as a single dose on an "as required" basis (i.e., as needed or desired).

Generally, in humans, oral administration of the compounds of the invention is the preferred route, being the most convenient and, for example in MED, avoiding the well-known disadvantages associated with intracavernosal 10 (i.c.) administration. A preferred oral dosing regimen in MED for a typical man is from 25 to 250 mg of compound when required. In circumstances where the recipient suffers from a swallowing disorder or from impairment of drug absorption after oral administration, the drug may be administered parenterally, sublingually or buccally.

15 For veterinary use, a compound of formula (IA) or (IB), or a veterinarianily acceptable salt thereof, or a veterinarianily acceptable solvate of either entity, is administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a 20 particular animal.

Thus the invention provides a pharmaceutical composition comprising a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, together with a pharmaceutically acceptable diluent or carrier.

25 It further provides a veterinary formulation comprising a compound of formula (IA) or (IB), or a veterinarianily acceptable salt thereof, or a veterinarianily acceptable solvate of either entity, together with a veterinarianily acceptable diluent or carrier.

The invention also provides a compound of formula (IA) or (IB), or a 30 pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing, for use as a human medicament.

-21-

5 In addition, it provides a compound of formula (IA) or (IB), or a
veterinarily acceptable salt thereof, or a veterinarily acceptable solvate of either
entity, or a veterinary formulation containing any of the foregoing, for use as an
animal medicament.

10 In yet another aspect, the invention provides the use of a compound of
formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a
pharmaceutically acceptable solvate of either entity, for the manufacture of a
human medicament for the curative or prophylactic treatment of a medical
condition for which a cGMP PDE5 inhibitor is indicated. There is further
provided the use of a compound of formula (IA) or (IB) or a suitable salt or
solvate thereof, in the manufacture of a medicament for the treatment of a
medical condition in which inhibition of a cGMP PDE5 is desirable.

15 It also provides the use of a compound of formula (IA) or (IB), or a
veterinarily acceptable salt thereof, or a veterinarily acceptable solvate of either
entity, for the manufacture of an animal medicament for the curative or
prophylactic treatment of a medical condition for which a cGMP PDE5 inhibitor
is indicated.

20 Moreover, the invention provides the use of a compound of formula (IA)
or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically
acceptable solvate containing either entity, for the manufacture of a human
medicament for the curative or prophylactic treatment of male erectile
dysfunction (MED), female sexual dysfunction (FSD), premature labour,
25 dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction,
incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension,
pulmonary hypertension, congestive heart failure, atherosclerosis, stroke,
peripheral vascular disease, conditions of reduced blood vessel patency, (e.g.
post transluminal coronary angioplasty (post-PTCA)), chronic asthma,
30 bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised
by disorders of gut motility (e.g. irritable bowel syndrome (IBS)). Other
conditions which may be mentioned include pre-eclampsia, Kawasaki's
syndrome, nitrate tolerance, multiple sclerosis, peripheral diabetic neuropathy,

-22-

stroke, Alzheimer's disease, acute respiratory failure, psoriasis, skin necrosis, cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and hypoxic vasoconstriction. Particularly preferred conditions include MED and FSD.

5 It also provides the use of a compound of formula (IA) or (IB), or a
veterinarily acceptable salt thereof, or a 'veterinarily acceptable solvate
containing either entity, for the manufacture of an animal medicament for the
curative or prophylactic treatment of male erectile dysfunction (MED), female
10 sexual dysfunction (FSD), premature labour, dysmenorrhoea, benign prostatic
hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable
and variant (Prinzmetal) angina, hypertension, pulmonary hypertension,
congestive heart failure, atherosclerosis, stroke, peripheral vascular disease,
conditions of reduced blood vessel patency (e.g. post-PTCA), chronic asthma,
15 bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised
by disorders of gut motility (e.g. IBS). Other conditions which may be mentioned
include pre-eclampsia, Kawasaki's syndrome, nitrate tolerance, multiple
sclerosis, peripheral diabetic neuropathy, stroke, Alzheimer's disease, acute
respiratory failure, psoriasis, skin necrosis, cancer, metastasis, baldness,
20 nutcracker oesophagus, anal fissure and hypoxic vasoconstriction. Particularly
preferred conditions include MED and FSD.

Additionally, the invention provides a method of treating or preventing a
medical condition for which a cGMP PDE5 inhibitor is indicated, in a mammal
(including a human being), which comprises administering to said mammal a
therapeutically effective amount of a compound of formula (IA) or (IB), or a
25 pharmaceutically or 'veterinarily acceptable salt thereof, or a pharmaceutically
or 'veterinarily acceptable solvate of either entity, or a pharmaceutical
composition or veterinary formulation containing any of the foregoing.

Still further, the invention provides a method of treating or preventing
male erectile dysfunction (MED), female sexual dysfunction (FSD), premature
30 labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet
obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina,
hypertension, pulmonary hypertension, congestive heart failure,
atherosclerosis, stroke, peripheral vascular disease, conditions of reduced

-23-

blood vessel patency (e.g. post PTCA), chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (IA) or (IB), or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, or a pharmaceutical composition or veterinary formulation containing any of the foregoing.

10

The invention also includes any novel intermediates described herein, for example those of formulae (IIA), (IIB), (IVA), (IVB), (IXA), (IXB), (VA) and (VB).

15 The syntheses of the compounds of the invention and of the intermediates for use therein are illustrated by the following Examples and Preparations.

20 ¹H Nuclear magnetic resonance (NMR) spectra were recorded using either a Varian Unity 300 or a Varian Inova 400 spectrometer and were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million downfield from tetramethylsilane using conventional abbreviations for designation of major peaks: e.g. s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad.

25 Mass spectra (m/z) were recorded using a Fisons Instruments Trio mass spectrometer in the thermospray ionisation mode.

Room temperature means 20 to 25°C.

- 24 -

EXAMPLE 1

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5

Alternative A

60% Sodium hydride dispersion in mineral oil (14.3mg, 0.36mmol) was added to a stirred suspension of the title compound of Preparation 44 (150mg, 0.325mmol) in anhydrous tetrahydrofuran (5ml) under nitrogen. After 1 hour, a 10 solution of 2-(chloromethyl)pyridine (45.5mg, 0.36mmol) in tetrahydrofuran (1ml) was added and the reaction mixture heated at 40°C for 16 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue partitioned between dichloromethane (15ml) and water (5ml). The organic phase was separated, combined with a dichloromethane extract 15 (20ml) of the aqueous phase, dried ($MgSO_4$) and evaporated under reduced pressure. The residual yellow foam was purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as eluant, followed by HPLC using a 5 μ m Spherisorb silica column with water: acetonitrile: diethylamine (50:50:0.1) as eluant at a rate of 1ml/min, to give the title compound (30mg, 20 17%) as a white foam. δ ($CDCl_3$): 1.03 (3H,t), 1.30 (3H,t), 1.57 (3H,t), 2.40 (2H,q), 2.53 (4H,m), 3.05 (2H,q), 3.12 (4H,m), 4.75 (2H,q), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.56 (1H,d), 8.64 (1H,s), 9.04 (1H,s), 10.65 (1H,s). LRMS: m/z 553 ($M+1$)⁺.

25 Alternative B

A mixture of the title compound of Preparation 45B (17.4g, 30.5mmol) and potassium bis(trimethylsilyl)amide (7.28g, 36.5mmol) in ethanol (155ml) was heated at 120°C in a sealed vessel for 10 hours, allowed to cool and evaporated under reduced pressure. The residue was suspended in water 30 (200ml), the suspension extracted with dichloromethane (2x300ml) and the

- 25 -

combined extracts dried ($MgSO_4$) and evaporated under reduced pressure.

The crude product was purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as eluant, to give a pale yellow foam (11.2g,

5 66%) which was crystallised from diisopropyl ether-methanol to yield the title compound as a crystalline solid. Found: C, 55.58; H, 5.90; N, 19.58.

$C_{26}H_{32}N_8O_4S$; 0.50 H_2O requires C, 55.60; H, 5.92; N, 19.95%.

EXAMPLE 2

10 5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

1-Methylpiperazine (0.2ml, 1.8mmol) was added dropwise to a stirred suspension of the title compound of Preparation 63 (450mg, 0.92mmol) in ethanol (40ml) and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate solution (30ml) and ethyl acetate (90ml), then the organic phase separated, washed with brine (2x20ml), dried (Na_2SO_4) and evaporated under reduced pressure. The residual oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4), followed by crystallisation from hexane-ethyl acetate to provide the title compound (340mg, 67%) as a white solid. Found: C, 55.90; H, 5.85; N, 20.04. $C_{26}H_{32}N_8O_4S$; 0.50 H_2O requires C, 55.60; H, 5.92; N, 19.95%. δ ($CDCl_3$): 0.94 (3H,t), 1.58 (3H,t), 1.74 (2H,m), 2.27 (3H,s), 2.40 (4H,m), 2.99 (2H,t), 3.14 (4H,m), 4.69 (2H,q), 5.68 (2H,s), 7.09 (1H,d), 7.23 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.63 (1H,s), 9.03 (1H,s), 10.64 (1H,s). LRMS: m/z 552 (M)⁺.

- 26 -

EXAMPLE 3

3-Ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 Triethylamine (83 μ l, 0.59mmol) and 1-methylpiperazine (36mg, 0.356mmol) were added to a stirred, ice-cooled suspension of the title compound of Preparation 64 (150mg, 0.30mmol) in dichloromethane (10ml) and the reaction mixture stirred for 2 hours at room temperature. The resulting 10 mixture was washed with water (5ml), dried ($MgSO_4$) and evaporated under reduced pressure to give a beige solid, which was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (98:2 to 95:5), followed by trituration with ether, to furnish the title compound (145mg, 85%) as a white solid. Found: C, 54.53; H, 5.69; N, 19.38.

15 $C_{26}H_{32}N_6O_5S$ requires C, 54.92; H, 5.67; N, 19.71%. δ ($CDCl_3$): 1.30 (3H,t), 2.28 (3H,s), 2.50 (4H,m), 3.04 (2H,q), 3.14 (4H,m), 3.57 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.68 (2H,s), 7.09 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.97 (1H,s), 10.81 (1H,s). LRMS: m/z 569 ($M+1$)⁺.

20

EXAMPLE 4

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Alternative A

25 Potassium *t*-butoxide (56mg, 0.50mmol) was added to a stirred solution of the title compound of Preparation 45A (200mg, 0.35mmol) in 2-methoxyethanol (10ml) and the reaction mixture stirred under reflux for 2 hours, then allowed to cool. Saturated aqueous ammonium chloride solution (1ml) was added, followed by water (5ml), and the mixture extracted with ethyl acetate (2x10ml).

30 The combined extracts were dried ($MgSO_4$) and evaporated under reduced pressure, then the residue purified by column chromatography on silica gel,

- 27 -

using an elution gradient of dichloromethane: methanol (100:0 to 95:5), to afford the title compound (11mg, 5%) as a solid. δ (CDCl_3): 1.03 (3H,t), 1.30 (3H,t), 2.41 (2H,q), 2.54 (4H,m), 3.04 (2H,q), 3.14 (4H,m), 3.56 (3H,s), 3.87 (2H,t), 4.78 (2H,t), 5.69 (2H,s), 7.10 (1H,d), 7.21 (1H,m), 7.61 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 8.95 (1H,s), 10.82 (1H,s). LRMS: m/z 583 (M+1)⁺.

Alternative B

A mixture of potassium bis(trimethylsilyl)amide (16.58g, 83mol) and 2-methoxyethanol (250ml) was stirred at 90°C for 30 minutes, then allowed to cool. The title compound of Example 1 (9.21g, 16.7mmol) was then added and the reaction mixture stirred at 110°C for 6 hours. The resulting mixture, when cool, was evaporated under reduced pressure, the residue dissolved in water (300ml) and the solution neutralised to pH 7 with 2M hydrochloric acid and then extracted with ethyl acetate (3x200ml). The combined extracts were washed with brine (3x200ml), dried (Na_2SO_4) and evaporated under reduced pressure. The residual yellow solid was purified by column chromatography on silica gel, using dichloromethane: methanol (98:2) as eluant, followed by trituration with ether, crystallisation from ethyl acetate and recrystallisation from acetone, to afford a solvate (with acetone) of the title compound (7.7g, 79%) as colourless crystals, m.p. 171.5-173°C. Found: C, 55.59; H, 5.94; N, 18.78. $\text{C}_{27}\text{H}_{34}\text{N}_8\text{O}_5\text{S}$; 0.125 $\text{C}_3\text{H}_6\text{O}$ requires C, 55.72; H, 5.94; N, 19.00%.

The product was suspended in water (200ml), sufficient 2M hydrochloric acid added to achieve dissolution and then the solution washed with ether (3x50ml) and neutralised with saturated aqueous sodium bicarbonate solution. The resulting precipitate was collected, washed with water and dried at 80°C to afford a hemihydrate of the title compound (5.99g, 61.6%) as a white solid, m.p.

- 28 -

139-140°C. Found: C, 54.74; H, 5.92; N, 18.86. $C_{27}H_{34}N_8O_5S$; 0.50 H₂O requires C, 54.81; H, 5.96; N, 18.94%.

5

EXAMPLE 5

3-Ethyl-5-{2-(2-methoxyethoxy)-5-[4-(prop-1-yl)piperazin-1-ylsulphonyl]-pyridin-3-yl}-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a yellow foam (88%) from the title compound of Preparation 10 64 and 1-(prop-1-yl)piperazine dihydropotassium, using the procedure of Example 3. Found: C, 56.12; H, 6.06; N, 18.62. $C_{28}H_{36}N_8O_5S$ requires C, 56.36; H, 6.08; N, 18.78%. δ (CDCl₃): 0.86 (3H,t), 1.30 (3H,t), 1.43 (2H,m), 2.30 (2H,t), 2.53 (4H,m), 3.04 (2H,q), 3.12 (4H,m), 3.57 (3H,s); 3.88 (2H,t), 4.78 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.23 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.97 (1H,s), 10.81 (1H,s). LRMS: m/z 597 (M+1)⁺.

EXAMPLE 6

3-Ethyl-5-{2-(2-methoxyethoxy)-5-[4-(prop-2-yl)piperazin-1-ylsulphonyl]-pyridin-3-yl}-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-

20

one

Obtained as a white powder (78%) from the title compound of Preparation 64 and 1-(prop-2-yl)piperazine, using the procedure of Example 3. Found: C, 55.95; H, 6.06; N, 18.46. $C_{28}H_{36}N_8O_5S$ requires C, 56.36; H, 6.08; N, 18.78%. δ (CDCl₃): 1.00 (6H,2xd), 1.30 (3H,t), 2.61 (4H,m), 2.68 (1H,m), 3.02 (2H,q), 3.12 (4H,m), 3.57 (3H,s), 3.86 (2H,t), 4.79 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.97 (1H,s), 10.71 (1H,s). LRMS: m/z 597 (M+1)⁺.

- 29 -

EXAMPLE 7

5-[5-[4-(2-Aminoethyl)piperazin-1-ylsulphonyl]-2-(2-methoxyethoxy)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A solution of the title compound of Preparation 64 (100mg, 0.198mmol) in dichloromethane (10ml) was added dropwise over 1 hour to a stirred solution of 1-(2-aminoethyl)piperazine (102mg, 0.79mmol) in dichloromethane (10ml) and the reaction mixture stirred for a further 1 hour at room temperature. The 10 resulting mixture was washed with water (10ml), dried (MgSO_4) and evaporated under reduced pressure to give a beige solid, which was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol:0.88 ammonia (90:10:0 to 90:10:1), to yield the title compound (104mg, 88%) as a white foam. δ (CDCl_3): 1.29 (3H,t), 2.43 (2H,t), 2.54 (4H,m), 2.74 (2H,t), 3.04 (2H,q), 3.12 (4H,m), 3.56 (3H,s), 3.88 (2H,t), 4.79 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 8.99 (1H,s). LRMS: m/z 598 ($\text{M}+1$)⁺:

EXAMPLE 8

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Potassium *t*-butoxide (104mg, 0.97mmol) was added to a stirred suspension of the title compound of Preparation 53 (380mg, 0.618mmol) in 3-methylpentan-3-ol (30ml) and the reaction mixture heated under reflux for 1 25 hour, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residual yellow gum partitioned between dichloromethane (20ml) and saturated aqueous sodium bicarbonate solution (10ml). The phases were separated, the aqueous phase extracted with dichloromethane (2x10ml) and the combined extracts dried (MgSO_4) and 30 evaporated under reduced pressure. The crude product was purified by

- 30 -

column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (98:2 to 95:5) to provide the title compound (75mg, 13%) as a white foam. δ ($CDCl_3$): 0.93 (3H,t), 1.04 (3H,t), 1.73 (2H,m), 2.41 (2H,q), 2.54 (4H,m), 2.97 (2H,t), 3.13 (4H,m), 3.56 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.68 (2H,s), 7.08 (1H,d), 7.21 (1H,m), 7.61 (1H,m), 8.54 (1H,d), 8.62 (1H,s), 8.97 (1H,s), 10.80 (1H,s). LRMS: m/z 597 ($M+1$)⁺.

EXAMPLE 9

10 5-[2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A stirred mixture of potassium bis(trimethylsilyl)amide (434mg, 2.2mmol) and 2-ethoxyethanol (2ml) was heated at 90°C for 30 minutes, then allowed to cool. A solution of the title compound of Example 1 (153mg, 0.27mmol) in 2-ethoxyethanol (2ml) was added and the reaction mixture stirred at 110°C for 18 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residual brown oil purified by column chromatography on silica gel, using dichloromethane: methanol (95:5) as eluant, to furnish the title compound (110mg, 68%) as a yellow foam. δ ($CDCl_3$): 1.04 (3H,t), 1.31 (6H,m), 2.41 (2H,q), 2.54 (4H,m), 3.04 (2H,q), 3.14 (4H,m), 3.72 (2H,q), 3.90 (2H,t), 4.78 (2H,t), 5.67 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 8.99 (1H,s), 10.78 (1H,s). LRMS: m/z 597 ($M+1$)⁺.

25 EXAMPLE 10

5-[2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of potassium *t*-butoxide (110mg, 0.98mmol), the title compound of Preparation 54 (400mg, 0.63mmol) and 3-methylpentan-3-ol (5ml) was stirred at 150°C for 3 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue partitioned between

- 31 -

water (5ml) and ethyl acetate (5ml). The phases were separated, the aqueous phase extracted with ethyl acetate (2x10ml) and the combined organic solutions dried ($MgSO_4$) and evaporated under reduced pressure. The residue was 5 purified by column chromatography on silica gel, using an elution gradient of dichloromethane:methanol:0.88 aqueous ammonia (99:1:0.5 to 98:2:0.5), to afford the title compound (74mg, 12%) as a white foam. Found: C, 56.92; H, 6.33; N, 17.80. $C_{29}H_{36}N_8O_5S$ requires C, 57.21; H, 5.96; N, 18.41%. δ ($CDCl_3$): 0.94 (3H,t), 1.03 (3H,t), 1.30 (3H,t), 1.72 (2H,m), 2.41 (2H,q), 2.54 (4H,m), 3.14 10 (4H,m), 3.72 (2H,q), 3.90 (2H,t), 4.78 (2H,t), 5.67 (2H,s), 7.09 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 8.98 (1H,s), 10.77 (1H,s).

EXAMPLE 11

15 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)-
pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-
one

A mixture of the title compound of Example 1 (200mg, 0.36mmol), potassium bis(trimethylsilyl)amide (361mg, 1.81mmol) and 3-methoxypropan-1-ol (1.5ml) was stirred at 90°C for 18 hours, then allowed to cool. The resulting 20 mixture was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (97:3 to 95:5), to give the title compound (81mg, 38%) as a foam. Found: C, 55.36; H, 6.11; N, 18.18. $C_{28}H_{36}N_8O_5S$; 0.50 H_2O requires C, 55.52; H, 6.16; N, 18.50%. δ ($CDCl_3$): 1.01 (3H,t), 1.29 (3H,t), 2.19 25 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 3.02 (2H,q), 3.12 (4H,m), 3.39 (3H,s), 3.65 (2H,t), 4.76 (2H,t), 5.68 (2H,s), 7.09 (1H,d), 7.21 (1H,m), 7.62 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 8.93 (1H,s), 10.84 (1H,s). LRMS: m/z 597 (M+1)⁺.

- 32 -

EXAMPLE 12

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-

5

one

Obtained as a foam (26%) from the title compound of Preparation 55, using the procedure of Example 10. Found: C, 56.86; H, 6.47; N, 17.78. $C_{29}H_{38}N_8O_5S$ requires C, 57.04; H, 6.27; N, 18.35%. δ ($CDCl_3$): 0.93 (3H,t), 1.02 (3H,t), 1.72 (2H,m), 2.20 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 2.97 (2H,t), 3.12 (4H,m), 3.40 (3H,s), 3.65 (2H,t), 4.77 (2H,t), 5.67 (2H,s), 7.08 (1H,d), 7.21 (1H,m), 7.61 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.94 (1H,s), 10.83 (1H,s). LRMS: m/z 611 ($M+1$)⁺.

EXAMPLE 13

15

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methoxyprop-2(S)-oxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

20

Obtained as a foam (33%) from the title compound of Example 1 and 1-methoxypropan-2(S)-ol (J.Chem.Soc., Perkin Trans. I, 1996, 1467), using the procedure of Example 9, but with ether:methanol:0.88 aqueous ammonia (97:3:1) as chromatographic eluant. Found: C, 55.91; H, 6.17; N, 18.10. $C_{28}H_{36}N_8O_5S$; 0.50 H_2O requires C, 55.52; H, 6.16; N, 18.50%. δ ($CDCl_3$): 1.04 (3H,t), 1.30 (3H,t), 1.52 (3H,d), 2.42 (2H,q), 2.56 (4H,m), 3.04 (2H,q), 3.14 (4H,m), 3.55 (3H,s), 3.66 (1H,dd), 3.74 (1H,dd), 5.60 (1H,m), 5.68 (2H,s), 7.08 (1H,d), 7.21 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.61 (1H,s), 8.89 (1H,s), 10.85 (1H,s). LRMS: m/z 597 ($M+1$)⁺.

- 33 -

EXAMPLE 14

5-[2-(2-Methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 A mixture of potassium bis(trimethylsilyl)amide (460mg, 2.3mmol) and 2-methoxyethanol (40ml) was stirred at 90°C for 30 minutes, then allowed to cool. The title compound of Example 2 (270mg, 0.46mmol) was added and the reaction mixture stirred at 110°C for 5 hours, allowed to cool and evaporated under reduced pressure. The residue was suspended in water (20ml), the pH 10 adjusted to 7 with hydrochloric acid and the resulting solution extracted with ethyl acetate (3x30ml). The combined extracts were washed with brine (3x20ml), dried (Na₂SO₄) and evaporated under reduced pressure. The 15 residual oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4), followed by crystallisation from hexane-ethyl acetate, to yield the title compound (200mg, 75%) as a white solid. Found: C, 54.83; H, 5.83; N, 18.90. C₂₇H₃₄N₈O₆S; 0.50 H₂O requires C, 54.81; H, 5.96; N, 18.94%. δ (CDCl₃): 0.94 (3H,t), 1.74 (2H,m), 2.28 (3H,s), 2.50 (4H,m), 2.98 (2H,t), 3.15 (4H,m), 3.57 (3H,s), 3.87 (2H,t), 4.80 (2H,t), 5.68 (2H,s), 7.08 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.64 20 (1H,s), 8.96 (1H,s), 10.80 (1H,s). LRMS: m/z 583 (M+1)⁺.

EXAMPLE 15

5-[2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25 A mixture of the title compound of Preparation 72 (70mg, 0.10mmol), potassium t-butoxide (23mg, 0.20mmol) and 3-methylpentan-3-ol (3ml) was stirred under reflux for 4 hours, then allowed to cool and evaporated under reduced pressure. The residue was purified by column chromatography on 30 silica gel, using dichloromethane: methanol (98:2) as eluant, to provide the title

- 34 -

compound (6mg, 9%) as an off-white solid. δ (CDCl₃): 0.93 (3H,t), 1.03 (3H,t), 1.72 (2H,m), 2.42 (2H,q), 2.55 (4H,m), 2.98 (2H,t), 3.16 (4H,m), 3.50 (6H,s), 3.77 (2H,m), 3.86 (2H,m), 5.68 (3H,m), 7.08 (1H,d), 7.21 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.61 (1H,s), 8.84 (1H,s), 10.87 (1H,s). LRMS: m/z 641 (M+1)⁺.

EXAMPLE 16

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-1-(pyridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

10 Obtained as a white solid (50%) from the title compound of Preparation 65, using the procedure of Example 10. Found: C, 55.45; H, 5.91; N, 18.94. C₂₇H₃₄N₈O₅S requires C, 55.66; H, 5.88; N, 19.23%. δ (CDCl₃): 1.02 (3H,t), 1.40 (3H,t), 2.42 (2H,q), 2.56 (4H,m), 3.00 (2H,q), 3.16 (4H,m), 3.55 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.95 (2H,s), 7.01 (1H,d), 7.17 (1H,m), 7.60 (1H,m), 8.57 15 (1H,d), 8.62 (1H,s), 9.02 (1H,s), 11.04 (1H,s). LRMS: m/z 583 (M+1)⁺.

- 35 -

EXAMPLE 17

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(S)-yloxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5

Obtained as a solid (29%) from the title compound of Preparation 56, using the procedure of Example 10. Found: C, 55.85; H, 5.98; N, 17.86. $C_{28}H_{34}N_8O_6S$; 0.20 H_2O ; 0.10 CH_2Cl_2 requires C, 55.24; H, 5.73; N, 18.41%. δ ($CDCl_3$): 1.02 (3H,t), 1.28 (3H,t), 2.40 (4H,m), 2.55 (4H,m), 3.02 (2H,q), 3.13 (4H,m), 4.00 (2H,m), 4.16 (2H,m), 5.68 (2H,s), 5.86 (1H,m), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.56 (1H,d), 8.63 (1H,s), 8.98 (1H,s), 10.42 (1H,s). LRMS: m/z 594 (M) $^+$. $[\alpha]_D^{25} -13.8^\circ$ ($c = 0.10, CH_3OH$).

15

EXAMPLE 18

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-yloxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a solid (24%) from the title compound of Preparation 75, using the procedure of Example 10. Found: C, 55.32; H, 5.82; N, 17.70. $C_{28}H_{34}N_8O_5S$; H_2O requires C, 54.88; H, 5.92; N, 18.29%. δ ($CDCl_3$): 1.02 (3H,t), 1.28 (3H,t), 2.40 (4H,m), 2.55 (4H,m), 3.02 (2H,q), 3.13 (4H,m), 4.00 (2H,m), 4.16 (2H,m), 5.68 (2H,s), 5.86 (1H,m), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.56 (1H,d), 8.63 (1H,s), 8.98 (1H,s), 10.42 (1H,s). LRMS: m/z 595 (M+1) $^+$. $[\alpha]_D^{25} +14.0^\circ$ ($c = 0.14, CH_3OH$).

EXAMPLE 19

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

30 Obtained as a white solid (30%) from the title compound of Preparation

- 36 -

76, using the procedure of Example 10. δ (CDCl₃): 0.94 (3H,t), 1.03 (3H,t), 1.73 (2H,m), 2.01 (2H,m), 2.22 (2H,m), 2.40 (2H,q), 2.55 (4H,m), 2.98 (2H,t), 3.12 (4H,m), 3.66 (2H,m), 4.06 (2H,m), 5.60 (1H,m), 5.69 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.61 (1H,s), 9.01 (1H,s), 10.55 (1H,s).
5 LRMS: m/z 623 (M+1)⁺.

EXAMPLE 20

10 3-Ethyl-5-[5-(4-methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Potassium t-butoxide (540mg, 4.8mmol) was added to a stirred solution of the title compound of Preparation 52 (683mg, 1.2mmol) in n-propanol (10ml) and the reaction mixture stirred under reflux for 18 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residual 15 oil purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5) to furnish the title compound (290mg, 44%) as a foam. Found: C, 56.32; H, 6.04; N, 19.36. C₂₆H₃₂N₆O₄S requires C, 56.50; H, 5.83; N, 20.27%. δ (CDCl₃): 1.02 (3H,t), 1.30 (3H,t), 1.98 (2H,m), 2.38 (3H,s), 2.50 (4H,m), 3.04 (2H,q), 3.13 (4H,m), 4.64 (2H,t), 5.69 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.30 (1H,m), 8.58 (1H,d), 8.63 (1H,s), 9.04 (1H,s), 10.66 (1H,s). LRMS: m/z 553 (M+1)⁺.

EXAMPLE 21

25 3-Ethyl-5-[5-(4-methylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Potassium t-butoxide (290mg, 2.60mmol) was added to a stirred solution of the title compound of Example 20 (239mg, 0.43mmol) in propan-2-ol (7ml) under nitrogen and the reaction mixture heated under reflux for 48 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure 30 and the residue partitioned between water (20ml) and ethyl acetate (20ml).

- 37 -

The phases were separated, the aqueous phase extracted with ethyl acetate and the combined organic solutions dried ($MgSO_4$) and evaporated under reduced pressure. The residue was purified by column chromatography on 5 silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5), to afford the title compound (84mg, 35%) as a foam. δ ($CDCl_3$): 1.28 (3H,t), 1.56 (6H,2xd), 2.28 (3H,s), 2.50 (4H,m), 3.04 (2H,q), 3.14 (4H,m), 5.68 (3H,m), 7.09 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 9.02 (1H,s), 10.68 (1H,s). LRMS: m/z 553 ($M+1$)⁺.

10

EXAMPLE 22

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of the title compound of Preparation 45A (200mg, 0.35mmol), 15 60% sodium hydride dispersion in mineral oil (400mg, 10mmol) and propan-2-ol (20ml) was stirred under reflux for 18 hours, then allowed to cool. Saturated aqueous ammonium chloride solution (20ml) was added, the resulting mixture extracted with ethyl acetate (3x50ml), then the combined extracts washed with aqueous sodium bicarbonate solution (150ml), dried ($MgSO_4$) and evaporated 20 under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5), to give the title compound (11mg, 6%) as a foam. δ ($CDCl_3$): 1.04 (3H,t), 1.30 (3H,t), 1.56 (6H,2xd), 2.1 (2H,q), 2.55 (4H,m), 3.04 (2H,q), 3.13 (4H,m), 5.68 (3H,m), 7.10 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 25 9.02 (1H,s), 10.68 (1H,s). LRMS: m/z 567 ($M+1$)⁺.

- 38 -

EXAMPLE 23

5-[2-n-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 A mixture of the title compound of Example 1 (200mg, 0.36mmol), potassium bis(trimethylsilyl)amide (360mg, 1.81mmol) and n-butanol (5ml) was stirred at 100°C for 18 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue partitioned between water (5ml) and dichloromethane (5ml). The phases were separated and the aqueous layer extracted with dichloromethane (2x10ml), then the combined organic solutions dried (MgSO_4) and evaporated under reduced pressure. The residual yellow solid was purified by column chromatography on silica gel, using dichloromethane: methanol (97.5:2.5) as eluant, to yield the title compound (145 mg, 69%) as a white solid. Found: C, 57.43; H, 6.29; N, 18.82.

10 $\text{C}_{28}\text{H}_{36}\text{N}_8\text{O}_4\text{S}$; 0.20 H_2O requires C, 57.56; H, 6.28; N, 19.18%. δ (CDCl_3): 1.03 (6H,2xt), 1.30 (3H,t), 1.55 (2H,m), 1.94 (2H,m), 2.40 (2H,q), 2.55 (4H,m), 3.03 (2H,q), 3.13 (4H,m), 4.67 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 9.01 (1H,s), 10.64 (1H,s). LRMS: m/z 581 (M+1)⁺.

15

20

EXAMPLE 24

5-[2-i-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a white solid (67%) from the title compound of Example 1 and i-butanol, using the procedure of Example 23. Found: C, 57.25; H, 6.24; N, 18.84. $\text{C}_{28}\text{H}_{36}\text{N}_8\text{O}_4\text{S}$; 0.20 H_2O requires C, 57.56; H, 6.28; N, 19.18%. δ (CDCl_3): 1.03 (3H,t), 1.12 (6H,d), 1.30 (3H,t), 2.30 (1H,m), 2.40 (2H,q), 2.55 (4H,m), 3.04 (2H,q), 3.13 (4H,m), 4.45 (2H,d), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 9.02 (1H,s), 10.63 (1H,s).

25

30 LRMS: m/z 581 (M+1)⁺.

- 39 -

EXAMPLE 25

5-[2-Cyclobutoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 A stirred mixture of the title compound of Preparation 45A (200mg, 0.35mmol), cyclobutanol (144mg, 2mmol), potassium t-butoxide (80mg, 0.70mmol) and 1,4-dioxan (5ml) was heated under reflux for 24 hours, then allowed to cool. The resulting mixture was poured into stirred aqueous sodium bicarbonate solution (20ml) and this mixture extracted with ethyl acetate (3x20ml). The combined extracts were dried (MgSO_4) and evaporated under reduced pressure, then the residue purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4), to provide the title compound (9 mg, 4%) as a solid. δ (CDCl_3): 1.03 (3H,t), 1.29 (3H,t), 1.78 (2H,m), 1.98 (2H,m), 2.35 (2H,m), 2.55 (6H,m), 3.04 (2H,q), 3.12 (4H,m), 5.48 (1H,m), 5.68 (2H,s), 7.10 (1H,d), 7.23 (1H,m), 7.63 (1H,m), 8.56, (1H,d), 8.60 (1H,s), 9.01 (1H,s), 10.67 (1H,s). LRMS: m/z 579 ($\text{M}+1$)⁺.

EXAMPLE 26

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

20 Potassium t-butoxide (2.38g, 21.2mmol) was added to a solution of the title compound of Preparation 77 (3.1g, 5.3mmol) in absolute ethanol (95ml) and the reaction mixture heated at 100°C in a sealed vessel for 40 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure, 25 the residue dissolved in water (20ml) and the aqueous solution acidified to pH 5 with 2M hydrochloric acid. The aqueous suspension thus obtained was extracted with dichloromethane (3x30ml) and the combined extracts dried (MgSO_4) and evaporated under reduced pressure. The residual brown foam was purified by column chromatography on silica gel, using an elution gradient

- 40 -

of dichloromethane: methanol (99:1 to 97:3), to furnish the title compound (1.39 g, 46%) as a foam. δ (CDCl_3): 0.93 (3H,t), 1.02 (3H,t), 1.58 (3H,t), 1.74 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 2.98 (2H,t), 3.13 (4H,m), 4.75 (2H,q), 5.68 (2H,s), 5 7.09 (1H,d), 7.23 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.63 (1H,s), 9.02 (1H,s), 10.64 (1H,s).

EXAMPLE 27

10 5-[5-[4-(3-Dimethylaminoprop-1-yl)piperazin-1-ylsulphonyl]-2-ethoxypyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one trihydrochloride

A solution of freshly distilled 1-(3-dimethylaminoprop-1-yl)piperazine (J.Chem.Soc. (C); 1971, 132; 160mg, 0.93mmol) in ethanol (2ml) was added to a stirred solution of the title compound of Preparation 63 (230mg, 0.467mmol) 15 in ethanol (10ml) and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was suspended in aqueous sodium bicarbonate solution (30ml), the suspension extracted with ethyl acetate (3x30ml) and the combined extracts washed with brine (2x30ml), dried (Na_2SO_4), and evaporated under reduced pressure. The residual oil was 20 purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 90:10), then the product dissolved in the minimum volume of ethyl acetate. Saturated ethereal hydrogen chloride solution was added and the resulting white precipitate collected, triturated with ether and dried under suction to afford the title compound (140mg, 37%) as a 25 white solid. Found: C, 44.45; H, 6.34; N, 15.38. $\text{C}_{30}\text{H}_{41}\text{N}_9\text{O}_4\text{S}$; 3HCl; 4 H_2O requires C, 44.75; H, 6.51; N, 15.66%. δ (DMSO_d_6): 0.86 (3H,t), 1.34 (3H,t), 1.64 (2H,m), 2.12 (2H,m), 2.72 (6H,2xs), 2.95 (2H,t), 3.00 (2H,m), 3.12 (2H,t), 3.18 (2H,m), 3.56 (2H,m), 3.84 (2H,m), 4.50 (2H,q), 5.75 (2H,s), 7.27 (1H,d), 7.42 (1H,m), 7.90 (1H,m), 8.28 (1H,s), 8.57 (1H,d), 8.73 (1H,s), 10.63 (1H,s), 30 11.47 (1H,s), 11.96 (1H,s). LRMS: m/z 624 ($\text{M}+1$)⁺.

- 41 -

EXAMPLE 28

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 Obtained as a colourless solid (40%) from the title compound of Preparation 80, using the procedure of Example 20. Found: C, 57.16; H, 6.15; N, 18.85. $C_{28}H_{36}N_8O_4S$; 0.50 H₂O requires C, 57.03; H, 6.32; N, 19.00%. δ (CDCl₃): 0.94 (3H,t), 1.02 (3H,t), 1.13 (3H,t), 1.74 (2H,m), 1.98 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 2.98 (2H,t), 3.12 (4H,m), 4.62 (2H,t), 5.66 (2H,s), 7.09 (1H,d), 7.21 (1H,m), 7.62 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 9.02 (1H,s), 10.63 (1H,s). LRMS: m/z 582 (M+2)⁺.

EXAMPLE 29

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15 Obtained as a solid (48%) from the title compound of Example 26 and propan-2-ol, using the procedure of Example 21. δ (CDCl₃): 0.94 (3H,t), 1.03 (3H,t), 1.57 (6H,d), 1.74 (2H,m), 2.41 (2H,q), 2.56 (4H,m), 2.98 (2H,t), 3.12 (4H,m), 5.68 (3H,m), 7.08 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.63 (1H,s), 9.02 (1H,s), 10.67 (1H,s). LRMS: m/z 581 (M+1)⁺.

EXAMPLE 30

5-{2-Ethoxy-5-[4-(2-hydroxyethyl)piperazin-1-ylsulphonyl]pyridin-3-yl}-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25 Obtained as a white solid (49%) from the title compound of Preparation 63 and 1-(2-hydroxyethyl)piperazine, using the procedure of Example 2. Found: C, 55.48; H, 5.93; N, 18.85. $C_{27}H_{34}N_8O_5S$; 0.10 C₄H₈O₂ requires C, 55.64; H, 5.93; N, 18.94%. δ (CDCl₃): 0.95 (3H,t), 1.59 (3H,t), 1.75 (2H,m), 2.28 (1H,s), 2.58 (2H,m), 2.65 (4H,m), 3.00 (2H,t), 3.16 (4H,m), 3.60 (2H,t), 4.76 (2H,q), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.64 (1H,s), 9.04 (1H,s), 10.66 (1H,s). LRMS: m/z 583 (M+1)⁺.

- 42 -

EXAMPLE 31

5-{2-Ethoxy-5-[4-(3-hydroxyprop-1-yl)piperazin-1-ylsulphonyl]pyridin-3-yl}-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 Obtained as a white solid (52%) from the title compound of Preparation 63 and 1-(3-hydroxyprop-1-yl)piperazine, using the procedure of Example 2. Found: C, 56.27; H, 6.13; N, 18.38. $C_{28}H_{36}N_8O_5S$ requires C, 56.36; H, 6.08; N, 18.78%. δ ($CDCl_3$): 0.94 (3H,t), 1.60 (3H,t), 1.72 (4H,m), 2.63 (6H,m), 2.98 (2H,t), 3.12 (4H,m), 3.72 (2H,t), 4.15 (1H,s), 4.77 (2H,q), 5.69 (2H,s), 7.08 (1H,d), 7.23 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.61 (1H,s), 9.01 (1H,s), 10.67 (1H,s). LRMS: m/z 596 (M)⁺.

EXAMPLE 32

5-[2-(2-Benzylxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-

15 2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

1 Obtained as a yellow oil (57%) from the title compound of Example 1 and 2-benzylxyethanol, using the procedure of Example 11. δ ($CDCl_3$): 1.02 (3H,t), 1.32 (3H,t), 2.40 (2H,q), 2.54 (4H,m), 3.04 (2H,q), 3.13 (4H,m), 3.94 (2H,t), 4.76 (2H,s), 4.80 (2H,t), 5.69 (2H,s), 7.11 (1H,d), 7.20-7.37 (4H,m), 7.41 (2H,m), 7.64 (1H,m), 8.60 (2H,m), 8.98 (1H,s), 10.80 (1H,s). LRMS: m/z 659 (M+1)⁺.

EXAMPLE 33

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-hydroxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25 Ammonium formate (62mg, 0.99mmol) was added to a mixture of the title compound of Example 32 (130mg, 0.197mmol), 10% palladium on charcoal (15mg) and acetone (9ml) and the reaction mixture stirred under reflux for 14 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 90:10), to

- 43 -

give the title compound (18mg, 16%) as a solid. δ (CD₃OD): 1.06 (3H,t), 1.28 (3H,t), 2.44 (2H,q), 2.58 (4H,m), 3.06 (2H,q), 3.14 (4H,m), 3.97 (2H,t), 4.68 (2H,t), 5.75 (2H,s), 7.20 (1H,d), 7.36 (1H,m), 7.80 (1H,m), 8.54 (2H,m), 8.68 (1H,s). LRMS: m/z 569 (M+1)⁺.

EXAMPLE 34

5-[2-(2-Benzylxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

10 A stirred mixture of the title compound of Preparation 84 (500mg, 0.72mmol), potassium bis(trimethylsilyl)amide (347mg, 3.09mmol) and 3-methylpentan-3-ol (8ml) was heated under reflux for 36 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue partitioned between water (10ml) and dichloromethane (10ml). The 15 phases were separated, the aqueous phase extracted with dichloromethane (2x10ml) and the combined organic solutions dried (MgSO₄) and evaporated under reduced pressure. The crude product was purified by two column chromatography operations on silica gel, using firstly dichloromethane: methanol:0.88 aqueous ammonia (90:10:1) and then a gradient of ethyl 20 acetate: methanol (100:0 to 80:20) as eluants, to yield the title compound as an oil. δ (CDCl₃): 0.92 (3H,t), 1.02 (3H,t), 1.73 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 2.99 (2H,t), 3.10 (4H,m), 3.84 (2H,t), 4.58 (2H,s), 4.78 (2H,t), 5.68 (2H,s), 7.09 (1H,d), 7.18-7.42 (6H,m), 7.62 (1H,m), 8.55 (1H,d), 8.61 (1H,s), 8.97 (1H,s), 10.81 (1H,s). LRMS: m/z 673 (M+1)⁺.

- 44 -

EXAMPLE 35

2-Benzyl-5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 Obtained as a white foam (27%) from the title compound of Preparation 87, using the procedure of Example 10. δ (CDCl₃): 0.90 (3H,t), 1.03 (3H,t), 1.28 (3H,t), 2.40 (2H,q), 2.54 (4H,m), 2.94 (2H,q), 3.12 (4H,m), 4.75 (2H,q), 5.58 (2H,s), 7.22 (2H,m), 7.31 (3H,m), 8.62 (1H,s), 9.01 (1H,s), 10.65 (1H,s). LRMS: m/z 552 (M+1)⁺.

10

EXAMPLE 36

2-Benzyl-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15 Obtained as a cream foam (80%) from the title compound of Example 35 and 2-methoxyethanol, using the procedure of Example 9. Found: C, 57.05; H, 6.19; N, 16.15. C₂₈H₃₅N₇O₅S; 0.10 CH₂Cl₂ requires C, 57.19; H, 6.01; N, 16.61%. δ (CDCl₃): 1.02 (3H,t), 1.27 (3H,t), 2.40 (2H,q), 2.55 (4H,m), 2.94 (2H,q), 3.13 (4H,m), 3.57 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.56 (2H,s), 7.22 (2H,m), 7.32 (3H,m), 8.61 (1H,s), 8.96 (1H,s), 10.80 (1H,s).

20

EXAMPLE 37

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(1-methylimidazol-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25 Obtained as a foam (33%) from the title compound of Preparation 90, using the procedure of Example 10. δ (CDCl₃): 1.05 (3H,t), 1.34 (3H,t), 2.41 (2H,q), 2.54 (4H,m), 3.13 (4H,m), 3.19 (2H,q), 3.57 (3H,s), 3.79 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.65 (2H,s), 6.84 (1H,s), 7.00 (1H,s), 8.62 (1H,s), 8.94 (1H,s), 10.83 (1H,s). LRMS: m/z 586 (M+1)⁺.

- 45 -

EXAMPLE 38

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(1-methylimidazol-2-yl)methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 A mixture of the title compounds of Preparation 28 (232mg, 0.58mmol) and Preparation 92 (152mg, 0.58mmol), triethylamine (403μl, 2.9mmol) and dichloromethane (8ml) was stirred at room temperature for 18 hours. Brine (20ml) was added and the resulting mixture extracted with dichloromethane (2x20ml), then the combined extracts were dried (MgSO_4) and evaporated 10 under reduced pressure.

15 A stirred solution of this intermediate and potassium bis(trimethylsilyl)amide (305mg, 1.53mmol) in ethanol (10ml) was heated at 100°C for 14 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue purified by column chromatography on 20 silica gel, using dichloromethane: methanol (95:5) as eluant, to provide the title compound (163mg, 49%) as a yellow oil. δ (CDCl_3): 0.96 (3H,t), 1.01 (3H,t), 1.57 (3H,t), 1.72 (2H,m), 2.40 (2H,q), 2.55 (4H,m), 3.13 (6H,m), 3.77 (3H,s), 4.75 (2H,q), 5.67 (2H,s), 6.85 (1H,s), 7.00 (1H,s), 8.63 (1H,s), 9.00 (1H,s), 10.65 (1H,s). LRMS: m/z 570 ($\text{M}+1$)⁺.

20

EXAMPLE 39

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(1-methylimidazol-2-yl)methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25 Obtained as a solid (61%) from the title compound of Example 38 and 2-methoxyethanol, using the procedure of Example 9. δ (CDCl_3): 0.97 (3H,t), 1.02 (3H,t), 1.74 (2H,m), 2.41 (2H,q), 2.55 (4H,m), 3.14 (6H,m), 3.57 (3H,s), 3.76 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.66 (2H,s), 6.86 (1H,s), 7.00 (1H,s), 8.62 (1H,s), 8.94 (1H,s), 10.82 (1H,s). LRMS: m/z 600 ($\text{M}+1$)⁺.

30

- 46 -

EXAMPLE 40

5-[2-n-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(1-methylimidazol-2-yl)methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5

Obtained as a cream coloured foam (76%) from the title compound of Example 38 and n-butanol, using the procedure of Example 9. Found: C, 54.83; H, 6.74; N, 20.08. $C_{26}H_{39}N_9O_4S$; H_2O requires C, 54.62; H, 6.71; N, 20.47%. δ ($CDCl_3$): 0.93 (3H,t), 1.00 (6H,m), 1.54 (2H,m), 1.77 (2H,m), 1.92 (2H,m), 2.40 (2H,q), 2.53 (4H,m), 3.12 (6H,m), 3.76 (3H,s), 4.66 (2H,t), 5.67 (2H,s), 6.85 (1H,s), 6.98 (1H,s), 8.62 (1H,s), 8.97 (1H,s), 10.64 (1H,s). LRMS: m/z 599 ($M+2$)⁺.

EXAMPLE 41

15 5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(prop-2-oxy)pyridin-3-yl]-3-n-propyl-2-(pyridazin-3-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of the title compound of Preparation 98 (230mg, 0.38mmol), potassium t-butoxide (258mg, 2.3mmol) and propan-2-ol (10ml) was heated in a sealed vessel at 100°C for 24 hours, then allowed to cool. The resulting 20 mixture was evaporated under reduced pressure, then the residue purified by two column chromatography operations on silica gel, using firstly an elution gradient of dichloromethane: methanol (100:0 to 95:5) and then an elution gradient of ethyl acetate: methanol (90:10 to 80:20), to furnish the title compound (42mg, 19%) as an orange gum. δ ($CDCl_3$): 0.93 (3H,t), 1.01 (3H,t), 1.55 (6H,d), 1.75 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 3.02 (2H,t), 3.12 (4H,m), 5.67 (1H,m), 5.88 (2H,s), 7.47 (2H,m), 8.60 (1H,s), 8.98 (1H,s), 9.16 (1H,d), 25 10.70 (1H,s). LRMS: m/z 582 ($M+1$)⁺.

- 47 -

EXAMPLE 42

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-3-n-propyl-2-(pyrimidin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 Obtained as a yellow foam (14%) from the title compound of Preparation 102b, using the procedure of Example 10. δ (CDCl₃): 0.99 (3H,t), 1.03 (3H,t), 1.81 (2H,m), 2.42 (2H,q), 2.55 (4H,m), 2.97 (2H,t), 3.14 (4H,m), 3.54 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.80 (2H,s), 7.22 (1H,m), 8.62 (1H,s), 8.70 (2H,d), 8.99 (1H,s), 10.72 (1H,s). LRMS: m/z 597 (M)⁺.

10

EXAMPLE 43a

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-1-(pyrimidin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15

and

EXAMPLE 43b

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyrimidin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

20 A stirred mixture of the title compounds of Preparation 103a and Preparation 103b (390mg, 0.66mmol), potassium t-butoxide (224mg, 2.0mmol), 4Å molecular sieves and ethanol (10ml) was heated in a sealed vessel for 18 hours at 100°C, then allowed to cool and filtered. The filtrate was evaporated under reduced pressure and the residual brown oil suspended in 25 dichloromethane (25ml). This mixture was washed with water (5ml), dried (MgSO₄) and evaporated under reduced pressure, then the residue purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (99:1 to 95:5) to give an orange foam. This product was further purified by HPLC using a C₁₈ Magellan column and

- 48 -

methanol: water:diethylamine (50:50:0.1) as eluant, at a rate of 20ml/min, to afford the first title compound (1-isomer; 20mg) as a white solid. δ ($CDCl_3$): 1.04 (6H,m), 1.58 (3H,t), 1.88 (2H,m), 2.42 (2H,q), 2.57 (4H,m), 2.98 (2H,t), 3.14 (4H,m), 4.75 (2H,q), 6.07 (2H,s), 7.18 (1H,m), 8.64 (3H,m), 9.10 (1H,s), 10.75 (1H,s). LRMS: m/z 568 ($M+1$)⁺;

5 followed by the second title compound (2-isomer; 20mg) as a white solid. δ ($CDCl_3$): 1.02 (6H,m), 1.58 (3H,t), 1.82 (2H,m), 2.42 (2H,q), 2.55 (4H,m), 2.98 (2H,t), 3.15 (4H,m), 4.74 (2H,q), 5.80 (2H,s), 7.23 (1H,m), 8.63 (1H,s), 8.70 (2H,m), 9.03 (1H,s), 10.56 (1H,s). LRMS: m/z 568 ($M+1$)⁺.

EXAMPLE 44

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-1-(pyridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15 A stirred mixture of the title compound of Preparation 105 (304mg, 0.52mmol), potassium t-butoxide (175mg, 1.56mmol) and ethanol (10ml) was heated in a sealed vessel at 100°C for 18 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residual brown oil partitioned between dichloromethane (15ml) and water (5ml). The 20 phases were separated, then the organic phase dried ($MgSO_4$) and evaporated under reduced pressure to give a brown foam, which was purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as eluant, to provide the title compound (230mg, 78%) as a white foam. Found: C, 56.93; H, 6.03; N, 19.42. $C_{27}H_{34}N_8O_4S$ requires C, 57.22; H, 6.04; N, 19.77%.

25 δ ($CDCl_3$) 1.01 (3H,t), 1.59 (6H,m), 1.86 (2H,m), 2.42 (2H,q), 2.57 (4H,m), 2.97 (2H,t), 3.16 (4H,m), 4.74 (2H,q), 5.94 (2H,s), 7.02 (1H,d), 7.18 (1H,m), 7.60 (1H,m), 8.57 (1H,d), 8.63 (1H,s), 9.10 (1H,s), 10.85 (1H,s). LRMS: m/z 567 ($M+1$)⁺.

5 - 49 -

EXAMPLE 45

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-(1-methylimidazol-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 Obtained as a pale yellow solid (60%) from the title compound of Preparation 107, using the procedure of Example 44. δ (CDCl₃): 1.02 (3H,t), 1.38 (3H,t), 1.59 (3H,t), 2.41 (2H,q), 2.56 (4H,m), 2.97 (2H,q), 3.15 (4H,m), 3.78 (3H,s), 4.75 (2H,q), 5.89 (2H,s), 6.85 (1H,s), 7.00 (1H,s), 8.64 (1H,s), 9.07 (1H,s), 10.87 (1H,s). LRMS: m/z 556 (M+1)⁺.

10

EXAMPLE 46

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-1-(1-methylimidazol-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15 A stirred mixture of the title compound of Example 45 (150mg, 0.27mmol), potassium t-butoxide (126mg, 1.1mmol) and 2-methoxyethanol (6ml) was heated under reflux for 48 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using dichloromethane:methanol:0.88 aqueous ammonia (90:10:1) as eluant. The product was triturated with 20 diisopropyl ether, the mixture filtered and the filtrate evaporated under reduced pressure to yield the title compound (43mg, 27%) as a foam. δ (CDCl₃): 1.10 (3H,t), 1.36 (3H,t), 2.52 (2H,q), 2.65 (4H,m), 2.96 (2H,q), 3.22 (4H,m), 3.56 (3H,s), 3.75 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.92 (2H,s), 6.85 (1H,s), 7.01 (1H,s), 8.63 (1H,s), 8.99 (1H,s), 11.10 (1H,s). LRMS: m/z 585 (M)⁺.

25

EXAMPLE 47

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-1-(1-methylimidazol-2-yl)methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

30 Obtained as a solid (11%) from the title compound of Preparation 109, using the procedure of Example 10. Found: C, 52.43; H, 6.11; N, 20.12.

- 50 -

$C_{27}H_{37}N_9O_5S$; H_2O requires C, 52.50; H, 6.36; N, 20.41%. δ ($CDCl_3$): 0.98 (3H,t), 1.03 (3H,t), 1.81 (2H,m), 2.41 (2H,q), 2.55 (4H,m), 2.90 (2H,t), 3.15 (4H,m), 3.58 (3H,s), 3.75 (3H,s), 3.86 (2H,t), 4.78 (2H,t), 5.92 (2H,s), 6.85 (1H,s), 7.00 (1H,s), 8.63 (1H,s), 9.00 (1H,s), 11.07 (1H,s). LRMS: m/z 600 (M+1)⁺.

EXAMPLE 48

10 5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-3-n-propyl-1-(pyrimidin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a yellow foam (5%) from the title compound of Preparation 102a, using the procedure of Example 10. δ ($CDCl_3$): 1.02 (6H,m), 1.86 (2H,m), 2.42 (2H,q), 2.56 (4H,m), 2.97 (2H,t), 3.17 (4H,m), 3.54 (3H,s), 3.83 (2H,t), 4.77 (2H,t), 6.09 (2H,s), 7.16 (1H,m), 8.65 (3H,m), 9.03 (1H,s), 11.00 (1H,s). LRMS: 15 m/z 598 (M+1)⁺.

EXAMPLE 49

20 5-[2-Ethoxy-5-[4-(pyrrolidin-1-ylcarbonylmethyl)piperazin-1-ylsulphonyl]pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of the title compound of Preparation 63 (350mg, 0.715mmol), 1-(pyrrolidin-1-ylcarbonylmethyl)piperazine (150mg, 0.715mmol) and ethanol (40ml) was stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was suspended in aqueous sodium 25 bicarbonate solution (30ml) and the suspension extracted with ethyl acetate (3x30ml). The combined extracts were washed with brine (3x20ml), dried (Na_2SO_4) and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4) to give an oil, which was triturated 30 with ether to furnish the title compound (240mg, 52%) as a colourless foam.

- 51 -

Found: C, 56.79; H, 6.30; N, 18.49. $C_{31}H_{39}N_9O_5S$; 0.50 H_2O ; 0.25 $C_4H_{10}O$ requires C, 56.75; H, 6.32; N, 18.61%. δ ($CDCl_3$): 0.94 (3H,t), 1.60 (3H,t), 1.66-1.86 (4H,m), 1.92 (2H,m), 2.68 (4H,m), 2.98 (2H,t), 3.14 (2H,s), 3.18 (4H,m), 3.32-3.46 (4H,m), 4.75 (2H,q), 5.70 (2H,s), 7.18 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.63 (1H,s), 9.00 (1H,s), 10.66 (1H,s). LRMS: m/z 650 ($M+1$)⁺.

EXAMPLE 50

10 5-[2-Ethoxy-5-(4-allyl-2(S),5(R)-dimethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
 A solution of (-)-1-allyl-2(R),5(S)-dimethylpiperazine (WO 93/15062; 502mg, 3.2mmol) in ethanol (4ml) was added dropwise to a stirred suspension of the title compound of Preparation 63 (800mg, 1.6mmol) in ethanol and the 15 reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was partitioned between aqueous sodium carbonate solution (20ml) and ethyl acetate (20ml), the phases separated and the aqueous phase extracted with ethyl acetate (2x20ml). The combined organic solutions were washed with brine (20ml), dried (Na_2SO_4) and 20 evaporated under reduced pressure. The residual orange oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 98:2), followed by trituration with ether, to afford the title compound (550mg, 57%) as a colourless foam. Found: C, 59.07; H, 6.37; N, 18.18. $C_{30}H_{38}N_8O_4S$ requires C, 59.39; H, 6.31; N, 18.47%.
 25 δ ($CDCl_3$): 0.95 (3H,t), 0.99 (3H,d), 1.24 (3H,d), 1.58 (3H,t), 1.72 (2H,m), 2.27 (1H,dd), 2.73 (1H,dd), 2.92 (1H,m), 3.00 (4H,m), 3.20 (1H,dd), 3.48 (1H,dd), 3.85 (1H,m), 4.75 (2H,q), 5.22 (2H,m), 5.68 (2H,s), 5.74 (1H,m), 7.09 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.67 (1H,s), 9.08 (1H,s), 10.69 (1H,s).
 LRMS: m/z 607 ($M+1$)⁺.

Example 50a


5 3-Ethyl-5-[5-(4-ethylpiperazine-1-ylsulphonyl)-2-(2-methoxy-1(R)-
methylethoxy)pyridin-3-yl]-2-(1-methylimidazol-2-yl)methyl-2,6-dihydro-7H-
pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a white foam (82%), from the title compounds of Preparations 165 and 170, following a similar procedure to that described in Example 11.

10 Found: C, 52.14; H, 6.15; N, 19.73. $C_{27}H_{37}N_9O_5S \cdot 1.5H_2O$ requires C, 51.74; H, 6.43; N, 20.11%. δ ($CDCl_3$) : 1.02 (3H, t), 1.32 (3H, t), 1.50 (3H, d), 2.40 (2H, q), 2.56 (4H, m), 3.04-3.22 (6H, m), 3.54 (3H, s), 3.62-3.80 (5H, m), 5.59 (1H, m), 5.66 (2H, s), 6.83 (1H, s), 6.99 (1H, s), 8.60 (1H, s), 8.84 (1H, s), 10.87 (1H, s).
LRMS: m/z 600 (M+1)⁺

- 53 -

EXAMPLE 51 to 60












5

A group of analogues based on the structural formula identified above, in which the R¹⁰ substituent is varied, was obtained by the technique of high-speed analogue synthesis (HSAS) as described hereinafter.

A 0.4 M solution of triethylamine in dichloromethane (100µl, 40µmol) was 10 added to each well of a 96-well plate containing the required range of 1- substituted piperazines (10µmol). A 0.1M solution of the title compound of Preparation 63 in dichloromethane (100µl, 10µmol) was added to each well, then the plate covered and shaken at room temperature for 18 hours. The reaction mixtures were filtered through a 96-well filtration block, which was 15 washed with dichloromethane (1ml), then the filtrates evaporated under reduced pressure. The residues were dissolved in dimethylsulphoxide (1ml) and purified by HPLC using a 5µ Hypersil C18 column (10x0.46cm) with a flow rate of 4ml/min and an elution gradient of 0.1% trifluoroacetic acid in water: acetonitrile.

-54-

The following compounds were thus obtained:

Example	R^{10}	LRMS (m/z)	Retention time (min)
51		581 (M+1) ⁺	5.25
52		581 (M+1) ⁺	5.10
53		629 (M+1) ⁺	5.70
54		659 (M+1) ⁺	6.02
55		672 (M) ⁺	5.36
56		706 (M+2) ⁺	8.24
57		687 (M+1) ⁺	6.64
58		617 (M+2) ⁺	5.45
59		616 (M+1) ⁺	5.57
60		617 (M+1) ⁺	7.38

* = point of attachment of R^{10}

- 55 -

EXAMPLE 61

3-Ethyl-5-[2-(2-methoxyethoxy)-5-(3,4,5-trimethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a white solid (170mg, 47%) from the title compound of Preparation 64 and 1,2,6-trimethylpiperazine (J.Med.Chem., 1968, 11, 592), using the procedure of Example 50. Found: C, 55.78; H, 6.02; N, 18.42. C₂₈H₃₆N₈O₅S; 0.50 H₂O requires C, 55.22; H, 6.16; N, 18.58%. δ (CDCl₃): 1.09 (6H,d), 1.31 (3H,t), 2.01 (5H,m), 2.36 (2H,m), 3.04 (2H,q), 3.60 (5H,m), 3.88 (2H,t), 4.79 (2H,t), 5.68 (2H,s), 7.12 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.95 (1H,s), 10.79 (1H,s). LRMS: m/z 597 (M+1)⁺.

EXAMPLE 62

3-Ethyl-5-[2-(2-methoxyethoxy)-5-piperazin-1-ylsulphonyl)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A solution of the title compound of Preparation 64 (200mg, 0.40mmol) in dichloromethane (10ml) was added dropwise to a stirred solution of piperazine (136mg, 1.58mmol) and triethylamine (110μl, 0.79mmol) in dichloromethane (10ml) and the reaction mixture stirred at room temperature for 1 hour, then washed with water (10ml), dried (MgSO₄) and evaporated under reduced pressure. The residual yellow solid was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (98:2 to 92:8), followed by trituration with dichloromethane, to give the title compound (189mg, 86%) as a white foam. Found: C, 52.75; H, 5.43; N, 19.18. C₂₅H₃₀N₈O₅S; 0.75 H₂O requires C, 52.85; H, 5.59; N, 19.72%. δ (CDCl₃): 1.30 (3H,t), 2.94-3.13 (10H,m), 3.58 (3H,s), 3.88 (2H,t), 4.79 (2H,t), 5.68 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.62 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.98 (1H,s), 10.82 (1H,s). LRMS: m/z 555 (M+1)⁺.

- 56 -

EXAMPLE 63

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-methoxypyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 A stirred mixture of the title compound of Example 1 (350mg, 0.63mmol), potassium bis(trimethylsilyl)amide (630mg, 3.15mmol) and n-propanethiol (5ml) was heated in a sealed vessel at 110°C for 48 hours, then allowed to cool and evaporated under reduced pressure. The residue was azeotroped with dichloromethane: methanol (95:5), then partitioned between water (10ml) and dichloromethane (15ml). The phases were separated, the aqueous phase extracted with dichloromethane (2x15ml) and the combined organic solutions dried (MgSO_4) and evaporated under reduced pressure. This residue was purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as eluant, to yield the title compound (170mg, 50%) as a yellow solid. Found: C, 54.50; H, 5.64; N, 19.93. $\text{C}_{25}\text{H}_{30}\text{N}_8\text{O}_4\text{S}$; 0.75 H_2O requires C, 54.38; H, 5.75; N, 20.29%. δ (CDCl_3): 1.02 (3H,t), 1.32 (3H,t), 2.40 (2H,q), 2.55 (4H,m), 3.06 (2H,q), 3.14 (4H,m), 4.26 (3H,s), 5.68 (2H,s), 7.14 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.58 (1H,d), 8.66 (1H,s), 9.05 (1H,s), 10.59 (1H,s). LRMS: m/z 540 ($\text{M}+2$)⁺.

10

15

20

EXAMPLE 64

5-[2-Benzylxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Potassium bis(trimethylsilyl)amide (360mg, 1.81mmol) was added to a 25 stirred solution of the title compound of Example 1 (200mg, 0.36mmol) in benzyl alcohol (5ml) at 100°C and the reaction mixture stirred for 14 hours, then allowed to cool. The resulting mixture was partitioned between dichloromethane (10ml) and brine (10ml), the phases separated, the aqueous phase extracted with dichloromethane (2x10ml) and the combined organic 30 solutions dried (Na_2SO_4) and evaporated under reduced pressure. The residual benzyl alcohol was removed by Kugelrohr distillation, then the crude

- 57 -

product purified by column chromatography on silica gel, using dichloromethane: methanol (97.5:2.5) as eluant, to provide the title compound (86mg, 39%) as a white solid. Found: C, 59.92; H, 5.64; N, 17.60. 5 $C_{31}H_{34}N_8O_4S$; 0.40 H_2O requires C, 59.87; H, 5.64; N, 18.02%. δ ($CDCl_3$): 1.05 (3H,t), 1.29 (3H,t), 2.41 (2H,q), 2.56 (4H,m), 3.05 (2H,q), 3.15 (4H,m); 5.68 (2H,s) 5.75 (2H,s), 7.10 (1H,d), 7.24 (1H,m), 7.42 (3H,m), 7.52 (2H,m), 7.64 (1H,m), 8.58 (1H,d), 8.65 (1H,s), 9.02 (1H,s), 10.58 (1H,s). LRMS: m/z 615 (M+1)⁺.

10

EXAMPLE 65

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(furan-3-ylmethoxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Potassium bis(trimethylsilyl)amide (176mg, 0.88mmol) was added to a 15 stirred suspension of the title compound of Example 26 (100mg, 0.17mmol) in 3-hydroxymethylfuran (4ml) and the reaction mixture heated under reflux for 24 hours then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using dichloromethane: methanol (95:5) as eluant, to furnish the title 20 compound (33mg, 31%) as a pale yellow foam. δ ($CDCl_3$) 0.93 (3H,t), 1.04 (3H,t), 1.72 (2H,m), 2.41 (2H,q), 2.55 (4H,m), 2.99 (2H,t), 3.14 (4H,m), 5.63 (2H,s), 5.68 (2H,s), 6.60 (1H,s), 7.09 (1H,d), 7.22 (1H,m), 7.44 (1H,s), 7.64 (2H,m), 8.57 (1H,d), 8.68 (1H,s), 9.02 (1H,s), 10.53 (1H,s). LRMS: m/z 619 (M+1)⁺.

25

EXAMPLE 66

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(pyridin-2-ylmethoxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A stirred mixture of potassium bis(trimethylsilyl)amide (260mg, 30 1.32mmol) and 2-hydroxymethylpyridine (5ml) was heated at 100°C for 1 hour,

- 58 -

then the title compound of Example 26 (150mg, 0.26mmol) added and the reaction mixture stirred at 100°C for 14 hours. The resulting cool mixture was partitioned between dichloromethane (10ml) and brine (10ml), the phases separated and the aqueous phase extracted with dichloromethane (2x10ml). The combined organic solutions were dried ($MgSO_4$) and evaporated under reduced pressure, then the residual yellow oil purified by column chromatography on silica gel, using dichloromethane: ethyl acetate: methanol (47.5:47.5:5) as eluant, to afford the title compound (35mg, 21%) as a white solid. δ ($CDCl_3$): 0.94 (3H,t), 1.03 (3H,t), 1.73 (2H,m), 2.40 (2H,q), 2.55 (4H,m), 2.98 (2H,t), 3.14 (4H,m), 5.69 (2H,s), 5.92 (2H,s), 7.07 (1H,d), 7.21 (1H;m), 7.33 (2H,m), 7.62 (1H,m), 7.76 (1H,m), 8.58 (2H,m), 8.81 (1H,s), 8.85 (1H,d), 12.80 (1H,s). LRMS: m/z 630 ($M+1$)⁺.

15

EXAMPLE 67

5-[2-(2-Dimethylaminoethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of the title compound of Example 26 (200mg, 0.35mmol), potassium bis(trimethylsilyl)amide (352mg, 1.76mmol) and 2-dimethylaminoethanol (1.5ml) was stirred at 90°C for 18 hours, then allowed to cool. Water (5ml) was added, the mixture extracted with ethyl acetate (3x5ml) and the combined extracts dried ($MgSO_4$) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (95:5 to 90:10), to give the title compound (147mg, 68%) as an off-white foam. Found: C, 56.35; H, 6.37; N, 20.12. $C_{29}H_{39}N_9O_4S$; 0.50 H_2O requires C, 56.29; H, 6.52; N, 20.37%. δ ($CDCl_3$): 0.94 (3H,t), 1.04 (3H,t), 1.72 (2H,m), 2.43 (8H,m), 2.56 (4H,m), 2.74 (2H,t), 2.95 (2H,t), 3.15 (4H,m), 4.80 (2H,t), 5.67 (2H,s), 7.07 (1H,d), 7.21 (1H,m), 7.61 (1H,m), 8.56 (1H,d), 8.62 (1H,s), 8.75 (1H,s), 12.23 (1H,s). 30 LRMS: m/z 610 ($M+1$)⁺.

- 59 -

EXAMPLE 68

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-[2-(morpholin-4-yl)ethoxy]pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 A mixture of potassium bis(trimethylsilyl)amide (180mg, 0.88mmol) and 4-(2-hydroxyethyl)morpholine (4ml) was stirred at 100°C for 1 hour, then the title compound of Example 26 (100mg, 0.17mmol) added and the reaction mixture stirred at 110°C for 18 hours. The resulting, cool mixture was partitioned between water (10ml) and dichloromethane (20ml), the phases 10 separated and the organic phase washed with water (10ml), dried ($MgSO_4$) and evaporated under reduced pressure. The residual yellow oil was purified by column chromatography on silica gel, using an elution gradient of ethyl acetate: methanol (90:10 to 80:20), to yield the title compound (33mg, 30%) as a white 15 solid. δ ($CDCl_3$): 0.95 (3H,t), 1.04 (3H,t), 1.74 (2H,m), 2.42 (2H,q), 2.56 (4H,m), 2.64 (4H,m), 2.90 (2H,t), 2.99 (2H,t), 3.15 (4H,m), 3.80 (4H,m), 4.75 (2H,t), 5.68 (2H,s), 7.12 (1H,d), 7.25 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.62 (1H,s), 8.92 (1H,s), 11.16 (1H,s). LRMS: m/z 652 ($M+1$)⁺.

EXAMPLE 69

20 5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Caesium t-butoxide (76mg, 0.37mmol) was added to a stirred solution of the title compound of Preparation 119 (160mg, 0.24mmol) in 3-methylpentan-3-ol (5ml) and the reaction mixture stirred at 120°C for 3 hours, then allowed to 25 cool. The resulting mixture was evaporated under reduced pressure and the residue partitioned between dichloromethane (10ml) and water (10ml). The phases were separated, the aqueous phase extracted with dichloromethane (2x10ml) and the combined organic solutions dried ($MgSO_4$) and evaporated under reduced pressure. The residual yellow oil was purified by

- 60 -

column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (95:5 to 92.5:7.5), to provide the title compound as a yellow foam. δ (CDCl_3): 0.94 (3H,t), 1.03 (3H,t), 1.74 (2H,m), 2.10 (2H,m), 2.22 (2H,m), 2.42 (5H,m), 2.58 (6H,m), 2.78 (2H,m), 2.99 (2H,t), 3.13 (4H,m), 5.59 (1H,m), 5.67 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.57 (1H,d), 8.61 (1H,s), 9.00 (1H,s), 10.63 (1H,s). LRMS: m/z 636 ($M+1$)⁺.

EXAMPLE 70

10 5-[2-Ethoxy-5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of the title compound of Example 1 (180mg, 0.32mmol), 3-chlorobenzoic acid (13mg, 0.08mmol) and dichloromethane (10ml) was stirred at room temperature for 20 minutes, 3-chloroperoxybenzoic acid (112mg, 0.32mmol) added and the reaction mixture stirred for a further 18 hours, then 15 partitioned between dichloromethane (20ml) and aqueous sodium bicarbonate solution (10ml). The phases were separated, the aqueous phase extracted with dichloromethane (2x20ml) and the combined organic solutions dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using dichloromethane: methanol (80:20) as 20 eluant, to furnish the title compound (82mg, 45%) as a white powder. Found: C, 52.73; H, 5.67; N, 17.69. $\text{C}_{26}\text{H}_{32}\text{N}_8\text{O}_5\text{S}$; 0.50 CH_2Cl_2 requires C, 52.08; H, 5.44; N, 18.34%. δ (CDCl_3): 1.30 (3H,t), 1.40 (3H,t), 1.58 (3H,t), 3.02 (2H,q), 3.20 (2H,m), 3.32 (4H,m), 3.48 (2H,m), 3.72 (2H,m), 4.76 (2H,q), 5.68 (2H,s), 7.08 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.58 (1H,d), 8.65 (1H,s), 9.03 (1H,s), 25 10.70 (1H,s).

EXAMPLE 71

30 5-[5-(4-Ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

3-Chloroperoxybenzoic acid (93mg, 0.27mmol) was added to a stirred

- 61 -

solution of the title compound of Example 28 (155mg, 0.27mmol) in dichloromethane (2ml) and the reaction mixture stirred at room temperature for 2 hours, then evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using dichloromethane:methanol:0.88 aqueous ammonia (90:10:1) as eluant, to afford the title compound (40mg, 25%) as a solid. δ ($CDCl_3$): 0.93 (3H,t), 1.14 (3H,t), 1.41 (3H,t), 1.72 (2H,m), 2.00 (2H,m), 2.97 (2H,t), 3.15 (2H,m), 3.31 (4H,m), 3.50 (2H,m), 3.70 (2H,m), 4.65 (2H,t), 5.68 (2H,s), 7.06 (1H,d), 7.24 (1H,m), 7.64 (1H,m), 8.58 (1H,d), 8.66 (1H,s), 9.06 (1H,s), 10.67 (1H,s). LRMS: m/z 598 (M+1)⁺.

EXAMPLE 72

3-Ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo

[4,3-d]pyrimidin-7-one

15

and

EXAMPLE 73

3-Ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(1-oxidopyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

3-Chlorobenzoic acid (15mg, 0.096mmol) was added to a stirred solution of the title compound of Example 4 (223mg, 0.38mmol) in dichloromethane (3ml) and the mixture stirred at room temperature for 30 minutes. 25 3-Chloroperoxybenzoic acid (132mg, 0.38mmol) was then added and the reaction mixture stirred at room temperature for 14 hours, then partitioned between dichloromethane (5ml) and aqueous sodium bicarbonate solution (5ml). The phases were separated, the aqueous phase extracted with dichloromethane

- 62 -

(3x10ml) and the combined organic solutions dried ($MgSO_4$) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (90:10 to 5 80:20), to give the first title compound (78mg, 34%) as a solid. Found: C, 51.77; H, 5.82; N, 17.33. $C_{27}H_{34}N_8O_6S$; 1.75 H_2O requires C, 51.46; H, 6.00; N, 17.78%. δ ($CDCl_3$): 1.28 (3H,t), 1.42 (3H,t), 3.02 (2H,q), 3.18 (2H,m), 3.30 (4H,m), 3.50 (2H,m), 3.56 (3H,s), 3.72 (2H,m), 3.88 (2H,t), 4.80 (2H,t), 5.68 (2H,s), 7.08 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.58 (1H,d), 8.68 (1H,s), 8.99 (10 1H,s), 10.84 (1H,s);

followed by the second title compound (50mg, 22%) as a solid. Found: C, 50.15; H, 5.81; N, 16.85. $C_{27}H_{34}N_8O_6S$; 2.0 H_2O requires C, 49.84; H, 5.89; N, 17.22%. δ ($CDCl_3$): 1.32 (3H,t), 1.42 (3H,t), 3.05 (2H,q), 3.18 (2H,m), 3.32 (4H,m), 3.53 (5H,m), 3.72 (2H,m), 3.86 (2H,t), 4.80 (2H,t), 5.81 (2H,s), 6.78 (15 1H,d), 7.22 (2H,m), 8.29 (1H,d), 8.66 (1H,s), 8.99 (1H,s), 10.90 (1H,s).

EXAMPLE 74

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(2-morpholin-4-yl)ethyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

20 Potassium t-butoxide (110mg, 0.99mmol) was added to a stirred solution of the title compound of Preparation 120 (400mg, 0.66mmol) in 3-methylpentan-3-ol (20ml) and the reaction mixture heated under reflux for 3 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure, the residue suspended in water (10ml) and the suspension 25 extracted with dichloromethane (3x10ml). The combined extracts were dried ($MgSO_4$) and evaporated under reduced pressure, then the residual yellow oil purified by column chromatography on silica gel, using dichloromethane: methanol (97.5:2.5) as eluant, to yield the title compound (65mg, 17%) as a white foam. Found: C, 54.51; H, 6.95; N, 18.18.

- 63 -

$C_{27}H_{40}N_8O_5S$; 0.15 CH_2Cl_2 requires C, 54.51; H, 6.92; N, 18.14%. δ ($CDCl_3$): 1.04 (6H,m), 1.58 (3H,t), 1.88 (2H,m), 2.41 (2H,q), 2.54 (8H,m), 2.99 (4H,m), 3.15 (4H,m), 3.68 (4H,m), 4.40 (2H,t), 4.75 (2H,q), 8.62 (1H,s), 9.04 (1H,s), 10.61 (1H,s). LRMS: m/z 589 ($M+1$)⁺.

EXAMPLE 75

5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(2-morpholin-4-yl)ethyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

10 Obtained as a white solid (24%) from the title compound of Example 74 and 2-methoxyethanol, using the procedure of Example 66. Found: C, 53.81; H, 6.93; N, 16.89. $C_{28}H_{42}N_8O_6S$; 0.30 $C_4H_8O_2$; 0.20 H_2O requires C, 54.06; H, 6.96; N, 17.27%. δ ($CDCl_3$): 1.04 (6H,m), 1.87 (2H,m), 2.42 (2H,q), 2.55 (8H,m), 2.99 (4H,m), 3.16 (4H,m), 3.56 (3H,s), 3.69 (4H,m), 3.88 (2H,t), 4.40 (2H,t), 4.79 (2H,t), 8.63 (1H,s), 8.98 (1H,s), 10.78 (1H,s). LRMS: m/z 619 ($M+1$)⁺.

EXAMPLE 76

3-t-Butyl-5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-1-(pyridin-2-yl)methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

20 A stirred mixture of the title compound of Preparation 121 (150mg, 0.25mmol), potassium t-butoxide (71mg, 0.625mmol) and ethanol (10ml) was heated at 100°C for 18 hours in a sealed vessel, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue 25 partitioned between water (10ml) and ethyl acetate (15ml). The phases were separated, the aqueous phase extracted with ethyl acetate (2x15ml) and the combined organic solutions dried ($MgSO_4$) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel, using dichloromethane: methanol (100:0 to 95:5) as eluant, to provide the 30 title compound (140mg, 97%) as a white solid. Found: C, 56.30; H, 6.39; N, 18.43. $C_{28}H_{36}N_6O_4S$; H_2O requires C, 56.17; H, 6.40; N, 18.72%.

- 64 -

δ (CDCl₃): 1.04 (3H,t), 1.56 (12H,m), 2.42 (2H,q), 2.56 (4H,m), 3.16 (4H,m), 4.76 (2H,q), 5.95 (2H,s), 6.94 (1H,d), 7.18 (1H,m), 7.60 (1H,m), 8.58 (1H,d), 8.64 (1H,s), 9.08 (1H,s), 10.82 (1H,s). LRMS: m/z 581 (M+1)⁺.

5

EXAMPLE 77


5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-1-(2-morpholin-4-yl)ethyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a white solid (68%) from the title compound of Preparation 10 122, using the procedure of Example 74. Found: C, 54.59; H, 6.91; N, 18.08. C₂₇H₄₀N₈O₅S; 0.15 CH₂Cl₂ requires C, 54.59; H, 6.89; N, 18.08%. δ (CDCl₃): 1.01 (6H,m), 1.60 (3H,t), 1.84 (2H,m), 2.42 (2H,q), 2.53 (8H,m), 2.86 (2H,t), 2.94 (2H,t), 3.15 (4H,m), 3.62 (4H,m), 4.72 (4H,m), 8.63 (1H,s), 9.09 (1H,s), 10.81 (1H,s). LRMS: m/z 589 (M+1)⁺.

15

EXAMPLE 78

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



20 A mixture of the title compound of Preparation 152 (25.9g, 52.5mmol), and potassium bis(trimethylsilyl)amide (22.0g, 110.0mmol) in ethanol (1500ml) was heated at 120°C for 18 hours in a sealed vessel. The cooled solution was concentrated under reduced pressure, and pre-adsorbed onto silica gel. The crude product was purified by column chromatography on silica gel, using an 25 elution gradient of ethyl acetate: diethylamine (97:3 to 95:5) and triturated with ether to afford the title compound (11.0g, 44%) as a white solid.


-65-

δ (CDCl₃) : 1.03 (3H, t), 1.40 (3H, t), 1.59 (3H, t), 2.41 (2H, q), 2.57 (4H, m),
 3.04 (2H, q), 3.14 (4H, m), 4.09 (3H, s), 4.75 (2H, q), 8.62 (1H, s), 9.04 (1H, s),
 5 10.64 (1H, s).

LRMS : m/z 476 (M+1)⁺

EXAMPLE 79

10 5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-3-n-
propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



The title compound of Preparation 151 (500mg, 1.0mmol) was added to a solution of potassium bis(trimethylsilyl)amide (610mg, 3.06mmol) in ethanol (20ml), and the reaction heated at 110°C in a sealed vessel for 18 hours. The 15 cooled mixture was evaporated under reduced pressure and the residue dissolved in water and neutralised using hydrochloric acid. This aqueous suspension was extracted with dichloromethane (3x30ml), the combined organic extracts washed with brine (3x30ml), dried (Na₂SO₄) and evaporated under reduced pressure. The residual oil was purified by column chromatography on silica gel using an elution gradient of dichloromethane:
 20 methanol (100:0 to 97.5:2.5), and triturated with ether, to afford the title compound (207mg, 44%) as an off-white solid.


δ (CDCl₃) : 1.03 (3H, t), 1.59 (3H, t), 1.83 (2H, m), 2.29 (3H, s), 2.53 (4H, m),
 3.00 (2H, t), 3.16 (4H, m), 4.10 (3H, s), 4.75 (2H, q), 8.63 (1H, s), 9.06 (1H, s),
 25 10.65 (1H, s).

LRMS : m/z 476 (M+1)⁺

-66-

EXAMPLES 80 TO 84

The compounds of the general formula:



5




were prepared from the appropriate pyrazole-5-carboxamides, i.e. Preparations 153, 154, 156, 157 and 155 respectively, following procedures similar to that described in Example 79. In Examples 80 to 84, R¹ is methyl and R¹³ is -OR³.

10

15

20


25

Ex	R1	R2	R3	R10	Data
80	CH ₃	(CH ₂) ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	Found: C, 53.97; H, 6.38; N, 19.75. C ₂₂ H ₃₁ N ₇ O ₄ S requires C, 53.97; H, 6.38; N, 20.03% δ (CDCl ₃) : 1.03 (6H, t), 1.58 (3H, t), 1.82 (2H, m), 2.41 (2H, q), 2.56 (4H, m), 2.99 (2H, t), 3.14 (4H, m), 4.09 (3H, s), 4.76 (2H, q), 8.63 (1H, s), 9.05 (1H, s), 10.64 (1H, s). LRMS : m/z 490 (M+1) ⁺
81	CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	δ (CDCl ₃) : 1.02 (3H, t), 1.40 (3H, t), 1.58 (6H, m), 2.41 (2H, q), 2.55 (4H, m), 3.00-3.18 (6H, m), 4.38 (2H, q), 4.75 (2H, q), 8.63 (1H, s), 9.04 (1H, s), 10.63 (1H, s). LRMS : m/z 490 (M+1) ⁺
82 _{1,2}		CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	Found: C, 56.66; H, 6.03; N, 19.57 C ₂₇ H ₃₄ N ₈ O ₄ S; 0.25 H ₂ O requires C, 56.78; H, 6.09; N, 19.62%. δ (CDCl ₃) : 1.02 (3H, t), 1.30 (3H, t), 1.58 (3H, t), 2.41 (2H, q), 2.57 (7H, m), 3.04 (2H, q), 3.15 (4H, m), 4.77 (2H, q), 5.64 (2H, s), 6.80 (1H, d), 7.08 (1H, d), 7.50 (1H, m), 8.62 (1H, s), 9.02 (1H, s), 10.66 (1H, s). LRMS : m/z 567 (M+1) ⁺
83		CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	δ (CDCl ₃) : 1.04 (3H, t), 1.40 (3H, t), 1.58 (3H, t), 2.42 (2H, q), 2.58 (4H, m), 3.01 (2H, q), 3.16 (4H, m), 3.80 (3H, s), 4.75 (2H, q), 5.82 (2H, s), 6.54 (1H, d), 6.60 (1H, d), 7.46 (1H, m), 8.64 (1H, s), 9.10 (1H, s), 10.85 (1H, s). LRMS : m/z 583 (M+1) ⁺
84 ₁		CH ₂ CH ₃	CH ₂ CH ₃	CH ₂ CH ₃	δ (CDCl ₃) : 1.03 (3H, t), 1.25 (3H, t), 1.58 (3H, t), 2.13 (3H, d), 2.40 (2H, q), 2.55 (4H, m), 3.01 (2H, q), 3.14 (4H, m), 4.77 (2H, q), 5.84 (1H, q), 7.19 (2H, m), 7.61 (1H, m), 8.56 (1H, d), 8.62 (1H, s), 9.00 (1H, s), 10.60 (1H, s). LRMS : m/z 567 (M+1) ⁺

1 = 1.5 equivalents of potassium bis(trimethylsilyl)amide were used

2 = dichloromethane:methanol:0.88 ammonia (96:4:0.4) was used as the chromatographic eluant

-68-

EXAMPLE 853-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-methoxypyridin-3-yl]-2-methyl-5 2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of the title compound of Example 78 (100mg, 0.21mmol), and copper (II) sulphate heptahydrate (75mg, 0.3mmol) in saturated methanolic ammonia (20ml) was heated at 100°C for 4 hours in a sealed vessel. The cooled mixture was evaporated under reduced pressure and the residue suspended in aqueous sodium carbonate solution (20ml) and extracted with dichloromethane (3x20ml). The combined organic extracts were washed with brine (3x20ml), dried (Na_2SO_4) and evaporated under reduced pressure to give a green solid.

10 The crude product was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 97:3) and recrystallised from hexane/ethyl acetate/methanol to afford the title compound (23mg, 24%) as a white solid.

15 Found : C, 51.22; H, 5.81; N, 20.61. $\text{C}_{20}\text{H}_{27}\text{N}_7\text{O}_4\text{S}; 0.5\text{H}_2\text{O}$ requires C, 51.05; H, 6.00; N, 20.84%

20 δ (CDCl_3) : 1.07 (3H, t), 1.40 (3H, t), 2.40-2.65 (6H, m), 3.04 (2H, q), 3.19 (4H, m), 4.09 (3H, s), 4.24 (3H, s), 8.65 (1H, s), 9.05 (1H, s), 10.58 (1H, s).


LRMS : m/z 462 ($\text{M}+1$)⁺

-69-

EXAMPLE 86

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2- (1(R)-methyl-n-propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5




The title compound of Example 78 (400mg, 0.84mmol) was added to a mixture of potassium bis(trimethylsilyl)amide (840mg, 4.2mmol) in (R)-2-butanol (4ml) and the mixture stirred at 110°C for 18 hours. The cooled mixture was 10 concentrated under reduced pressure and the residue suspended in water (10ml) and neutralised using 2N hydrochloric acid. This aqueous suspension was extracted with ethyl acetate (3x30ml), the combined organic extracts washed with sodium hydroxide solution (20ml), brine (2x30ml), dried (Na₂SO₄) and evaporated under reduced pressure. The crude product was purified by 15 column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 97.5:2.5) and the product suspended in ether and evaporated under reduced pressure. This solid was recrystallised from hexane/ethyl acetate to afford the title compound (72mg, 17%) as a white solid.

20 [α]_D = -20.88° (c=0.083, dichloromethane)
 Found : C, 54.65; H, 6.63; N, 19.25. C₂₃H₃₃N₇O₄S;0.5H₂O requires C, 53.89; H, 6.69; N, 19.13%
 δ (CDCl₃) : 1.06 (6H, m), 1.40 (3H, t), 1.50 (3H, d), 1.86 (1H, m), 1.99 (1H, m), 2.42 (2H, q), 2.58 (4H, m), 3.04 (2H, q), 3.16 (4H, m), 4.09 (3H, s), 5.56 (1H, m), 8.62 (1H, s), 9.05 (1H, s), 10.70 (1H, s).
 25 LRMS : m/z 504 (M+1)[†]

-70-

EXAMPLES 87 TO 97

The compounds of the general formula wherein R¹ is methyl and R¹³ is -OR³:



were prepared from the appropriate alcohols and pyrazolo[4,3-d]pyrimidin-7-ones, following procedures similar to that described in Example 86.

Ex	R2	R3	R10	Data
87	CH ₂ CH ₃		CH ₂ CH ₃	Found : C, 54.02; H, 6.59; N, 18.87 C ₂₃ H ₃₃ N ₇ O ₄ S:0.5H ₂ O requires C, 53.89; H, 6.69; N, 19.13% δ (CDCl ₃) : 1.02 (3H, t), 1.14 (6H, d), 1.40 (3H, t), 2.30 (1H, m), 2.42 (2H, q), 2.58 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 4.09 (3H, s), 4.44 (2H, d), 8.62 (1H, s), 9.03 (1H, s), 10.62 (1H, s).
88	(CH ₂) ₂ CH ₃		CH ₂ CH ₃	δ (CDCl ₃) : 1.02 (6H, m), 1.14 (6H, d), 1.82 (2H, m), 2.30 (1H, m), 2.42 (2H, q), 2.56 (4H, m), 2.99 (2H, t), 3.16 (4H, m), 4.08 (3H, s), 4.45 (2H, d), 8.62 (1H, s), 9.03 (1H, s), 10.62 (1H, s). LRMS : m/z 518 (M+1) ⁺
89	CH ₂ CH ₃		CH ₂ CH ₃	Found : C, 55.11; H, 6.25; N, 19.45. C ₂₃ H ₃₁ N ₇ O ₄ S requires C, 55.07; H, 6.23; N, 19.55%. δ (CDCl ₃) : 1.04 (3H, t), 1.40 (3H, t), 1.90 (1H, m), 1.98 (1H, m), 2.30-2.44 (4H, m), 2.57 (6H, m), 3.02 (2H, q), 3.14 (4H, m), 4.09 (3H, s), 5.50 (1H, m), 8.60 (1H, s), 9.04 (1H, s), 10.68 (1H, s). LRMS : m/z 502 (M+1) ⁺
90	(CH ₂) ₂ CH ₃		CH ₂ CH ₃	Found : C, 56.08; H, 6.45; N, 18.72. C ₂₄ H ₃₃ N ₇ O ₄ S requires C, 55.90; H, 6.45; N, 19.01% δ (CDCl ₃) : 0.47 (2H, m), 0.77 (2H, m), 1.02 (6H, m), 1.47 (1H, m), 1.83 (2H, m), 2.41 (2H, q), 2.56 (4H, m), 2.99 (2H, t), 3.15 (4H, m), 4.09 (3H, s), 4.50 (2H, d), 8.60 (1H, s), 9.05 (1H, s), 10.76 (1H, s). LRMS : m/z 516 (M+1) ⁺

-71-

91 ²	(CH ₂) ₂ CH ₃		CH ₂ CH ₃	Found : C, 56.53; H, 6.68; N, 18.43. C ₂₅ H ₃₅ N ₇ O ₄ S requires C, 56.69; H, 6.66; N, 18.51% δ (CDCl ₃) : 1.02 (6H, m), 1.82 (2H, m), 1.91-2.10 (4H, m), 2.26 (2H, m), 2.41 (2H, q), 2.57 (4H, m), 2.98 (3H, m), 3.14 (4H, m), 4.08 (3H, s), 4.62 (2H, d), 8.61 (1H, s), 9.02 (1H, s), 10.60 (1H, s). LRMS : m/z 530 (M+1) ⁺
92	CH ₂ CH ₃		CH ₂ CH ₃	Found : C, 52.20; H, 6.16; N, 19.26. C ₂₂ H ₃₁ N ₇ O ₅ S requires C, 52.26; H, 6.18; N, 19.39% δ (CDCl ₃) : 1.04 (3H, t), 1.40 (3H, t), 2.42 (2H, q), 2.56 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.58 (3H, s), 3.86 (2H, t), 4.09 (3H, s), 4.79 (2H, t), 8.62 (1H, s), 9.00 (1H, s), 10.78 (1H, s). LRMS : m/z 506 (M+1) ⁺
93 ³	(CH ₂) ₂ CH ₃		CH ₂ CH ₃	Found : C, 52.86; H, 6.39; N, 18.67. C ₂₃ H ₃₃ N ₇ O ₅ S requires C, 53.16; H, 6.40; N, 18.62% δ (CDCl ₃) : 1.04 (6H, m), 1.82 (2H, m), 2.40 (2H, q), 2.55 (4H, m), 2.98 (2H, t), 3.14 (4H, m), 3.57 (3H, s), 3.85 (2H, t), 4.07 (3H, s), 4.78 (2H, t), 8.61 (1H, s), 8.99 (1H, s), 10.76 (1H, s). LRMS : m/z 520 (M+1) ⁺
94 ³	CH ₂ CH ₃		CH ₂ CH ₃	Found : C, 53.16; H, 6.48; N, 18.32. C ₂₃ H ₃₃ N ₇ O ₅ S;0.5H ₂ O requires C, 52.26; H, 6.48; N, 18.55% δ (CDCl ₃) : 1.04 (3H, t), 1.38 (6H, m), 1.50 (3H, d), 2.41 (2H, q), 2.57 (4H, m), 2.96 (1H, s), 3.01 (2H, m), 3.15 (4H, m), 4.08 (3H, s), 4.18 (1H, m), 5.22 (1H, m), 8.60 (1H, s), 8.82 (1H, s), 11.27 (1H, s). [α] _D = +35.46° (c=0.073, dichloromethane)
95 ²	(CH ₂) ₂ CH ₃		CH ₂ CH ₃	δ (CDCl ₃) : 1.04 (6H, m), 1.84 (2H, m), 2.41 (2H, q), 2.56 (4H m), 2.99 (2H, t), 3.15 (4H, m), 4.08 (3H, s), 5.91 (2H, s), 7.24-7.37 (2H, m), 7.76 (1H, m), 8.59 (1H, s), 8.83 (2H, m), 12.70 (1H, s). LRMS : m/z 553 (M+1) ⁺

-72-


96	(CH ₂) ₂ CH ₃		CH ₂ CH ₃	Found : C, 55.22; H, 5.76; N, 19.42, C ₂₆ H ₃₂ N ₆ O ₄ S; 0.2CH ₂ Cl ₂ requires C, 55.24; H, 5.73; N, 19.67% δ (CDCl ₃) : 1.01 (6H, m), 1.82 (2H, m), 2.41 (2H, q), 2.56 (4H, m), 2.98 (2H, t), 3.15 (4H, m), 4.09 (3H, s), 5.78 (2H, s), 7.38 (1H, m), 7.88 (1H, d), 8.61 (2H, m), 8.79 (1H, s); 9.02 (1H, s), 10.45 (1H, s). LRMS : m/z 553 (M+1) ⁺
97	(CH ₂) ₂ CH ₃		CH ₂ CH ₃	δ (CDCl ₃) : 1.02 (6H, m), 1.82 (2H, m), 2.41 (2H, q), 2.56 (4H, m), 2.98 (2H, t), 3.16 (4H, m), 4.06 (3H, s), 5.62 (2H, s), 6.60 (1H, s), 7.43 (1H, s), 7.62 (1H, s), 8.66 (1H, s), 9.02 (1H, s), 10.51 (1H, s). LRMS : m/z 542 (M+1) ⁺

1 = dichloromethane:methanol:0.88 ammonia (100:0:0.5 to 99.5:1:0.5) used as chromatographic eluant, and the compound was isolated without crystallisation.

5 2 = dichloromethane:methanol:0.88 ammonia (100:0:0.5 to 99.5:1:0.5) used as chromatographic eluant, and the compound was triturated with ether.

3 = isolated without crystallisation

-73-

EXAMPLE 983-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-(R)-methoxy-1-(R)-methylpropoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5


(R,R)-2,3 butanediol (7.78ml, 85mmol) was added dropwise to an ice-cold solution of sodium hydride (3.74g, 60% dispersion in mineral oil, 93.5mmol) in ether (800ml), and the solution stirred at room temperature for 30 minutes. Methyl iodide (5.6ml, 89.3mmol) was added dropwise and the reaction stirred under reflux for 48 hours. 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (10.24ml, 85mmol) was added and stirring continued for a further 90 minutes under reflux. The cooled reaction was washed with aqueous ammonium chloride solution (500ml), dried (MgSO_4) and evaporated under reduced pressure. The residual oil was purified by column chromatography on silica gel using an elution gradient of ether: pentane (10:90 to 50:50) to give a pale yellow oil. The title compound of Example 78 (100mg, 0.2mmol) and potassium bis(trimethylsilyl)amide (121mg, 0.61mmol) in the intermediate alcohol (1ml), was heated at 110°C for 30 hours, then the reaction cooled and concentrated under reduced pressure. The residual brown solid was purified by column chromatography on silica gel using diethylamine: ethyl acetate (5:95) as eluant, and repeated using methanol: ethyl acetate (5:95) as eluant. The product was triturated with ether to afford the title compound (7mg, 6%) as a white solid.

δ (CDCl_3) : 1.03 (3H, t), 1.25 (3H, d), 1.40 (3H, t), 1.48 (3H, d), 2.41 (2H, q), 2.55 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.52 (3H, s), 3.70 (1H, m), 4.09 (3H, s), 5.39 (1H, m), 8.60 (1H, s), 8.97 (1H, s). LRMS : m/z 534 ($\text{M}+1$)⁺

-74-

EXAMPLE 99

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(pyridin-2-yl)methoxypyridin-3-yl]-
 5 2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



A mixture of the title compound of Example 78 (100mg, 0.2mmol), potassium bis(trimethylsilyl)amide (210mg, 1.1mmol) in pyridine-2-methanol (1ml) was heated to 110°C for 18 hours. The cooled mixture was partitioned between ethyl acetate (10ml) and water (10ml), and the phases separated. The aqueous layer was extracted with ethyl acetate (2x5ml) and dichloromethane (10ml), the combined organic solutions dried (Na₂SO₄) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using methanol: ethyl acetate (10:90) as eluant, and triturated with ether, to afford the title compound (49mg, 43%) as a solid.

δ (CDCl₃) : 1.02 (3H, t), 1.40 (3H, t), 2.40 (2H, q), 2.55 (4H, m), 3.04 (2H, q),
 20 3.14 (4H, m), 4.10 (3H, s), 5.90 (2H, s), 7.32 (2H, m), 7.76 (1H, m), 8.58 (1H, s), 8.82 (2H, m), 12.72 (1H, s).


LRMS : m/z 539 (M+1)⁺.

-75-

EXAMPLE 100

5-[2-Cyclobutylmethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5



Obtained (69%) from the title compound of Example 78 and cyclobutanemethanol, following a procedure similar to that described in Example 99.

10 Found : C, 55.71; H, 6.44; N, 18.83. $C_{24}H_{33}N_7O_4S$ requires C, 55.90; H, 6.45; N, 19.01%.

δ ($CDCl_3$) : 1.03 (3H, t), 1.40 (3H, t), 1.98 (4H, m), 2.26 (2H, m), 2.42 (2H, q), 2.57 (4H, m), 3.02 (3H, m), 3.15 (4H, m), 4.10 (3H, s), 4.62 (2H, d), 8.62 (1H, s), 9.04 (1H, s), 10.61 (1H, s).

15 LRMS : m/z 516 ($M+1$)⁺


20

25

-76-

EXAMPLE 101

5-[2-n-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-3-n-
5 propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



10 A mixture of the title compound of Example 90 (104mg, 0.2mmol) and potassium bis(trimethylsilyl)amide (200mg, 1.0mmol) in n-butanol (5ml) was stirred under reflux for 5 days. The cooled mixture was concentrated under reduced pressure, the residue suspended in ethyl acetate (20ml) and the mixture neutralised using 1M hydrochloric acid. The layers were separated, the organic phase washed with brine (10ml), dried ($MgSO_4$) and evaporated under

15 reduced pressure. The crude product was triturated with ether, and the resulting solid, filtered and further purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (100:0:0.5 to 99:1:0.5) to afford the title compound, (86mg, 82%) as a solid.

20 δ ($CDCl_3$) : 1.02 (9H, m), 1.57 (2H, m), 1.82 (2H, m), 1.95 (2H, m), 2.42 (2H, q), 2.58 (4H, m), 2.99 (2H, t), 3.15 (4H, m), 4.08 (3H, s), 4.68 (2H, t), 8.62 (1H, s), 9.02 (1H, s), 10.62 (1H, s).

LRMS : m/z 518 ($M+1$)⁺

-77-

EXAMPLE 102


3-Ethyl-5-[2-(2-methoxy-1-methylethoxy)-5-(4-n-propylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 1)

5

and

EXAMPLE 103

3-Ethyl-5-[2-(2-methoxy-1-methylethoxy)-5-(4-n-propylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 2)



10 Potassium bis(trimethylsilyl)amide (325mg, 1.63mmol) was added to a solution of the title compound of Example 119 (200mg, 0.41mmol) in 1-methoxy-2-propanol (6ml) and the reaction stirred under reflux for 18 hours. The cooled mixture was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using dichloromethane: methanol (95:5) as eluant to give 193mg of a colourless oil. This product was further purified by HPLC using an AD250 column, using hexane:isopropanol:diethylamine (70:30:0.3) as eluant to afford, the title compound of Example 102 (58mg, 26%, 99.5%ee). δ (CDCl_3) : 0.86 (3H, t), 1.40 (5H, m), 1.50 (3H, d), 2.32 (2H, t), 2.56 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.55 (3H, s), 3.66 (1H, m), 3.76 (1H, m), 4.08 (3H, s), 5.61 (1H, m), 8.61 (1H, s), 8.92 (1H, s), 10.82 (1H, s).

15 LRMS : m/z 534 ($M+1$)⁺, and the title compound of Example 103 (47mg, 21%, 98.7%ee). δ (CDCl_3) : 0.86 (3H, t), 1.41 (5H, m), 1.50 (3H, d), 2.32 (2H, t), 2.56 (4H, m), 3.04 (2H, q), 3.14 (4H, m), 3.55 (3H, s), 3.66 (1H, m), 3.76 (1H, m), 4.08 (3H, s), 5.61 (1H, m), 8.60 (1H, s), 8.92 (1H, s), 10.82 (1H, s).

20 LRMS : m/z 534 ($M+1$)⁺

-78-

EXAMPLE 104

(+)-5-[2-(2-Methoxy-1-methylethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one


5 (isomer 1)

and

EXAMPLE 105

(-)-5-[2-(2-Methoxy-1-methylethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

10 (isomer 2)



The title compound of Example 79 (198mg, 0.42mmol) was added to a solution of potassium bis(trimethylsilyl)amide (415mg, 2.1mmol) in 1-methoxy-2-propanol (5ml), and the reaction heated at 110°C for 72 hours. The cooled 15 mixture was evaporated under reduced pressure, the residue dissolved in water and neutralised using 2M hydrochloric acid. This aqueous solution was extracted with ethyl acetate (3x30ml), the combined organic extracts washed with brine (3x20ml), dried (Na₂SO₄) and evaporated under reduced pressure. The residual yellow oil was purified by column chromatography on silica gel 20 using an elution gradient of dichloromethane: methanol (100:0 to 97:3), and evaporated from ether to give a white solid.

The racemic product was purified by chiral HPLC using an AD250 column, and hexane: isopropanol:trifluoroacetic acid (80:20:0.5) as eluant. The first enantiomer was redissolved in water, basified using aqueous sodium carbonate 25 solution, and this mixture extracted with ethyl acetate (3x20ml). The combined

-79-

5 organic extracts were washed with brine (2x20ml) dried (Na_2SO_4) and evaporated under reduced pressure. This product was then further purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 97:3), and evaporated from ether, to afford the title compound of Example 104 (39mg, 18%, 98.1%ee) as a colourless solid.

10

$[\alpha]_D = +30.31^\circ$ (c=0.067, dichloromethane)

Found : C, 53.32; H, 6.49; N, 18.48. $\text{C}_{23}\text{H}_{33}\text{N}_7\text{O}_5\text{S}$ requires C, 53.16; H, 6.40; N, 18.87%.

15 δ (CDCl_3) : 1.02 (3H, t), 1.50 (3H, d), 1.82 (2H, m), 2.28 (3H, s), 2.53 (4H, m),
2.98 (2H, t), 3.16 (4H, m), 3.55 (3H, s), 3.66 (1H, m), 3.76 (1H, m), 4.07 (3H, s),
5.61 (1H, m), 8.61 (1H, s), 8.92 (1H, s), 10.82 (1H, s);

LRMS : m/z 520 ($\text{M}+1$)⁺

20 The title compound of Example 105 was isolated using the same procedure as
for Example 104, (26mg, 12%, 94.0%ee).

$[\alpha]_D = -30.31^\circ$ (c=0.067, dichloromethane)

25 δ (CDCl_3) : 1.02 (3H, t), 1.51 (3H, d), 1.82 (2H, m), 2.29 (3H, s), 2.53 (4H, m),
2.98 (2H, t), 3.14 (4H, m), 3.55 (3H, s), 3.65 (1H, m), 3.77 (1H, m), 4.08 (3H, s),
5.61 (1H, m), 8.61 (1H, s), 8.92 (1H, s), 10.82 (1H, s).

LRMS : m/z 520 ($\text{M}+1$)⁺

30

-80-

EXAMPLE 106

(+)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyridin-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5


and

EXAMPLE 107

(-)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyridin-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

10

(isomers 1 and 2)



Potassium bis(trimethylsilyl)amide (1.47g, 7.4mmol) was added to a solution of the title compound of Example 80 (720mg, 1.5mmol) in 1-methoxy-2-propanol (10ml) and the reaction stirred under reflux for 72 hours. The cooled mixture 15 was evaporated under reduced pressure and the residual brown gum purified by column chromatography on silica gel, using ethyl acetate: diethylamine (97:3) as eluant. This racemic mixture was purified by chiral HPLC using an AD 250 column, and hexane: isopropanol: diethylamine (70:30:0.3) as eluant, to give each enantiomer. The first enantiomer was partitioned between 20 dichloromethane (20ml) and aqueous sodium carbonate solution (10ml), the phases separated, and the organic layer dried (Na_2SO_4), and evaporated under reduced pressure. The product was further purified by column chromatography on silica gel, using ethyl acetate: methanol (95:5) as eluant, to afford the title compound of Example 106 (130mg, 16%, 99.76%ee) as a white foam.

25 $[\alpha]_D = +15.65^\circ$ ($c=0.093$, methanol).

-81-

Found : C, 53.47; H, 6.66; N, 17.92. $C_{24}H_{35}N_7O_5S \cdot 0.3H_2O$ requires C, 53.48; H, 6.66; N, 18.19%

δ ($CDCl_3$) : 1.02 (6H, m), 1.52 (3H, t), 1.82 (2H, m), 2.42 (2H, q), 2.57 (4H, m), 2.98 (2H, t), 3.14 (4H, m), 3.55 (3H, s), 3.65 (1H, m), 3.76 (1H, m), 4.08 (3H, s), 5.60 (1H, s), 8.61 (1H, s), 8.90 (1H, s), 10.81 (1H, s).

LRMS : m/z 534 ($M+1$)⁺

The title compound of Example 107 was obtained (94mg, 12%, 97.2%ee) as a white foam, using the same procedure as in Example 106.

10 [α]_D = -14.52° (c=0.10, methanol)

Found : C, 53.66; H, 6.73; N, 17.89. $C_{24}H_{35}N_7O_5S \cdot 0.25H_2O$ requires C, 53.57; H, 6.65; N, 18.22%

δ ($CDCl_3$) : 1.03 (6H, m), 1.50 (3H, d), 1.82 (2H, m), 2.42 (2H, q), 2.57 (4H, m), 2.98 (2H, m), 3.17 (4H, m), 3.55 (3H, s), 3.65 (1H, m), 3.75 (1H, m), 4.08 (3H, s), 5.60 (1H, m), 8.60 (1H, s), 8.91 (1H, s), 10.81 (1H, s).

LRMS : m/z 534 ($M+1$)⁺

EXAMPLE 108


20 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-n-propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 1)
and

EXAMPLE 109

3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-n-propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 2)

25

-82-



The title compounds were prepared from the title compound of Example 78, and 2-methoxy-1-propanol following a similar procedure to that described for Examples 104 and 105.

The racemate was further purified by HPLC using an AD250 column and hexane: ethanol:diethylamine (60:40:1) as eluant, to give isomer 1. This product was re-purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 97:3) and triturated with ether to afford the title compound of Example 108 (8mg, 2%, 82%ee) as a white solid.

δ (CDCl₃) : 1.19-1.36 (6H, m), 1.40 (3H, t), 2.68-3.10 (8H, m), 3.32-3.59 (7H, m), 3.92 (1H, m), 4.09 (3H, s), 4.47 (1H, m), 4.72 (1H, m), 8.62 (1H, s), 8.97 (1H, s), 10.90 (1H, s).

LRMS : m/z 520 (M+1)⁺

The title compound of Example 109 was isolated (5mg, 1%, 93%ee) as a white solid, using the same procedure as described for Example 108.

δ (CDCl₃) : 1.26 (3H, t), 1.32 (3H, d), 1.40 (3H, t), 2.80-3.10 (8H, m), 3.38-3.60 (7H, m), 3.92 (1H, m), 4.09 (3H, s), 4.48 (1H, m), 4.72 (1H, m), 8.61 (1H, s), 8.98 (1H, s), 10.89 (1H, s).

LRMS : m/z 520 (M+1)⁺

-83-


EXAMPLE 110

5 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxy-1-methyl-n-
propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
 and

EXAMPLE 111

10 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxy-1-methyl-n-
propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

(isomers 1 and 2)



15 A mixture of the title compound of Example 78 (330mg, 0.70mmol) and potassium bis(trimethylsilyl)amide (693mg, 3.47mmol) in the title compound of preparation 166 (2.5ml) was heated at 110°C for 16 hours. The cooled reaction was suspended in ethyl acetate (25ml), and washed with saturated ammonium chloride solution (5ml), then saturated sodium bicarbonate solution (10ml), dried ($MgSO_4$) and evaporated under reduced pressure. The residue was 20 purified by column chromatography on silica gel using methanol: dichloromethane (5:95) as eluant, and repeated using diethylamine: ethyl acetate (10:90) as eluant to give a gum.

This racemate was purified by HPLC using an AD250 column, and hexane: ethanol:diethylamine (85:15:1) as eluant to afford the title compound of 25 Example 110 (25mg, 6.7%, 98.9%ee)

-84-

5 δ (CDCl₃) : 1.04 (3H, t), 1.39 (3H, t), 1.49 (3H, d), 2.04 (1H, m), 2.24 (1H, m),
 2.42 (2H, q), 2.56 (4H, m), 3.01 (2H, m), 3.16 (4H, m), 3.33 (3H, s), 3.57 (1H, m), 3.68 (1H, m), 4.06 (3H, s), 5.75 (1H, m), 8.61 (1H, s), 8.88 (1H, s), 10.98 (1H, s).

LRMS : m/z 534 (M+1)⁺

and the title compound of Example 111 (29mg, 7.8%, 99.7%ee).

10 δ (CDCl₃) : 1.03 (3H, t), 1.40 (3H, t), 1.48 (3H, d), 2.04 (1H, m), 2.24 (1H, m),
 2.42 (2H, q), 2.58 (4H, m), 3.02 (2H, q), 3.16 (4H, m), 3.34 (3H, s), 3.57 (1H, m), 3.66 (1H, m), 4.08 (3H, s), 5.74 (1H, m), 8.60 (1H, s), 8.98 (1H, s), 10.98 (1H, s).

LRMS : m/z 534 (M+1)⁺

15

EXAMPLE 112


(+)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-ethoxy-1-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 1)

and

20

EXAMPLE 113

(-)-3-Ethyl-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-ethoxy-1-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 2)



25

-85-

The racemate was prepared (70%) from the title compound of Example 78 and 1-ethoxy-2-propanol, following the procedure described for Examples 104 and 105.

5

This racemate was purified by chiral HPLC using an AD 250 column, and hexane: isopropanol:diethylamine (70:30:0.3) as eluant, to give enantiomer 1. This product was further purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as eluant, and evaporated from ether, to afford the title compound of Example 112 (52mg, 15%, 99.5%ee) as a foam.

$[\alpha]_D = +18.60^\circ$ (c=0.067, dichloromethane)

Found : C, 53.20; H, 6.70; N, 17.78. $C_{24}H_{35}N_7O_5S \cdot 0.5H_2O$ requires C, 53.12; H, 6.69; N, 18.07%

15 δ ($CDCl_3$) : 1.04 (3H, t), 1.25 (3H, t), 1.40 (3H, t), 1.52 (3H, d), 2.42 (2H, q), 2.57 (4H, m), 3.02 (2H, q), 3.15 (4H, m), 3.60-3.82 (4H, m), 4.08 (3H, s), 5.60 (1H, m), 8.61 (1H, s), 8.94 (1H, s), 10.81 (1H, s).

LRMS : m/z 534 (M+1)⁺

20 The title compound of Example 113 was isolated (11mg, 3%, 99.5%ee) following the same procedure to that described for Example 112.

$[\alpha]_D = -19.43^\circ$ (c=0.070, dichloromethane)

Found : C, 53.34; H, 6.66; N, 17.86. $C_{24}H_{35}N_7O_5S \cdot 0.5H_2O$ requires C, 53.12; H, 6.69; N, 18.07%

25 δ ($CDCl_3$) : 1.04 (3H, t), 1.25 (3H, t), 1.40 (3H, t), 1.52 (3H, d), 2.42 (2H, q), 2.57 (4H, m), 3.03 (2H, q), 3.16 (4H, m), 3.60-3.82 (4H, m), 4.09 (3H, s), 5.60 (1H, m), 8.62 (1H, s), 8.92 (1H, s), 10.82 (1H, s).

LRMS : m/z 534 (M+1)⁺

-86-


EXAMPLE 114

(+)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methoxymethyl-n-propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

and

EXAMPLE 115

(-)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methoxymethyl-n-propoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

(isomers 1 and 2)

10

The title compounds of Examples 114 and 115 were obtained (11%, 93%ee) and (6.7%, 97%ee) respectively from the title compound of Example 78 and 1-methoxy-2-butanol, using the procedure described in Examples 108 and 109.

$[\alpha]_D = +37.04^\circ$ ($c=0.097$, dichloromethane)

15 Found : C, 53.36; H, 6.73; N, 17.84. $C_{24}H_{35}N_7O_5S;0.5H_2O$ requires C, 53.12; H, 6.69; N, 18.07%

δ ($CDCl_3$) : 1.03 (6H, m), 1.39 (3H, t), 1.92 (2H, m), 2.42 (2H, q), 2.57 (4H, m), 3.02 (2H, q), 3.16 (4H, m), 3.51 (3H, s), 3.66 (1H, m), 3.77 (1H, m), 4.08 (3H, s), 5.57 (1H, m), 8.60 (1H, s), 8.88 (1H, s), 10.84 (1H, s).

20 LRMS : m/z 534 ($M+1$) $^+$; and $\alpha_D = -40.08^\circ$ ($c=0.093$, dichloromethane)

Found : C, 53.44; H, 6.75; N, 17.76. $C_{24}H_{35}N_7O_5S;0.5H_2O$ requires C, 53.12; H, 6.69; N, 18.07%

δ ($CDCl_3$) : 1.03 (6H, m), 1.40 (3H, t), 1.92 (2H, m), 2.42 (2H, q), 2.57 (4H, m), 3.02 (2H, q), 3.16 (4H, m), 3.51 (3H, s), 3.68 (1H, m), 3.78 (1H, m), 4.10 (3H,

25 s), 5.57 (1H, m), 8.61 (1H, m), 8.89 (1H, s), 10.83 (1H, s).

-87-

EXAMPLE 116



(-)-3-Ethyl-5-{5-(4-ethylpiperazin-1-ylsulphonyl)-2-[1-(pyridin-2-yl)ethoxy]pyridin-3-yl}-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 1)

5

and

EXAMPLE 117

(+)-3-Ethyl-5-{5-(4-ethylpiperazin-1-ylsulphonyl)-2-[1-(pyridin-2-yl)ethoxy]pyridin-3-yl}-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 2)



10

The title compounds of Example 116 and 117 were obtained as solids, (4%, 99.0%ee) and (2%, 99.0%ee) respectively, from the title compound of Example 78 and 1-(pyridin-2-yl) ethanol (Helv.Chim.Acta., 1955, 38, 1114), following a similar procedure to that described for Examples 112 and 113, except that hexane: isopropanol: diethylamine (70:30:1) was used as the HPLC eluant.

15 [α]_D = -90.11° (c=0.033, dichloromethane)

δ (CDCl₃) : 1.02 (3H, t), 1.40 (3H, t), 1.80 (3H, d), 2.41 (2H, q), 2.54 (4H, m), 3.00-3.17 (6H, m), 4.10 (3H, s), 6.69 (1H, q), 7.32 (2H, m), 7.75 (1H, m), 8.54 (1H, s), 8.75 (1H, s), 8.80 (1H, d), 13.14 (1H, s).

20 LRMS : m/z 553 (M+1)⁺

[α]_D = +82.02° (c=0.040, dichloromethane)


δ (CDCl₃) : 1.04 (3H, t), 1.40 (3H, m), 1.80 (3H, d), 2.41 (2H, q), 2.55 (4H, m), 3.00-3.18 (6H, m), 4.10 (3H, s), 6.69 (1H, q), 7.34 (2H, m), 7.75 (1H, m), 8.52 (1H, s), 8.76 (1H, s), 8.80 (1H, d), 13.16 (1H, s).

25 LRMS : m/z 553 (M+1)⁺

-88-

EXAMPLE 118

5 (+)-3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methyl
ethoxy) pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



A mixture of the title compound of example 78 (2.0g, 4.2mmol) and potassium bis(trimethylsilyl)amide (4.2g, 21.0mmol) in the title compound of Preparation 10 165 (16ml), was heated at 110°C for 18 hours. The cooled mixture was concentrated under reduced pressure and the residue purified by column chromatography on silica gel using an elution gradient of diethylamine: methanol:ethyl acetate (2.5:0:97.5 to 0:10:90). The product was purified further by column chromatography on silica gel using methanol: ethyl acetate (2.5:97.5) as eluant to afford the title compound (640mg, 29%) as a solid.

15 Found : C, 53.16; H, 6.54; N, 18.37. $C_{23}H_{33}N_7O_5S;0.2CH_3CO_2C_2H_5$ requires C, 53.21; H, 6.49; N, 18.25%

$[\alpha]_D = +16.6^\circ$ (c=0.10 methanol)


20 δ ($CDCl_3$) : 1.04 (3H, t), 1.40 (3H, t), 1.52 (3H, d), 2.42 (2H, q), 2.57 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.56 (3H, s), 3.66 (1H, m), 3.77 (1H, m), 4.09 (3H, s), 5.61 (1H, m), 8.62 (1H, s), 8.93 (1H, s), 10.82 (1H, s).

LRMS : m/z 520 ($M+1$)⁺

-89-

EXAMPLE 119

5-[2-Ethoxy-5-(4-n-propylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



5


1-n-Propylpiperazine (308mg, 1.01mmol) and triethylamine (440ml, 3.2mmol) were added to a solution of the title compound of Preparation 164 (211mg, 0.53mmol) in dichloromethane (6ml), and the reaction mixture stirred at room temperature for 2 hours. The mixture was purified directly by column chromatography on silica gel, using dichloromethane: methanol (95:5) as eluant to afford the title compound (210mg, 85%) as a white foam.

10 δ (CDCl₃) : 0.86 (3H, t), 1.42 (5H, m), 1.58 (3H, t), 2.29 (2H, t), 2.56 (4H, m), 3.03 (2H, q), 3.14 (4H, m), 4.10 (3H, s), 4.76 (2H, q), 8.62 (1H, s), 9.04 (1H, s), 10.67 (1H, s). LRMS : m/z 490 (M+1)⁺

15

EXAMPLE 120

5-[2-Ethoxy-5-[4-(prop-2-yl)piperazin-1-ylsulphonyl]pyridin-3-yl]-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



-90-

Obtained as a white solid (71%), from the title compound of Preparation 164 and 1-(prop-2-yl)-piperazine, following the procedure described in Example 119.

δ (CDCl_3) : 0.99 (6H, d), 1.40 (3H, t), 1.57 (3H, t), 2.62 (4H, m), 2.70 (1H, m), 3.02 (2H, q), 3.13 (4H, m), 4.08 (3H, s), 4.74 (2H, q), 8.62 (1H, s), 9.03 (1H, s), 10.64 (1H, s).


LRMS : m/z 490 ($M+1$)⁺

10

EXAMPLE 121

5-{2-Ethoxy-5-[4-(pyridin-2-yl)piperazin-1-ylsulphonyl]pyridin-3-yl}-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15



Obtained as a white solid (58%), from the title compound of Preparation 164 and 1-(pyridin-2-yl)piperazine, following the procedure described in Example 119.

δ (CDCl_3) : 1.41 (3H, t), 1.59 (3H, t), 3.05 (2H, q), 3.22 (4H, m), 3.70 (4H, m), 4.10 (3H, s), 4.75 (2H, q), 6.62 (2H, m), 7.47 (1H, m), 8.16 (1H, d), 8.64 (1H, s), 9.07 (1H, s), 10.65 (1H, s).

LRMS : m/z 525 ($M+1$)⁺


25

-91-

EXAMPLE 122

3-Ethyl-5-{2-(2-methoxy-1-methylethoxy)-5-[4-(pyridin-2-yl)piperazin-1-ylsulphonyl]pyridin-3-yl}-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5



Potassium bis(trimethylsilyl)amide (76mg, 0.38mmol) was added to a solution
 10 of the title compound of Example 121 (50mg, 0.095mmol) in 1-methoxy-2-
 propanol (5ml) and the reaction heated under reflux for 18 hours. The cooled
 mixture was purified directly by column chromatography on silica gel, using
 dichloromethane: methanol (95:5) as eluant to afford the title compound (32mg,
 59%) as a yellow oil.

15

δ (CDCl₃) : 1.40 (3H, t), 1.50 (3H, d), 3.04 (2H, q), 3.22 (4H, m), 3.54 (3H, s),
 3.69 (6H, m), 4.09 (3H, s), 5.60 (1H, m), 6.63 (2H, m), 7.47 (1H, m), 8.16 (1H,
 d), 8.63 (1H, s), 8.94 (1H, s), 10.81 (1H, s).

LRMS : m/z 569 (M+1)⁺


20

25

-92-

EXAMPLE 1235-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1-methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5



A mixture of the title compound of Preparation 158 (596mg, 1.21mmol) and potassium bis(trimethylsilyl)amide (723mg, 3.62mmol) in ethanol (20ml) was heated at 120°C for 18 hours in a sealed vessel. The cooled mixture was 10 evaporated under reduced pressure and the residue purified by column chromatography on silica gel twice, using dichloromethane: methanol (95:5) as eluant. The product was triturated with ether to afford the title compound (358mg, 62%) as an off-white solid.

Found : C, 52.71; H, 6.00; N, 20.48. $C_{21}H_{29}N_7O_4S$ requires C, 53.04; H, 6.15; N, 15 20.62%

δ (CDCl₃) : 1.04 (3H, t), 1.40 (3H, t), 1.60 (3H, t), 2.42 (2H q), 2.58 (4H, m), 2.99 (2H, q), 3.16 (4H, m), 4.28 (3H, s), 4.78 (2H, q), 8.64 (1H, s), 9.08 (1H, s), 10.80 (1H, s).

LRMS : 476 (M+1)⁺


20

25

-93-

EXAMPLE 124

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



5


Obtained (42%) from the title compound of Preparation 159, following a similar procedure to that described in Example 123.

Found : C, 53.68; H, 6.34; N, 19.97. C₂₂H₃₁N₇O₄S requires C, 53.97; H, 6.38; N, 20.03%

10 δ (CDCl₃) : 1.02 (6H, m), 1.60 (3H, t), 1.85 (2H, m), 2.42 (2H, q), 2.58 (4H, m), 2.95 (2H, t), 3.16 (4H, m), 4.29 (3H, s), 4.78 (2H, q), 8.63 (1H, s), 9.08 (1H, s), 10.78 (1H, s). LRMS : m/z 491 (M+1)⁺

EXAMPLE 125

15 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-1-methyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one




A mixture of the title compound of Example 123 (70mg, 0.15mmol) and potassium bis(trimethylsilyl)amide (150mg, 0.74mmol) in the title compound of 5 Preparation 165 (1ml), was stirred at 110°C for 18 hours. The cooled mixture was concentrated under reduced pressure and the residue partitioned between water (5ml) and dichloromethane (5ml), and the mixture neutralised by the addition of solid carbon dioxide. The layers were separated, the aqueous phase extracted with dichloromethane (2x5ml), the combined organic solutions dried 10 (Na₂SO₄), and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel, using ethyl acetate: diethylamine (97:3) as eluant to afford the title compound (62mg, 80%).

δ (CDCl₃) : 1.04 (3H, t), 1.39 (3H, t), 1.50 (3H, d), 2.42 (2H, q), 2.58 (4H, m), 15 2.98 (2H, q), 3.15 (4H, m), 3.58 (3H, s), 3.70 (2H, m), 4.28 (3H, s), 5.58 (1H, m), 8.62 (1H, s), 8.90 (1H, s), 11.07 (1H, s).
LRMS : m/z 520 (M+1)⁺

EXAMPLE 126

20 5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



A mixture of the title compound of Example 124 (111mg, 0.23mmol) and 25 potassium bis(trimethylsilyl)amide (226mg, 1.13mmol) in 2-methoxyethanol (5ml) was stirred under reflux for 18 hours. The cooled mixture was evaporated

-95-

under reduced pressure and the residue purified by column chromatography on silica gel, using dichloromethane: methanol (96:4) as eluant, and triturated with ether to afford the title compound (75mg, 64%) as a white crystalline solid.


5 Found : C, 52.87; H, 6.35; N, 18.68. $C_{23}H_{33}N_7O_5S$ requires C, 53.16; H, 6.40; N, 18.87%.

10 δ (CDCl₃) : 1.02 (6H, m), 1.85 (2H, m), 2.42 (2H, q), 2.57 (4H, m), 2.94 (2H, t), 3.16 (4H, m), 3.60 (3H, s), 3.86 (2H, t), 4.27 (3H, s), 4.78 (2H, t), 8.62 (1H, s), 9.00 (1H, s), 10.51 (1H, s).

15 LRMS : m/z 521 (M+2)⁺

EXAMPLE 127

5-{5-(4-Ethylpiperazin-1-ylsulphonyl)-2-[(pyridin-2-yl)methoxy]pyridin-3-yl}-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



15

A mixture of the title compound of Example 124 (100mg, 0.20mmol) and potassium bis(trimethylsilyl)amide (204mg, 1.02mmol) in pyridine-2-methanol (2ml) was stirred at 110°C for 18 hours, then cooled. The solvent was removed by Kugelrohr distillation, and the residue was purified by column chromatography on silica gel, using dichloromethane: methanol (95:5) as eluant. This product was triturated with ether to afford the title compound (8mg, 7%) as a solid.

20 δ (CDCl₃) : 1.03 (6H, m), 1.87 (2H, m), 2.42 (2H, q), 2.56 (4H, m), 2.95 (2H, t), 3.16 (4H, m), 4.30 (3H, s), 5.94 (2H, s), 7.36 (2H, m), 7.68 (1H, m), 8.60 (1H, s), 8.86 (2H, d), 13.34 (1H, s).

25 LRMS : m/z 554 (M+1)⁺

-96-

EXAMPLE 128

(+)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyridin-3-yl]-1-methyl 3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one


5

and

EXAMPLE 129

(-)-5-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyridin-3-yl]-1-methyl 3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

(isomer 1 and isomer 2)



10

The title compounds of Examples 128 and 129 were prepared from Example 124 (17%, 99.5%ee) and (15%, 98.6%ee) respectively, following a procedure similar to that described in Examples 106 and 107, except that hexane :isopropanol : diethylamine :trifluoroacetic acid (85:15:0.2:0.3) was used as the

15 HPLC eluant. $[\alpha]_D = +31.21^\circ$ ($c=0.067$ dichloromethane)

Found : C, 53.77; H, 6.71; N, 17.89. $C_{24}H_{35}N_7O_5S; 0.5H_2O$ requires C, 53.12; H, 6.69; N, 18.07%

δ ($CDCl_3$) : 1.02 (6H, m), 1.50 (3H, d), 1.84 (2H, m), 2.42 (2H, q), 2.58 (4H, m), 2.94 (2H, t), 3.17 (4H, m), 3.58 (3H, s), 3.72 (2H, m), 4.28 (3H, s), 5.58 (1H, m), 8.62 (1H, s), 8.90 (1H, s), 11.08 (1H, s); and

$[\alpha]_D = -34.10^\circ$ ($c=0.072$ dichloromethane)


Found : C, 53.75; H, 6.67; N, 18.04. $C_{24}H_{35}N_7O_5S$ requires C, 54.02; H, 6.61; N, 18.37%

δ ($CDCl_3$) : 1.02 (6H, m), 1.50 (3H, d), 1.84 (2H, m), 2.42 (2H, q), 2.58 (4H, m), 2.94 (2H, t), 3.15 (4H, m), 3.59 (3H, s), 3.70 (2H, m), 4.28 (3H, s), 5.59 (1H, m), 8.62 (1H, s), 8.92 (1H, s), 11.17 (1H, s), respectively.

-97-

EXAMPLE 130

5-[5-(4-Ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-
5
2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



A mixture of the title compound of Example 93 (130mg, 0.25mmol) and 3-chloroperbenzoic acid (95mg, 0.275mmol) in dichloromethane (6ml) was stirred
10 at room temperature for 2 1/2 hours. The reaction mixture was washed with aqueous sodium bicarbonate solution (5ml), dried ($MgSO_4$), and evaporated under reduced pressure. The residual foam was purified by column chromatography on silica gel, using an elution gradient of dichloromethane:methanol:0.88 ammonia (93:7:0 to 93:7:1) to afford the title
15 compound (110mg, 82%) as a white solid.

Found : C, 50.71; H, 6.27; N, 17.82. $C_{23}H_{33}N_7O_6S$ requires C, 50.72; H, 6.30; N, 18.00%


δ ($CDCl_3$) : 1.00 (3H, t), 1.40 (3H, t), 1.81 (2H, m), 2.98 (2H, t), 3.19 (2H, m),
20 3.33 (4H, m), 3.54 (5H, m), 3.70 (2H, m), 3.86 (2H, t), 4.06 (3H, s), 4.78 (2H, t),
8.63 (1H, s), 8.97 (1H, s), 10.87 (1H, s).

LRMS : m/z 536 ($M+1$)⁺

-98-

EXAMPLE 131

5-[2-Ethoxy-5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)pyridin-3-yl]-2-methyl-3-n-propyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one




5

Obtained as a white foam (81%), from the title compound of Example 80 following the procedure described in Example 130.

δ (CDCl₃) : 1.00 (3H, t), 1.40 (2H, t), 1.38 (3H, t), 1.81 (2H, m), 2.97 (2H, t), 3.16 (2H, m), 3.30 (4H, m), 3.50 (2H, m), 3.70 (2H, m), 4.08 (3H, s), 4.74 (2H, q),
10 8.64 (1H, s), 9.00 (1H, s), 10.75 (1H, s). LRMS : m/z 506 (M+1)⁺

EXAMPLE 132

3-Ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methyl ethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



15

3-Chloroperbenzoic acid (95mg, 0.28mmol) was added to a solution of the title compound of Example 118 (130mg, 0.25mmol) in dichloromethane (2ml), and the reaction stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and the residue was purified by column

-99-

chromatography on silica gel, using an elution gradient of dichloromethane:methanol:0.88 ammonia (95:5:0 to 90:10:1) to afford the title compound (130mg, 87%).


δ (CDCl₃) : 1.40 (6H, m), 1.52 (3H, d), 3.01 (2H, q), 3.22 (2H, m), 3.34 (4H, m), 3.54 (5H, m), 3.73 (4H, m), 4.08 (3H, s), 5.62 (1H, m), 8.64 (1H, s), 8.94 (1H, s). LRMS : m/z 536 (M+1)⁺

10

EXAMPLE 133

5-[5-(4-Ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(methoxyethoxy)pyridin-3-yl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15




Obtained as a white solid (51%) from the title compound of Example 126, using a similar procedure to that described in Example 130.

20

δ (CDCl₃) : 1.02 (3H, t), 1.41 (3H, t), 1.84 (2H, q), 2.92 (2H, t), 3.32 (2H, d), 3.36 (4H, m), 3.46-3.60 (5H, m), 3.74 (2H, m), 3.86 (2H, t), 4.29 (3H, s), 4.78 (2H, t), 8.64 (1H, s), 9.01 (1H, s), 11.05 (1H, s). LRMS : m/z 535 (M)⁺

25

-100-


EXAMPLE 1342,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5

A mixture of the title compound of Example 81 (200mg, 0.41mmol), and potassium bis(trimethylsilyl)amide (407mg, 2.04mmol) in n-propanol (5ml) was stirred at 110°C for 18 hours and the cooled reaction, evaporated under reduced pressure. The residue was purified by column chromatography on 10 silica gel, using an elution gradient of ethyl acetate: diethylamine (100:0 to 95:5) and triturated with ether to afford the title compound (160mg, 68%) as a solid. (CDCl₃) : 1.02 (3H, t), 1.10 (3H, t), 1.42 (3H, t), 1.59 (3H, t), 2.00 (4H, m), 2.42 (2H, q), 2.58 (4H, m), 3.02 (2H, q), 3.14 (4H, m), 4.38 (2H, q), 4.63 (2H, t), 8.63 (1H, s), 9.04 (1H, s).

15 LRMS : m/z 504 (M+1)⁺

-101-

EXAMPLE 1355-[2-i-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2,3-diethyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5

Obtained as a solid (65%) from the title compound of Example 81 and i-butanol, using the procedure described in Example 134.


δ (CDCl₃) : 1.02 (3H, t), 1.15 (6H, d), 1.42 (3H, t), 1.58 (3H, t), 2.30 (1H, m), 2.42 (2H, q), 2.57 (4H, m), 3.06 (2H, q), 3.16 (4H, m), 4.38 (2H, q), 4.45 (2H, d),

10 8.62 (1H, s), 9.03 (1H, s).

LRMS : m/z 518 (M+1)⁺

EXAMPLE 1362,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

15



Obtained as a solid (33%) from the title compound of Example 81 and 2-methoxyethanol, using the procedure described in Example 134.

-102-

Found : C, 53.29; H, 6.20; N, 18.19. $C_{23}H_{33}N_7O_5S$ requires C, 53.16; H, 6.40; N, 18.87%


5 δ ($CDCl_3$) : 1.02 (3H, t), 1.42 (3H, t), 1.59 (3H, t), 2.44 (2H, q), 2.57 (4H, m), 3.05 (2H, q), 3.16 (4H, m), 3.58 (3H, s), 3.86 (2H, t), 4.28 (2H, q), 4.79 (2H, t), 8.62 (1H, s), 8.99 (1H, s).

LRMS : m/z 520 ($M+1$)⁺

10

EXAMPLE 137

2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-hydroxy-n-propoxy)pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



15 A mixture of the title compound of Example 81 (200mg, 0.41mmol) and potassium bis(trimethylsilyl)amide (407mg, 2.04mmol) in 1,3-propanediol (3ml) was stirred at 110°C for 18 hours, then cooled and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of ethyl acetate: diethylamine (100:0 to 95:5). The 20 product was partitioned between water (5ml) and dichloromethane (10ml), and the phases separated. The organic layer was washed with water (2x5ml), dried ($MgSO_4$), evaporated under reduced pressure and triturated with ether, to afford the title compound (90mg, 42%) as a solid.

25 δ ($CDCl_3$) : 1.02 (3H, t), 1.40 (3H, t), 1.57 (3H, t), 2.16 (2H, m), 2.42 (2H, q), 2.55 (4H, m), 3.02 (2H, q), 3.15 (4H, m), 4.00 (2H, t), 4.37 (2H, q), 4.80 (2H, t), 8.62 (1H, s), 8.96 (1H, s). LRMS : m/z 520 ($M+1$)⁺

-103-

EXAMPLE 138



2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methyl-n-propoxy)pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 1)

5

and

EXAMPLE 139

2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methyl-n-propoxy)pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 2)



10 A mixture of the title compound of Example 81 (500mg, 1.02mmol) and potassium bis(trimethylsilyl)amide (1.01g, 5.11mmol) in 1-methyl-n-propanol (5ml) was stirred at 110°C for 18 hours, then cooled and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of ethyl acetate: diethylamine (100:0 to 95:5)

15 and triturated with ether to give a solid. This racemate was further purified by chiral HPLC using an AD 250 column using hexane: isopropanol:diethylamine (90:10:1) as eluant, to afford the title compound of Example 138 (40mg, 8%, 95%ee) as a solid.

Found : C, 54.41; H, 6.71; N, 18.17; C₂₄H₃₅N₇O₄S;0.2CH₂Cl₂ requires C, 54.37; H, 6.67; N, 18.34%

δ (CDCl₃) : 1.04 (6H, m), 1.41 (3H, t), 1.50 (3H, d), 1.58 (3H, t), 1.86 (1H, m), 1.98 (1H, m), 2.41 (2H, q), 2.58 (4H, m), 3.02 (2H, q), 3.15 (4H, m), 4.38 (2H, q), 5.55 (1H, m), 8.61 (1H, s), 9.02 (1H, s), 10.66 (1H, s);

25 and the title compound of Example 139 (70mg, 13%, 86%ee) as a solid.

-104-

Found : C, 55.91; H, 7.11; N, 18.55 C₂₄H₃₅N₇O₄S. requires C, 55.69; H, 6.82; N, 18.95%.


δ (CDCl₃) : 1.05 (6H, m), 1.40 (3H, t), 1.50 (3H, d), 1.57 (3H, t), 1.84 (1H, m),
 5 1.98 (1H, m), 2.42 (2H, q), 2.58 (4H, m), 3.04 (2H, q), 3.15 (4H, m), 4.38 (2H, q), 5.54 (1H, m), 8.61 (1H, s), 9.03 (1H, s), 10.67 (1H, s).

EXAMPLE 140

10 2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 1)
 and

EXAMPLE 141

15 2,3-Diethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1-methylethoxy)pyridin-3-yl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 2)



Obtained as solids (10%, 99.5%ee) and (10%, 99.1%ee) respectively, from the
 20 title compound of Example 81 and 1-methoxy-2-propanol (5ml), following a similar procedure to that described above, except, that hexane: isopropanol: diethylamine (70:30:1) was used as the HPLC eluant.

δ (CDCl₃) : 1.03 (3H, t), 1.40 (3H, t), 1.50 (3H, d), 1.58 (3H, t), 2.42 (2H, q), 2.58 (4H, m), 3.03 (2H, q), 3.15 (4H, m), 3.55 (3H, s), 3.64 (1H, m), 3.76 (1H, m),
 25 4.37 (2H, q), 5.60 (1H, m), 8.60 (1H, s), 8.90 (1H, s).

LRMS : m/z 535 (M+2)⁺

-105-


Found : C, 54.09; H, 6.91; N, 17.03. $C_{24}H_{35}N_7O_5S$ requires C, 54.02; H, 6.61; N, 18.38%

5 δ (CDCl₃) : 1.04 (3H, t), 1.40 (3H, t), 1.50 (3H, d), 1.58 (3H, t), 2.42 (2H, q), 2.58 (4H, m), 3.02 (2H, q), 3.12 (4H, m), 3.56 (4H, m), 3.65 (1H, m), 3.74 (1H, m), 4.37 (2H, q), 5.60 (1H, m), 8.60 (1H, s), 8.90 (1H, s).

LRMS : m/z 535 (M+2)⁺, respectively.

EXAMPLE 142

10 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(6-methyl-pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



15 A mixture of the title compound of Example 82 (100mg, 0.176mmol), and potassium bis(trimethylsilyl)amide (175mg, 0.88mmol) in 2-methoxyethanol (1ml) was heated under reflux for 18 hours, then cooled. The solution was concentrated under reduced pressure and the residue partitioned between water (5ml) and dichloromethane (10ml), and the mixture neutralised using (2N) 20 hydrochloric acid. The phases were separated, the aqueous layer extracted with dichloromethane (10ml), and the combined organic solutions dried (MgSO₄), and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel, using dichloromethane:methanol:0.88 ammonia (96:4:0.4) as eluant, and triturated 25 with pentane, to afford the title compound (27mg, 26%) as an off-white solid.


-106-

Found : C, 56.14; H, 6.09; N, 18.53. $C_{28}H_{36}N_6O_5S$ requires C, 56.36; H, 6.08; N, 18.78%

δ (CDCl₃) : 1.02 (3H, t), 1.30 (3H, t), 2.42 (2H, q), 2.57 (7H, m), 3.04 (2H, q), 3.16 (4H, m), 3.58 (3H, s), 3.86 (2H, t), 4.79 (2H, t), 5.63 (2H, s), 6.78 (1H, d), 7.08 (1H, d), 7.48 (1H, m), 8.61 (1H, s), 8.98 (1H, s), 10.82 (1H, s).

EXAMPLE 143

10 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-(6-methylpyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



15 Obtained as a white solid (12%) from the title compounds of Examples 82 and 165, using a similar procedure to that described in Example 142, except the product was additionally purified by column chromatography on silica gel, using an elution gradient of ethyl acetate:methanol:0.88 ammonia (100:0:0 to 90:10:1), and then triturated with pentane.

20 δ (CDCl₃) : 1.03 (3H, t), 1.30 (3H, t), 1.50 (3H, d), 2.42 (2H, q), 2.55 (6H, m), 3.02 (2H, q), 3.15 (4H, m), 3.56 (4H, m), 3.66 (1H, m), 3.76 (1H, m), 5.62 (3H, m), 6.78 (1H, d), 7.06 (1H, d), 7.49 (1H, m), 8.61 (1H, s), 8.90 (1H, s), 10.84 (1H, s).


LRMS : m/z 611 (M+1)⁺

EXAMPLE 144

5 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (isomer 1)
and

EXAMPLE 145

10 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one(isomer2)



A mixture of the title compound of Example 84 (200mg, 0.35mmol) and potassium bis(trimethylsilyl)amide (350mg, 1.76mmol) in 2-methoxyethanol (5ml) was stirred at 120°C for 18 hours. The cooled mixture was concentrated under reduced pressure and the residue partitioned between aqueous saturated sodium bicarbonate solution (20ml) and ethyl acetate (20ml). The phases were separated, the aqueous layer extracted with ethyl acetate (2x10ml), and the combined organic solutions dried (MgSO_4), and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5) to give a foam. This racemate was further purified by HPLC using an AD 250 column and hexane: isopropanol:diethylamine (50:50:1) as eluant to afford the title compound of Example 144 (24mg, 11%, 100.0%ee)

-108-

δ (CDCl₃) : 1.02 (3H, t), 1.25 (3H, t), 2.10 (3H, q), 2.40 (2H, q), 2.56 (4H, m), 3.00 (2H, q), 3.13 (4H, m), 3.58 (3H, s), 3.86 (2H, t), 4.77 (2H, t), 5.83 (1H, q), 7.18 (2H, m), 7.60 (1H, m), 8.55 (1H, d), 8.60 (1H, s), 8.96 (1H, s), 10.82 (1H, s).

5 LRMS : m/z 598 (M+1)⁺


and the title compound of Example 145 (28mg, 13%, 99.8%ee).

δ (CDCl₃) : 1.00 (3H, t), 1.24 (3H, t), 2.10 (3H, d), 2.40 (2H, q), 2.55 (4H, m), 3.00 (2H, q), 3.14 (4H, m), 3.57 (3H, s), 3.84 (2H, t), 4.78 (2H, t), 5.82 (1H, q), 10 7.18 (2H, m), 7.60 (1H, m), 8.54 (1H, d), 8.60 (1H, s), 8.94 (1H, s), 10.82 (1H, s).

10 LRMS : m/z 598 (M+1)⁺

EXAMPLE 146

15 5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridazin-3-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



A suspension of the title compound of Preparation 142 (1.12g, 4.55mmol) and 20 triethylamine (1.5g, 13.7mmol) was added to an ice-cold suspension of the title compound of Preparation 28 (2.0g, 5.0mmol) in dichloromethane (25ml), and the reaction stirred at room temperature for 2 hours. The reaction mixture was washed with brine (15ml), saturated aqueous sodium bicarbonate solution (2x10ml), more brine (15ml), dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel 25

-109-

using an elution gradient of dichloromethane:methanol:0.88 ammonia (99:0:1 to 96:3:1) to give a solid (1.73g).

5 A mixture of this intermediate (829mg, 1.45mmol) and potassium bis(trimethylsilyl)amide (347mg, 1.74mmol) in 3-methyl-3-pentanol (3ml) was heated under reflux for 6 hours, and then stirred for 72 hours at room temperature. Additional potassium bis(trimethylsilyl)amide (87mg, 0.43mmol) was added, the reaction heated under reflux for a further 5 hours, then cooled, 10 2M hydrochloric acid (2ml) added and the mixture concentrated under reduced pressure. The residue was partitioned between dichloromethane (20ml) and water (10ml), the layers separated, the organic phase washed consecutively with water (10ml), saturated sodium bicarbonate solution (10ml), brine (10ml), dried (MgSO_4) and evaporated under reduced pressure. The crude product was 15 purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 98:2) to afford the title compound (1.24g, 49%) as a light brown foam.


18 δ (CDCl_3) : 1.02 (3H, t), 1.36 (3H, t), 1.59 (3H, t), 2.40 (2H, q), 2.55 (4H, m), 3.14 (6H, m), 4.76 (2H, q), 5.90 (2H, s), 7.46 (1H, m), 7.56 (1H, m), 8.63 (1H, s), 9.01 (1H, s), 9.18 (1H, d), 10.70 (1H, s).

20 LRMS : m/z 554 ($\text{M}+1$)⁺

EXAMPLE 147

5-[2-n-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(pyridazin-3-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

25




-110-

Potassium bis(trimethylsilyl)amide (35mg, 0.176mmol) was added to a solution of the title compound of Example 146 (80mg, 0.145mmol) in n-butanol (2ml), 5 and the reaction stirred at 110°C for 6 ½ hours. The cooled mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate (20ml) and sodium bicarbonate solution (10ml). The phases were separated, the organic layer washed with additional sodium bicarbonate solution (10ml), brine (10ml), dried (MgSO_4) and evaporated under reduced 10 pressure. The crude product was purified by column chromatography on silica gel using an elution gradient of dichloromethane:methanol:0.88 ammonia (100:0:0 to 99.6:0.4:0.5) to afford the title compound (50mg, 59%) as a white foam.

δ (CDCl_3) : 1.04 (6H, m), 1.35 (3H, t), 1.58 (2H, m), 1.95 (2H, m), 2.41 (2H, q), 15 2.57 (4H, m), 3.10 (6H, m), 4.66 (2H, t), 5.90 (2H, s), 7.46 (1H, m), 7.56 (1H, m), 8.62 (1H, s), 9.01 (1H, s), 9.17 (1H, d), 10.79 (1H, s).
LRMS : m/z 582 ($\text{M}+1$)⁺

EXAMPLE 148

20 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethylamino)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



25 A mixture of the title compound of Example 78 (200mg, 0.42mmol), and copper (II) sulphate pentahydrate (150mg, 0.60mmol) in 2-methoxyethylamine (2ml)

-111-

was heated under reflux for 2 hours, then cooled. The reaction was partitioned between dichloromethane (20ml) and aqueous sodium carbonate solution (5ml), and the layers separated. The organic phase was dried (Na_2SO_4) and 5 evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol (98:2 to 95:5) to afford the title compound (150mg, 69%).

10 δ (CDCl_3) : 1.04 (3H, t), 1.40 (3H, t), 2.42 (2H, q), 2.55 (4H, m), 2.92 (3H, s), 3.01 (2H, q), 3.13 (4H, m), 3.50 (4H, m), 3.48 (3H, s), 3.68 (2H, t), 3.88 (2H, t),


10 4.07 (3H, s), 8.34 (1H, s), 8.58 (1H, s).

LRMS : m/z 519 ($\text{M}+1$)⁺

EXAMPLES 149 TO 153

15

The compounds of the general formula:






were prepared from the appropriate pyrazolo[4,3-d]pyrimidin-7-ones and amines, using procedures similar to that described in Example 148.

20

25


-112-

Example	R1	R13	Data
149	CH ₃	N 	δ (CDCl ₃) : 1.02 (3H, t), 1.37 (3H, t), 2.26-2.42, (4H, m), 2.54 (4H, m), 3.01 (2H, q), 3.10 (4H, m), 4.05 (7H, m), 8.00 (1H, s), 8.57 (1H, s). LRMS : m/z 487 (M+1) ⁺
150	CH ₃	N 	δ (CDCl ₃) : 1.02 (3H, t), 1.35 (3H, t), 1.89 (4H, m), 2.39 (2H, q), 2.55 (4H, m), 3.00 (2H, q), 3.11 (4H, m), 3.40 (4H, m), 4.08 (3H, s), 8.00 (1H, s), 8.57 (1H, s). LRMS : m/z 501 (M+1) ⁺
151	CH ₂ CH ₃	N 	Found : C, 55.53; H, 6.70; N, 21.52. C ₂₄ H ₃₄ N ₈ O ₃ S requires C, 56.01; H, 6.66; N, 21.77% δ (CDCl ₃) : 1.03 (3H, t), 1.38 (3H, t), 1.60 (3H, t), 1.88 (4H, m), 2.41 (2H, q), 2.57 (4H, m), 3.01 (2H, q), 3.10 (4H, m), 3.42 (4H, m), 4.38 (2H, q), 8.00 (1H, s), 8.58 (1H, s), 9.20 (1H, s). LRMS : m/z 515 (M+1) ⁺
152		NH 	Found : C, 54.63; H, 6.15; N, 20.97. C ₂₇ H ₃₅ N ₉ O ₄ S requires C, 54.89; H, 6.14; N, 21.34% δ (CDCl ₃) : 1.01 (3H, t), 1.33 (3H, t), 2.38 (2H, q), 2.54 (4H, m), 3.07 (2H, q), 3.16 (4H, m), 3.41 (3H, s), 3.65 (2H, t), 3.85 (2H, q), 5.67 (2H, s), 7.19 (1H, d), 7.25 (1H, m), 7.68 (1H, m), 8.14 (1H, s), 8.56 (1H, s), 8.58 (1H, d), 9.92 (1H, s), 10.07 (1H, m). LRMS : m/z 582 (M+1) ⁺
153		N 	δ (CDCl ₃) : 1.03 (3H, t), 1.26 (3H, t), 1.92 (4H, m), 2.41 (2H, q), 2.56 (4H, m), 3.02 (2H, q), 3.10 (4H, m), 3.42 (4H, m), 5.68 (2H, s), 7.19 (1H, d), 7.26 (1H, m), 7.67 (1H, m), 8.01 (1H, s), 8.58 (2H, m), 9.24 (1H, s). LRMS : m/z 578 (M+1) ⁺

-113-

EXAMPLE 154

5-[2-(N-Cyclopropylmethyl-N-methylamino)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



A mixture of the title compound of Example 78 (200mg, 0.42mmol), and N-cyclopropylmethyl-N-methylamine (600mg, 7.05mmol; obtained from the title compound of Preparation 168) and potassium bis(trimethylsilyl)amide (250mg, 1.26mmol) in N,N-dimethylformamide (2ml), was stirred at 100°C for 18 hours. The cooled mixture was partitioned between ethyl acetate (20ml) and aqueous sodium bicarbonate solution (10ml), and the phases separated. The organic layer was dried (MgSO_4), and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 95:5) to afford the title compound (100mg, 46%) as a solid.


δ (CDCl_3) : 0.54 (2H, m), 0.71 (2H, m), 1.02 (3H, t), 1.37 (4H, m), 2.40 (2H, q), 2.56 (4H, m), 2.78-3.13 (11H, m), 4.08 (3H, s), 8.32 (1H, s), 8.60 (1H, s).

LRMS : m/z 515 ($\text{M}+1$)⁺

-114-

EXAMPLES 155 TO 156

5 The compounds of the general formula:




were prepared from the title compound of Example 78 and the appropriate
 10 amines, using procedures similar to that described in Example 154.

Example	R13	Data
155		δ (CDCl ₃) : 1.01 (3H, t), 1.40 (3H, t), 1.58 (2H, m), 1.64 (2H, m), 1.77 (4H, m), 2.41 (2H, q), 2.55 (4H, m), 3.02 (2H, q), 3.12 (4H, m), 3.26 (2H, m), 4.10 (3H, s), 8.55 (1H, s), 8.63 (1H, s), 10.63 (1H, s). LRMS : m/z 515 (M+1) ⁺
156		δ (CDCl ₃) : 1.04 (3H, t), 1.40 (3H, t), 2.42 (2H, q), 2.58 (4H, m), 3.03 (2H, q), 3.16 (4H, m), 3.35 (4H, m), 3.86 (4H, m), 4.10 (3H, s), 8.55 (1H, s), 8.68 (1H, s), 10.40 (1H, s). LRMS : m/z 517 (M+1) ⁺

-115-

EXAMPLE 157

5 3-Ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridin-3-yl]-2-
(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one



10 A mixture of the title compound of Preparation 160 (226mg, 0.39mmol) and potassium *t*-butoxide (112mg, 1.0mmol) in *n*-propanol (20ml), was stirred under reflux for 5 days, then cooled. Saturated ammonium chloride solution (5ml) was added, this solution poured into ethyl acetate (50ml), and the layers separated. The organic phase was washed with sodium bicarbonate solution (20ml), then brine (20ml), dried ($MgSO_4$) and evaporated under reduced pressure. The 15 residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 94:6) to give an oil. This was crystallised from ether to afford the title compound (9mg, 4%) as a white solid.

16 δ ($CDCl_3$) : 1.00 (3H, t), 1.18 (3H, t), 1.28 (3H, t), 1.70 (2H, m), 2.38 (2H, q), 2.50 (4H, m), 3.00 (2H, q), 3.07 (4H, m), 3.57 (2H, q), 5.62 (2H, s), 7.19 (1H, m), 7.63 (1H, m), 8.02 (1H, s), 8.55 (2H, m), 9.60 (1H, s), 9.80 (1H, s).

20 LRMS : m/z 566 ($M+1$)⁺

-116-

PREPARATION 1

2-Ethoxypyridine-3-carboxylic acid

A solution of potassium *t*-butoxide (44.9g, 0.40mol) in absolute ethanol (300ml) was added slowly to a solution of 2-chloronicotinic acid (30g, 0.19mol) in absolute ethanol (100ml) and the reaction mixture heated in a sealed vessel at 170°C for 20 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure, the residue dissolved in water (200ml) and the solution acidified to pH 3 with hydrochloric acid and extracted with dichloromethane (4x200ml). The combined extracts were dried (Na₂SO₄) and evaporated under reduced pressure to give the title compound (27.4g, 41%) as a white solid. δ (CDCl₃): 1.53 (3H,t), 4.69 (2H,q), 7.13 (1H,m), 8.37 (1H,d), 8.48 (1H,d).

15

PREPARATION 2

2-(2-Methoxyethoxy)pyridine-3-carboxylic acid

Obtained as a brown solid (92%) from 2-chloronicotinic acid and 2-methoxyethanol, using the procedure of Preparation 1. Found: C, 54.89; H, 5.61; N, 7.03. C₉H₁₁NO₄ requires C, 54.82; H, 5.62; N, 7.10%. δ (CDCl₃): 3.45 (3H,s), 3.79 (2H,t), 4.74 (2H,t), 7.14 (1H,m), 8.36 (1H,d), 8.46 (1H,d). LRMS: m/z 198 (M+1)⁺.

PREPARATION 3

2-Ethoxypyridine-3-carboxylic acid ethyl ester

25 A suspension of the title compound of Preparation 1 (16.4g, 98mmol) and caesium carbonate (32g, 98mmol) in dimethylformamide (240ml) was stirred at room temperature for 2 hours. Ethyl iodide (7.85ml, 98mmol) was added and the reaction mixture stirred for 24 hours, then evaporated under reduced pressure. The residue was partitioned between aqueous sodium carbonate solution (100ml) and ethyl acetate (100ml), the phases separated and the

-117-

aqueous phase extracted with ethyl acetate (2x100ml). The combined organic solutions were washed with brine, dried (Na_2SO_4) and evaporated under reduced pressure to yield the title compound (18.0g, 94%) as a pale yellow oil.

5 δ (CDCl_3): 1.41 (6H,m), 4.36 (2H,q), 4.48 (2H,q), 6.90 (1H,m), 8.12 (1H,d), 8.28 (1H,d).

PREPARATION 4

2-(2-Methoxyethoxy)pyridine-3-carboxylic acid ethyl ester

10 Obtained as a brown oil (98%) from the title compound of Preparation 2, using the procedure of Preparation 3. Found: C, 58.36; H, 6.74; N, 6.04. $\text{C}_{11}\text{H}_{15}\text{NO}_4$ requires C, 58.66; H, 6.71; N, 6.23%. δ (CDCl_3): 1.37 (3H,t), 3.44 (3H,s), 3.78 (2H,t), 4.34 (2H,q), 4.56 (2H,t), 6.92 (1H,m), 8.13 (1H,d), 8.26 (1H,d). LRMS: m/z 226 (M+1)⁺.

15

PREPARATION 5

2-Ethoxy-5-nitropyridine-3-carboxylic acid ethyl ester

10 Ammonium nitrate (5.36g, 66mmol) was added portionwise to a stirred, ice-cooled solution of the title compound of Preparation 3 (4.66g, 22.3mmol) in 20 trifluoroacetic anhydride (50ml) and the reaction mixture stirred for 18 hours at room temperature, then carefully poured into stirred ice-water (200g). The resulting suspension was stirred for 1 hour, then the precipitate collected, washed with water and dried under suction to provide the title compound (3.29g, 61%). δ (CDCl_3): 1.41 (3H,t), 1.48 (3H,t), 4.41 (2H,q), 4.62 (2H,q), 8.89 (1H,s), 9.16 (1H,s).

PREPARATION 6

2-(2-Methoxyethoxy)-5-nitropyridine-3-carboxylic acid ethyl ester

30 Ammonium nitrate (10.57g, 131mmol) was added portionwise to a stirred, ice-cooled solution of the title compound of Preparation 4 (14.80g,

-118-

65.7mmol) in trifluoroacetic anhydride (150ml) and the reaction mixture stirred for 3 hours at room temperature, then carefully poured onto stirred ice (120g). The resulting solution was extracted with dichloromethane (3x150ml), then the combined extracts dried (MgSO_4) and evaporated under reduced pressure. The residual orange oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 97:3), to furnish the title compound (11.49g, 65%) as a white solid. Found: C, 48.78; H, 5.13; N, 10.29. $\text{C}_{11}\text{H}_{14}\text{N}_2\text{O}_6$ requires C, 48.89; H, 5.22; N, 10.37%. δ (CDCl_3): 1.42 (3H,t), 3.46 (3H,s), 3.83 (2H,t), 4.41 (2H,q), 4.70 (2H,t), 8.92 (1H,s), 9.16 (1H,s). LRMS: m/z 271 (M+1)⁺.

PREPARATION 7

5-Amino-2-ethoxypyridine-3-carboxylic acid ethyl ester

15 A stirred mixture of the title compound of Preparation 5 (5.3g, 22mmol), Raney nickel (2.50g) and ethanol (150ml) was hydrogenated at 345kPa (50psi) and 50°C for 18 hours, then allowed to cool and filtered. The filtrate was combined with an ethanol wash (150ml) of the filter pad and then evaporated under reduced pressure. The residue was triturated with dichloromethane and 20 the resulting solid collected and dried to afford the title compound (4.56g, 98%) as a tan-coloured solid. Found: C, 57.12; H, 6.79; N, 12.98. $\text{C}_{10}\text{H}_{14}\text{N}_2\text{O}_3$ requires C, 57.13; H, 6.71; N, 13.33%. δ (CDCl_3): 1.39 (6H, 2xd), 3.41 (2H,s), 4.35 (4H,m), 7.55 (1H,s), 7.78 (1H,s). LRMS: m/z 211 (M+1)⁺.

25

PREPARATION 8

2-Ethoxy-5-nitropyridine-3-carboxylic acid

5M Aqueous sodium hydroxide solution (4ml, 20mmol) was added dropwise to a stirred solution of the title compound of Preparation 5 (5.1g, 20mmol) in ethanol (100ml) and the reaction mixture stirred at room 30 temperature for 18 hours, then evaporated under reduced pressure. The

-119-

residue was suspended in water (50ml) and the stirred suspension acidified to pH 3 with hydrochloric acid. The resulting aqueous solution was extracted with ethyl acetate (3x100ml), then combined extracts washed with brine (100ml), 5 dried (Na_2SO_4) and evaporated under reduced pressure to afford a beige solid. The crude product was crystallised from hexane-ethyl acetate to give the title compound (3.32g, 78%) as beige crystals. δ (CDCl_3): 1.55 (3H,t), 4.78 (2H,q), 9.17 (1H,s), 9.23 (1H,s).

10

PREPARATION 9

2-(2-Methoxyethoxy)-5-nitropyridine-3-carboxylic acid

1M Aqueous sodium hydroxide solution (40ml, 40mmol) was added to a stirred, ice-cooled solution of the title compound of Preparation 6 (4.0g, 14.8mmol) in 1,4-dioxan (40ml) and the reaction mixture stirred for 1.5 hours, 15 then concentrated under reduced pressure to half its volume and acidified with hydrochloric acid to pH 3. The resulting suspension was extracted with dichloromethane (3x50ml), then the combined extracts dried (MgSO_4) and evaporated under reduced pressure to yield the title compound (2.61g, 73%) as a buff-coloured solid. Found: C, 44.11; H, 4.04; N, 11.46. $\text{C}_9\text{H}_{10}\text{N}_2\text{O}_6$ requires C, 44.63; H, 4.16; N, 11.57%. δ (CDCl_3): 3.47 (3H,s), 3.83 (2H,t), 4.82 (2H,t), 20 9.15 (1H,s), 9.21 (1H,s). LRMS: m/z 243 (M+1)⁺.

PREPARATION 10

2-Aminopyridine-5-sulphonic acid

25 2-Aminopyridine (80g, 0.85mol) was added portionwise over 30 minutes to stirred oleum (320g) and the resulting solution heated at 140°C for 4 hours, then allowed to cool. The reaction mixture was poured onto stirred ice (200g) and this mixture stirred at ice-salt bath temperature for a further 2 hours.

-120-

The resulting suspension was filtered, then the collected solid washed successively with ice-water (200ml) and cold industrial methylated spirit (IMS) (200ml) and, finally, dried under suction to provide the title compound (111.3g, 75%) as a solid. LRMS: m/z 175 (M+1)⁺.

PREPARATION 11

2-Amino-3-bromopyridine-5-sulphonic acid

Bromine (99g, 0.62mol) was added dropwise, over 1 hour, to a stirred, hot solution of the title compound of Preparation 10 (108g, 0.62mol) in water (600ml), at such a rate as to maintain steady reflux. When the addition was complete, the reaction mixture was allowed to cool and then filtered. The resulting solid was washed with water and dried under suction to furnish the title compound (53.4g, 34%). δ (DMSO₆): 8.08 (1H,s), 8.14 (1H,s). LRMS: m/z 253 (M)⁺.

PREPARATION 12

3-Bromo-2-chloropyridine-5-sulphonyl chloride

A solution of sodium nitrite (7.6g, 110mmol) in water (30ml) was added dropwise to a stirred, ice-cooled solution of the title compound of Preparation 11 (25.3g, 100mmol) in 20% hydrochloric acid (115ml), at such a rate as to maintain the temperature below 6°C. The reaction mixture was stirred for 30 minutes at 0°C for a further 1 hour at room temperature, then evaporated under reduced pressure. The residue was dried under vacuum at 70°C for 72 hours, then a mixture of the resulting solid, phosphorus pentachloride (30g, 144mmol) and phosphorus oxychloride (1ml) was heated at 125°C for 3 hours and then allowed to cool. The reaction mixture was poured onto stirred ice (100g) and the resulting solid collected and washed with water. The crude product was dissolved in dichloromethane, then the solution dried (MgSO₄) and evaporated under reduced pressure to afford the title compound (26.58g, 91%) as a yellow solid. δ (CDCl₃): 8.46 (1H,s), 8.92 (1H,s).

-121-

PREPARATION 13

3-Bromo-2-chloro-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine

A solution of 1-ethylpiperazine (11.3ml, 89mmol) and triethylamine 5 (12.5ml, 89mmol) in dichloromethane (150ml) was added dropwise to a stirred, ice-cooled solution of the title compound of Preparation 12 (23g, 79mmol) in dichloromethane (150ml) and the reaction mixture stirred at 0°C for 1 hour, then evaporated under reduced pressure. The residual brown oil was purified by column chromatography on silica gel, using an elution gradient of 10 dichloromethane: methanol (99:1 to 97:3), to give the title compound (14.5g, 50%) as an orange solid. δ (CDCl₃): 1.05 (3H,t), 2.42 (2H,q), 2.55 (4H,m); 3.12 (4H,m), 8.24 (1H,s), 8.67 (1H,s).

PREPARATION 14

15 3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine

A 0.5M solution of potassium bis(trimethylsilyl)amide in toluene (8.1ml, 4.07mmol) was added to a stirred, ice-cooled solution of 2-methoxyethanol (416μl, 5.4mmol) in anhydrous tetrahydrofuran (30ml) and the resulting solution stirred at 0°C for 1 hour. Next, the title compound of Preparation 13 (1.0g, 20 2.71mmol) was added portionwise and the reaction mixture stirred at room temperature for 2 hours, then diluted with ethyl acetate (40ml). The resulting mixture was washed with water (10ml), dried (MgSO₄) and evaporated under reduced pressure to yield a yellow oil which was purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as 25 eluant, to provide the title compound (1.02g, 92%) as a colourless oil. Found: C, 40.83; H, 5.32; N, 9.99. C₁₄H₂₂BrN₃O₄S requires C, 41.18; H, 5.43; N, 10.29%. δ (CDCl₃): 1.04 (3H,t), 2.42 (2H,q), 2.53 (4H,m), 3.07 (4H,m), 3.46 (3H,s), 3.78 (2H,t), 4.60 (2H,t), 8.10 (1H,s), 8.44 (1H,s). LRMS: m/z 408 (M)⁺.

-122-

PREPARATION 15

3-Bromo-2-(2-ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine

Sodium metal (93mg, 4mmol) was added to a stirred solution of 2-ethoxyethanol (537 μ l, 5.5mmol) in anhydrous tetrahydrofuran (5ml). When the sodium had dissolved, the title compound of Preparation 13 (1.0g, 2.7mmol) was added portionwise and the reaction mixture stirred for 18 hours at room temperature, then concentrated under reduced pressure. The residue was partitioned between ethyl acetate (10ml) and brine (10ml), the phases separated and the aqueous phase extracted with ethyl acetate (2x10ml). The combined organic solutions were washed with brine, dried ($MgSO_4$) and evaporated under reduced pressure, then the residue purified by column chromatography on silica gel, using an elution gradient of hexane: dichloromethane: methanol (50:50:0 to 0:98:2), to furnish the title compound (985mg, 86%) as a yellow oil. δ ($CDCl_3$): 1.03 (3H,t), 1.22 (3H,t), 2.40 (2H,q), 2.54 (4H,m), 3.07 (4H,m), 3.61 (2H,q), 3.82 (2H,t), 4.59 (2H,t), 8.10 (1H,s), 8.43 (1H,s). LRMS: m/z 423 ($M+1$)⁺.

PREPARATION 16

20 3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridine

Obtained as an oil (95%) from the title compound of Preparation 13 and 3-methoxypropan-1-ol, using the procedure of Preparation 15. δ ($CDCl_3$): 1.04 (3H,t), 2.09 (2H,m), 2.42 (2H,q), 2.52 (4H,m), 3.08 (4H,m), 3.37 (3H,s), 3.57 (2H,t), 4.54 (2H,t), 8.09 (1H,s), 8.45 (1H,s). LRMS: m/z 423 ($M+1$)⁺.

25

PREPARATION 17

3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(S)-yloxy)pyridine

A mixture of a 2M solution of sodium bis(trimethylsilyl)amide in 30 tetrahydrofuran (1.83ml, 3.66mmol), (S)-(+)-3-hydroxytetrahydrofuran (272 μ l,

-123-

6mmol) and tetrahydrofuran (40ml) was stirred for 30 minutes at room temperature. Next, the title compound of Preparation 13 (750mg, 2mmol) was added and the reaction mixture stirred for 18 hours, then evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of hexane:ethyl acetate (25:75 to 0:100), to afford the title compound (430mg, 51%) as an oil. δ (CDCl₃): 1.06 (3H,t), 2.20 (1H,m), 2.30 (1H,m), 2.42 (2H,q), 2.56 (4H,m), 3.08 (4H,m), 3.94 (2H,m), 4.02 (1H,m), 4.11 (1H,m), 5.62 (1H,m), 8.12 (1H,s), 8.44 (1H,s). LRMS: m/z 420 (M)⁺.

PREPARATION 18

2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine- 3-carboxylic acid ethyl ester

15 Sodium nitrite (2.22g, 32.1mmol) was added to a stirred solution of the title compound of Preparation 7 (4.5g, 21.4mmol) in a mixture of concentrated hydrochloric acid (90ml) and glacial acetic acid (90ml) at -20°C and the resulting mixture stirred for 2 hours, whilst allowing the temperature to rise to 0°C. The mixture was cooled again to -20°C, liquid sulphur dioxide (50ml) and 20 a solution of copper(II) chloride (8.4g, 62.5mmol) in a mixture of water (9ml) and acetic acid (80ml) added, then the reaction mixture stirred for 30 minutes at 0°C, followed by a further 2 hours at room temperature. The resulting mixture was poured onto stirred ice (80g) and the aqueous solution thus obtained was extracted with dichloromethane (3x50ml). The combined extracts were dried 25 (MgSO₄) and evaporated under reduced pressure to give the crude sulphonyl chloride as a brown oil.

1-Ethylpiperazine (10.9ml, 85.6mmol) was added to a stirred solution of the sulphonyl chloride in ethanol (60ml) and the reaction mixture stirred for 18

-124-

hours at room temperature, then evaporated under reduced pressure. The residue was partitioned between water (20ml) and dichloromethane (30ml), the separated aqueous phase extracted with dichloromethane (2x30ml), then the 5 combined organic solutions dried ($MgSO_4$), and evaporated under reduced pressure. The residual brown oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 98:2), to yield the title compound (5.0g, 63%) as a pale brown oil. Found: C, 51.40; H, 6.77; N, 11.15. $C_{16}H_{25}N_3O_5S$ requires C, 51.74; H, 6.78; N, 11.31%.
10 δ ($CDCl_3$): 1.02 (3H,t), 1.39 (3H,t), 1.45 (3H,t), 2.40 (2H,q), 2.54 (4H,m), 3.08 (4H,m), 4.38 (2H,q), 4.55 (2H,q), 8.37 (1H,s), 8.62 (1H,s). LRMS: m/z 372 (M+1)⁺.

PREPARATION 19

15 5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine-3-carboxylic acid ethyl ester

Triethylamine (3ml, 19mmol) and tetrakis (triphenylphosphine) palladium (0) (260mg, 0.22mmol) were added to a solution of the title compound of Preparation 14 (1.30g, 3mmol) in ethanol (15ml) and the mixture heated under 20 carbon monoxide at 100°C and 1034 kPa (150psi) in a sealed vessel for 18 hours, then allowed to cool. The reaction mixture was filtered and the filtrate evaporated under reduced pressure to provide a yellow solid. The crude product was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 97.3), to furnish the title 25 compound (1.10g, 92%) as a yellow oil. δ ($CDCl_3$): 1.02 (3H,t), 1.38 (3H,t), 2.40 (2H,q), 2.53 (4H,m), 3.08 (4H,m), 3.43 (3H,s), 3.80 (2H,t), 4.38 (2H,q), 4.63 (2H,t), 8.40 (1H,s), 8.61 (1H,s). LRMS: m/z 402 (M+1)⁺.

-125-

PREPARATION 20

2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid ethyl ester

5 Obtained as a gum (96%) from the title compound of Preparation 15, using the procedure of Preparation 19. δ (CDCl₃): 1.03 (3H,t), 1.22 (3H,t), 1.38 (3H,t), 2.40 (2H,q), 2.52 (4H,m), 3.08 (4H,m), 3.60 (2H,q), 3.83 (2H,t), 4.38 (2H,q), 4.62 (2H,t), 8.40 (1H,s), 8.62 (1H,s). LRMS: m/z 416 (M+1)⁺.

10

PREPARATION 21

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)-pyridine-3-carboxylic acid ethyl ester

15 A mixture of triethylamine (5ml, 35.9mmol), tetrakis (triphenylphosphine) palladium (0) (200mg, 0.17mmol), the title compound of Preparation 16 (1.08g, 2.54mmol) and ethanol (25ml) was heated under carbon monoxide at 100°C and 1034 kPa (150psi) in a sealed vessel for 18 hours, then allowed to cool. The mixture was filtered and the filtrate evaporated under reduced pressure. The residue was dissolved in ethyl acetate (40ml) and the solution washed consecutively with saturated aqueous sodium bicarbonate solution (20ml), brine (20ml) and 2M hydrochloric acid (5x10ml). The combined acidic extracts were basified using solid sodium bicarbonate and the solution extracted with ethyl acetate (2x25ml). The combined organic extracts were dried (MgSO₄) and evaporated under reduced pressure to afford the title compound (640mg, 68%) as an oil. δ (CDCl₃): 1.05 (3H,t), 1.39 (3H,t), 2.09 (2H,m), 2.41 (2H,q), 2.54 (4H,m), 3.08 (4H,m), 3.36 (3H,s), 3.58 (2H,t), 4.39 (2H,q), 4.57 (2H,t), 8.40 (1H,s), 8.64 (1H,s). LRMS: m/z 416 (M+1)⁺.

-126-

PREPARATION 22

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(S)-yloxy)pyridine-3-carboxylic acid ethyl ester

5 Obtained as a yellow oil, (78%) from the title compound of Preparation 17, using the procedure of Preparation 19. δ (CDCl₃): 1.05 (3H,t), 1.39 (3H,t), 2.20 (1H,m), 2.30 (1H,m), 2.42 (2H,q), 2.55 (4H,m), 3.09 (4H,m), 3.97 (3H,m), 4.14 (1H,m), 4.38 (2H,q), 5.70 (1H,m), 8.41 (1H,s), 8.62 (1H,s). LRMS: m/z 414 (M+1)⁺.

10

PREPARATION 23

2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid

15 A mixture of the title compound of Preparation 18 (4.96g, 13.35mmol), 2M aqueous sodium hydroxide solution (25ml, 50mmol) and ethanol (25ml) was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure to half its volume, washed with ether and, acidified to pH 5 using 4M hydrochloric acid. This aqueous solution was extracted with dichloromethane (3x30ml), then the combined extracts dried (MgSO₄) and evaporated under reduced pressure to give the title compound 20 (4.02g, 88%) as a tan-coloured solid. δ (DMSO_d₆): 1.18 (3H,t), 1.37 (3H,t), 3.08 (2H,q), 3.17-3.35 (8H,m), 4.52 (2H,q), 8.30 (1H,s), 8.70 (1H,s).

PREPARATION 24

2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid sodium

25 salt

1M Aqueous sodium hydroxide solution (85ml, 85mmol) was added slowly to a stirred, ice-cooled solution of the title compound of Preparation 18 (30.2g, 85mmol) in ethanol (300ml) and the reaction mixture stirred at room

-127-

temperature for 18 hours. The resulting mixture was evaporated under reduced pressure and the residue partitioned between water (225ml) and ethyl acetate (250ml). The phases were separated, then the aqueous phase washed with 5 ethyl acetate (2x200ml) and evaporated under reduced pressure to yield the title compound (29.6g, 81%) as a white solid. δ (DMSO_d₆): 0.90 (3H,t), 1.25 (3H,t), 2.24 (2H,q), 2.40 (4H,m), 2.82 (4H,m), 4.39 (2H,q), 7.76 (1H,s), 8.28 (1H,s).

10

PREPARATION 25

4-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine-3-carboxylic acid hydrochloride

A solution of the title compound of Preparation 19 (1.18g, 2.94mmol) in a mixture of ethanol (10ml) and 1M aqueous sodium hydroxide solution (10ml, 15 10mmol) was stirred for 1 hour at room temperature. The resulting mixture was concentrated under reduced pressure to half its volume and the residual aqueous solution washed with ethyl acetate (10ml), then acidified to pH 3 with dilute hydrochloric acid. The acidic solution was extracted with dichloromethane: methanol (95:5) (6x20ml), then the combined extracts dried 20 (MgSO₄) and evaporated under reduced pressure to provide the title compound (995mg, 82%) as a white foam. δ (DMSO_d₆): 1.06 (3H,t), 2.28 (2H,q), 2.75-3.20 (8H,m), 3.28 (3H,s), 3.69 (2H,t), 4.56 (2H,t), 8.29 (1H,s), 8.68 (1H,s). LRMS: m/z 374 (M+1)⁺.

25

PREPARATION 26

2-(2-Ethoxyethoxy)-5-4-(ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid hydrochloride

A mixture of the title compound of Preparation 20 (859mg, 2.07mmol), 1M aqueous sodium hydroxide solution (4.6ml, 4.6mmol) and 1,4-dioxan (5ml)

-128-

was stirred at room temperature for 2 hours. The 1,4-dioxan was removed by evaporation under reduced pressure and the pH of the remaining aqueous solution was adjusted to 3 with hydrochloric acid. The resulting solution was 5 evaporated under reduced pressure, the residue triturated with hot ethanol and the mixture filtered. The filtrate was then evaporated under reduced pressure to furnish the title compound (760mg, 87%) as a tan-coloured solid. δ (DMSO_d₆): 1.08 (3H,t), 1.18 (3H,t), 2.98 (2H,m), 3.07 (4H,m), 3.37 (2H,m), 3.48 (2H,q), 3.72 (4H,m), 4.55 (2H,t), 8.30 (1H,s), 8.72 (1H,s). LRMS: m/z 387 10 (M)⁺.

PREPARATION 27

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridine-3-carboxylic acid hydrochloride

15 Obtained as a solid (87%) from the title compound of Preparation 21, using the procedure of Preparation 26. δ (DMSO_d₆): 1.17 (3H,t), 1.96 (2H,m), 3.08 (2H,q), 3.22 (3H,s), 3.33 (8H,m), 3.48 (2H,t), 4.48 (2H,t), 8.30 (1H,s), 8.73 (1H,s). LRMS: m/z 388 (M+1)⁺.

20

PREPARATION 28

2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid chloride hydrochloride

Oxalyl chloride (0.77ml, 8.85mmol) was added dropwise to a stirred, ice-cooled solution of the title compound of Preparation 23 (1.52g, 4.42mmol) and 25 dimethylformamide (2 drops) in dichloromethane (30ml) and the reaction mixture stirred for 18 hours at room temperature, then evaporated under reduced pressure. The residue was triturated with ethyl acetate and the

-129-

resulting solid collected, washed with ether and dried under suction to afford the title compound (1.68g, 95%). Found: C, 41.51; H, 5.27; N, 10.32. C₁₄H₂₁Cl₂N₃O₄S; 0.10 CH₂Cl₂ requires C, 41.73; H, 5.02; N, 10.36%. δ (CDCl₃): 5 1.46 (6H,m), 2.95 (2H,q), 3.11 (2H,m), 3.48 (2H,m), 3.55 (2H,m), 3.92 (2H,m), 4.60 (2H,q), 8.58 (1H,s), 8.66 (1H,s), 13.16 (1H,s).

PREPARATION 29

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridine-3-carboxylic acid chloride hydrochloride

10

Oxalyl chloride (270μl, 3.13mmol) was added dropwise to a stirred, ice-cooled suspension of the title compound of Preparation 25 (390mg, 1.04mmol), dimethylformamide (100μl) and dry dichloromethane (20ml), then the reaction mixture stirred for 3 hours at room temperature. The resulting mixture was 15 evaporated under reduced pressure and the residue azeotroped with toluene (2 x 20ml) to give the title compound (390mg, 95%) as a white solid. δ (DMSO_δ): 1.20 (3H,t), 2.92 (2H,q), 3.08 (4H,m), 3.30 (3H,s), 3.49 (2H,m), 3.70 (2H,t), 3.76 (2H,m), 4.58 (2H,t), 8.32 (1H,s), 8.72 (1H,s), 14.20 (1H,s).

20

PREPARATION 30

Ethyl 3-ethyl-1H-pyrazole-5-carboxylate

Ethanolic sodium ethoxide solution (21% w/w; 143ml, 0.39mol) was added dropwise to a stirred, ice-cooled solution of diethyl oxalate (59.8ml, 0.44mol) in absolute ethanol (200ml) under nitrogen and the resulting solution 25 stirred for 15 minutes. Butan-2-one (39ml, 0.44mol) was then added dropwise, the cooling bath removed, the reaction mixture stirred for 18 hours at room temperature and then for 6 hours at 40°C, then the cooling bath reintroduced. Next, glacial acetic acid (25ml, 0.44mol) was added dropwise, the resulting solution stirred for 30 minutes at 0°C, hydrazine hydrate (20ml, 0.44mol)

-130-

added dropwise, then the reaction mixture allowed to warm to room temperature and maintained there over a period of 18 hours, before being evaporated under reduced pressure. The residue was partitioned between 5 dichloromethane (300ml) and water (100ml), then the organic phase separated, washed with water (2x100ml), dried (Na_2SO_4) and concentrated under reduced pressure to give the title compound (66.0g). δ (CDCl_3): 1.04 (3H,t), 1.16 (3H,t), 2.70 (2H,q), 4.36 (2H,q), 6.60 (1H,s). LRMS: m/z 169 ($M+1$).

10

PREPARATION 31

3-Ethyl-1H-pyrazole-5-carboxylic acid

Aqueous sodium hydroxide solution (10M; 100ml, 1.0mol) was added dropwise to a stirred suspension of the title compound of Preparation 30 (66.0g, 0.39mol) in methanol (400ml) and the resulting solution heated under reflux for 15 4 hours. The cool reaction mixture was concentrated under reduced pressure to ca. 200ml, diluted with water (200ml) and this mixture washed with toluene (3x100ml). The resulting aqueous phase was acidified with concentrated hydrochloric acid to pH 4 and the white precipitate collected and dried by suction to provide the title compound (34.1g). δ (DMSO_d_6): 1.13 (3H,t), 20 2.56 (2H,q), 6.42 (1H,s).

PREPARATION 32

4-Nitro-3-n-propyl-1H-pyrazole-5-carboxylic acid

Fuming sulphuric acid (17.8ml) was added dropwise to stirred, ice-cooled 25 fuming nitric acid (16.0ml), the resulting solution heated to 50°C, then 3-n-propyl-1H-pyrazole-5-carboxylic acid (Chem. Pharm. Bull., 1984, 32, 1568; 16.4g, 0.106mol) added portionwise over 30 minutes whilst maintaining the reaction temperature below 60°C. The resulting solution was heated for 18

-131-

hours at 60°C, allowed to cool, then poured onto ice. The white precipitate was collected, washed with water and dried by suction to yield the title compound (15.4g), m.p. 170-172°C. Found: C, 42.35; H, 4.56; N, 21.07. C₇H₉N₃O₄ requires C, 42.21; H, 4.55; N, 21.10%. δ (DMSO_d₆): 0.90 (3H,t), 1.64 (2H,m), 2.83 (2H,m), 14.00 (1H,s).

PREPARATION 33

3-Ethyl-4-nitro-1H-pyrazole-5-carboxylic acid

10 Obtained from the title compound of Preparation 31, by analogy with Preparation 32, as a brown solid (64%). δ (DMSO_d₆): 1.18 (3H,t), 2.84 (2H,m), 13.72 (1H,s).

PREPARATION 34

4-Nitro-3-n-propyl-1H-pyrazole-5-carboxamide

15 A solution of the title compound of Preparation 32 (15.4g, 0.077mol) in thionyl chloride (75ml) was heated under reflux for 3 hours and then the cool reaction mixture evaporated under reduced pressure. The residue was azeotroped with tetrahydrofuran (2x50ml) and subsequently suspended in 20 tetrahydrofuran (50ml), then the stirred suspension ice-cooled and treated with gaseous ammonia for 1 hour. Water (50ml) was added and the resulting mixture evaporated under reduced pressure to give a solid which, after trituration with water and drying by suction, furnished the title compound (14.3g), m.p. 197-199°C. Found: C, 42.35; H, 5.07; N, 28.38. C₇H₁₀N₄O₃ requires C, 42.42; H, 5.09; N, 28.27%. δ (DMSO_d₆): 0.90 (3H,t), 1.68 (2H,m), 2.86 (2H,t), 7.68 (1H,s), 8.00 (1H,s).

-132-

PREPARATION 35

3-Ethyl-4-nitro-1H-pyrazole-5-carboxamide

Obtained from the title compound of Preparation 33, by analogy with Preparation 34, as a white solid (90%). δ (DMSO₆): 1.17 (3H,t), 2.87 (2H,m), 7.40 (1H,s), 7.60 (1H,s), 7.90 (1H,s). LRMS: m/z 185 (M+1)⁺.

PREPARATION 36

4-Amino-3-n-propyl-1H-pyrazole-5-carboxamide

10 A stirred mixture of the title compound of Preparation 34 (10.0g, 0.050mol), 10% palladium on charcoal (1.5g) and ethanol (400ml) was hydrogenated for 18 hours at 345kPa (50psi) and 50°C, then filtered. The filtrate was combined with an ethanol wash (200ml) of the filter pad and then evaporated under reduced pressure to give an orange solid which, on 15 crystallisation from ethyl acetate-methanol, afforded the title compound (6.8g) as a white solid, m.p. 196-201°C. Found: C, 48.96; H, 6.98; N, 32.08. C₇H₁₂N₄O; 0.25 H₂O requires C, 48.68; H, 7.30; N, 32.44%. δ (DMSO₆): 0.88 (3H,t), 1.55 (2H,m), 2.46 (2H,t), 4.40 (2H,s), 7.00 (1H,s), 7.12 (1H,s), 12.20 (1H,s).

20

PREPARATION 37

4-Amino-3-ethyl-1H-pyrazole-5-carboxamide

Obtained from the title compound of Preparation 35, by analogy with Preparation 36, as a brown solid (80%). δ (DMSO₆): 1.08 (3H,t), 2.45 (2H,q), 25 4.50 (1H,s), 6.88 (1H,s), 7.10 (1H,s), 7.26 (2H,s). LRMS: m/z 155 (M+1)⁺.

-133-

PREPARATION 38a

3-Ethyl-4-nitro-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

5

and

PREPARATION 38b

3-Ethyl-4-nitro-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

A mixture of the title compound of Preparation 35 (20.0g, 109mmol), 2-
10 (chloromethyl)pyridine hydrochloride (17.9g, 109mmol), caesium carbonate
(74.7g, 222mmol) and dimethylformamide (120ml) was stirred for 18 hours at
room temperature, then evaporated under reduced pressure. The residue was
partitioned between water (100ml) and dichloromethane (100ml) and the
phases separated. The aqueous layer was extracted with dichloromethane (3 x
15 100ml) and the combined extracts dried (MgSO_4) and evaporated under
reduced pressure. The residue was crystallised from dichloromethane-
methanol to yield the first title compound (1-isomer; 6.5g, 21%). δ (CDCl_3):
1.24 (3H,t), 2.90 (2H,q), 5.54 (2H,s), 6.03 (1H,s), 7.27 (1H,m), 7.36 (1H,d), 7.76
(1H,m), 8.52 (1H,d), 8.58 (1H,s).
20 The mother liquor was evaporated under reduced pressure and the residue
purified by column chromatography on silica gel, using an elution gradient of
dichloromethane: methanol (100:0 to 95:5), to provide the second title
compound (2-isomer; 17.36g, 58%) as a white solid. δ (CDCl_3): 1.16 (3H,t),
3.06 (2H,q), 5.48 (2H,s), 5.88 (1H,s), 7.19 (1H,d), 7.27 (1H,m), 7.70 (1H,m),
25 8.57 (1H,d).

-134-

PREPARATION 39a

4-Nitro-3-n-propyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

5

and

PREPARATION 39b

4-Nitro-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

2-(Chloromethyl)pyridine hydrochloride (24.6g, 150mmol) was added
10 portionwise to a stirred solution of the title compound of Preparation 34 (30.0g,
150mmol) and caesium carbonate (123.5g, 380mmol) in dimethylformamide
(300ml) and the reaction mixture stirred at room temperature for 18 hours, then
evaporated under reduced pressure. The residue was suspended in water and
the resulting solid collected and dried under suction. The crude product was
15 purified by two column chromatographic operations on silica gel, respectively
using dichloromethane: methanol (98:2) and ethyl acetate: pentane (20:80) as
eluents, to furnish the first title compound (1-isomer; 424mg, 1%) as a white
solid. Found: C, 53.74; H, 5.20; N, 23.91. $C_{13}H_{15}N_5O_3$ requires C, 53.97; H,
5.23; N, 24.21%. δ ($CDCl_3$): 0.94 (3H,t), 1.68 (2H,m), 2.86 (2H,t), 5.55 (2H,s),
20 6.07 (1H,s), 7.35 (1H,d), 7.75 (1H,m), 8.51 (1H,d), 8.56 (1H,s). LRMS: m/z
290 ($M+1$)⁺;
and the second title compound (2-isomer; 16.7g, 38%) as a white solid. δ
(DMSO d_6): 0.84 (3H,t), 1.46 (2H,m), 2.95 (2H,t), 5.49 (2H,s), 7.31 (2H,m), 7.60
(1H,s), 7.79 (1H,m), 7.90 (1H,s), 8.49 (1H,d).

25

PREPARATION 40

4-Amino-3-ethyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

A stirred mixture of the title compound of Preparation 38b (16.36g,
59mmol), 10% palladium on charcoal (4g) and ethanol (150ml) was
30 hydrogenated at 345kPa (50psi) for 4 hours, then filtered. The filtrate was
combined with an ethyl acetate wash (150ml) of the filter pad and then

-135-

concentrated under reduced pressure to a volume of ca. 70ml. The resulting precipitate was collected and dried under suction to afford the title compound (12.6g, 87%) as a white solid. δ (CDCl_3): 1.03 (3H,t), 2.53 (2H,q), 4.00 (2H,s), 5.22 (1H,s), 5.36 (2H,s), 6.60 (1H,s), 6.81 (1H,d), 7.20 (1H,m), 7.62 (1H,m), 8.57 (1H,d). LRMS: m/z 246 ($M+1$)⁺.

PREPARATION 41

4-Amino-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

10 A stirred mixture of the title compound of Preparation 39b (1.0g, 3.46mmol), Raney nickel (1g) and ethanol (50ml) was hydrogenated at 345kPa (50psi) and 50°C for 18 hours, then allowed to cool and filtered. The filtrate was combined with an ethanol wash (50ml) of the filter pad and then evaporated under reduced pressure to give the title compound (830mg, 93%) as a crystalline solid. δ (DMSO_d_6): 0.79 (3H,t), 1.33 (2H,m), 3.28 (2H,t), 4.60 (2H,s), 5.30 (2H,s), 6.88 (1H,d), 6.98 (1H,s), 7.13 (1H,s), 7.30 (1H,m), 7.74 (1H,m), 8.50 (1H,d). LRMS: m/z 274 (M)⁺.

PREPARATION 42

4-Amino-3-ethyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

20 Obtained as a solid (94%) from the title compound of Preparation 38a, using the procedure of Preparation 40. δ (CDCl_3): 1.20 (3H,t), 2.52 (2H,q), 3.72 (2H,s), 5.50 (2H,s), 7.21 (1H,m), 7.34 (1H,d), 7.68 (1H,m), 8.49 (1H,d). LRMS: m/z 246 ($M+1$)⁺.

25

PREPARATION 43

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-ethyl-1H-pyrazole-5-carboxamide hydrochloride

30 A mixture of the title compound of Preparation 28 (1.0g, 2.51mmol), Preparation 37 (387mg, 2.51mmol) and pyridine (15ml) was stirred at room

-136-

temperature for 18 hours. The resulting mixture was evaporated under reduced pressure and the residue triturated with ether to yield the title compound (1.05g, 87%) as a purple solid. Found: C, 44.82; H, 5.72; N, 18.62. $C_{20}H_{29}N_7O_5S$; 5 HCl; H_2O requires C, 44.98; H, 6.04; N, 18.36%. δ (DMSO d_6): 1.17 (6H,m), 1.46 (3H,t), 2.77 (2H,q), 3.09 (2H,q), 3.49 (4H,m), 3.78 (4H,m), 4.68 (2H,q), 7.30 (1H,s), 7.49 (1H,s), 8.52 (1H,s), 8.76 (1H,s), 10.54 (1H,s). LRMS: m/z 480 (M+1)⁺.

10

PREPARATION 44

5-[2-Ethoxy-5-(4-ethyl(piperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Potassium t-butoxide (943g, 8.41mmol) was added to a stirred suspension of the title compound of Preparation 43 (1.10g, 2.1mmol) in 15 absolute ethanol (50ml) and the reaction mixture heated in a sealed vessel at 100°C for 18 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue dissolved in water (15ml). The aqueous solution was acidified to pH 6 using hydrochloric acid and the resulting solid collected, washed with water and dried under suction. The crude product 20 was purified by column chromatography on silica gel, using dichloromethane: methanol (97:3) as eluant, to provide the title compound (445mg, 46%) as a yellow solid. Found: C, 51.95; H, 5.89; N, 20.87. $C_{20}H_{27}N_7O_4S$ requires C, 52.05; H, 5.90; N, 21.24%. δ (DMSO d_6): 0.92 (3H,t), 1.30 (6H,m), 2.30 (2H,q), 2.42 (4H,m), 2.86 (2H,q), 2.95 (4H,m), 4.49 (2H,q), 8.20 (1H,s), 8.64 (1H,s), 25 12.19 (1H,s), 13.80 (1H,s). LRMS: m/z 462 (M+1)⁺.

-137-

PREPARATION 45

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-ethyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

5 Alternative A

A mixture of the title compounds of Preparation 28 (1.0g, 2.5mmol), Preparation 40 (620mg, 2.5mmol), triethylamine (1.35ml, 10mmol) and dichloromethane (50ml) was stirred at room temperature for 18 hours. The resulting mixture was poured into stirred water (50 ml), the phases separated 10 and the aqueous phase extracted with dichloromethane (2 x 50ml). The combined organic solutions were dried (MgSO_4) and evaporated under reduced pressure, then the residue purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5), to furnish the title compound (1.29g, 90%) as a foam. δ (CDCl_3): 1.00 (6H,m), 15 1.55 (3H,t), 2.37 (2H,q), 2.50 (4H,m), 2.87 (2H,q), 3.08 (4H,m), 4.77 (2H,q), 5.28 (1H,s), 5.45 (2H,s), 6.68 (1H,s), 6.90 (1H,d), 7.18 (1H,m), 7.61 (1H,m), 8.57 (1H,d), 8.62 (1H,s), 8.80 (1H,s), 10.57 (1H,s).

Alternative B

20 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (17.6g, 91.8mmol) was added portionwise over 5 minutes to a stirred, ice-cooled suspension of 1-hydroxybenzotriazole hydrate (12g, 88.9mmol) and the title compound of Preparation 24 (24g, 65.7mmol) in tetrahydrofuran (300ml), then the mixture stirred for 1 hour. N-Ethylisopropylamine (12.7g, 98.3mmol) and 25 the title compound of Preparation 40 (12.9g, 52.6mmol) were added and the reaction mixture stirred at room temperature for 14 hours, then evaporated under reduced pressure. The residue was partitioned between water (100ml) and ethyl acetate (200ml), the phases separated and the organic phase washed consecutively with water (50ml), saturated aqueous sodium 30 bicarbonate solution (50ml) and brine (50ml), then dried (MgSO_4) and concentrated under reduced pressure to a low volume. The resulting

-138-

suspension was cooled in ice for 1 hour, then the precipitate collected and dried under suction to afford the title compound (14.1g, 47%) as a white crystalline solid, m.p. 185-187°C. Found: C, 54.59; H, 6.05; N, 19.32. $C_{26}H_{34}N_8O_3S$ requires C, 54.72; H, 6.00; N, 19.63%.

PREPARATION 46

2-n-Propoxypyridine-3-carboxylic acid

Obtained as a pale brown oil (50%) from 2-chloronicotinic acid and n-
10 propanol, using the procedure of Preparation 1. δ ($CDCl_3$): 1.08 (3H,t), 1.92
(2H,m), 4.56 (2H,t), 7.10 (1H,m), 8.35 (1H,d), 8.45 (1H,d).

PREPARATION 47

2-n-Propoxypyridine-3-carboxylic acid methyl ester

15 Diethyl azodicarboxylate (2.2ml, 14mmol) was added dropwise to a stirred solution of the title compound of Preparation 46 (2.30g, 12.7mmol), triphenylphosphine (3.67g, 14mmol) and methanol (0.60ml, 15mmol) in tetrahydrofuran (20ml) and the reaction mixture stirred for 18 hours at room temperature, then evaporated under reduced pressure. The residue was
20 triturated with pentane: ether (80:20) and the mixture filtered. The filtrate was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using pentane: ether (50:50) as eluant, to give the title compound (2.2g, 89%) as a pale yellow oil. δ ($CDCl_3$): 1.07 (3H,t), 1.86
(2H,m), 3.92 (3H,s), 4.38 (2H,t), 6.93 (1H,m), 8.15 (1H,d), 8.30 (1H,d).

25

PREPARATION 48

5-Nitro-2-n-propoxypyridine-3-carboxylic acid methyl ester

Obtained as pale yellow needles (32%), after crystallisation from methanol, from the title compound of Preparation 47, using the procedure of
30 Preparation 5. δ ($CDCl_3$): 1.04 (3H,t), 1.84 (2H,m), 3.92 (3H,s), 4.48 (2H,t), 8.88 (1H,s), 9.14 (1H,s).

-139-

PREPARATION 49

5-Amino-2-n-propoxypyridine-3-carboxylic acid methyl ester

A mixture of the title compound of Preparation 48 (1.8g, 7.46mmol),
5 Raney nickel (500mg) and methanol (50ml) was hydrogenated at 345 kPa
(50psi) and 50°C for 3 hours, then allowed to cool and filtered. The filtrate was
combined with a methanol wash (100ml) of the filter pad and then evaporated
under reduced pressure to yield the title compound (1.5g, 95%) as a brown oil.
δ (CDCl₃): 1.04 (3H,t), 1.80 (2H,m), 3.40 (2H,s), 3.89 (3H,s), 4.28 (2H,t), 7.57
10 (1H,s), 7.80 (1H,s). LRMS: m/z 211 (M+1).

PREPARATION 50

5-(4-Methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridine-3-carboxylic acid methyl ester

15 Obtained as an oil (56%) from the title compound of Preparation 49 and
1-methylpiperazine, using the procedure of Preparation 18.

PREPARATION 51

5-(4-Methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridine-3-carboxylic acid

20 Obtained as a white solid (82%) from the title compound of Preparation
50, using the procedure of Preparation 23. δ (DMSO_d₆): 0.97 (3H,t), 1.74
(2H,m), 2.15 (3H,s), 2.38 (4H,m), 2.93 (4H,m), 4.37 (2H,t), 8.15 (1H,s), 8.56
(1H,s).

PREPARATION 52

3-Ethyl-4-[5-(4-methylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3- ylcarboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

25 Oxalyl chloride (550μl, 6.37mmol), followed by dimethylformamide (2
drops), were added carefully to a stirred, ice-cooled suspension of the title

-140-

compound of Preparation 51 (605mg, 1.59mmol) in dichloromethane (10ml) and the reaction mixture stirred at room temperature for 2 hours, then evaporated under reduced pressure. The residue was azeotroped with toluene 5 to produce a powder.

A solution of crude acid chloride in dichloromethane (10ml) was added dropwise to a stirred, ice-cooled suspension of the title compound of Preparation 40 (430mg, 1.76mmol), triethylamine (558µl, 4mmol) and dichloromethane (10ml) and the reaction mixture stirred at room temperature 10 for 1.5 hours. The resulting mixture was washed successively with saturated aqueous sodium bicarbonate solution and brine, then the organic phase dried (MgSO_4) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel, using an elution gradient of hexane: ethyl acetate: methanol (70:30:0 to 0:90:10), to provide the title 15 compound (695mg, 76%) as a solid. Found: C, 53.96; H, 6.09; N, 19.00. $\text{C}_{26}\text{H}_{34}\text{N}_8\text{O}_5\text{S}$ requires C, 54.22; H, 6.00; N, 19.64%. δ (CDCl_3): 1.07 (6H,m), 2.01 (2H,m), 2.26 (3H,s), 2.48 (4H,m), 2.88 (2H,q), 3.10 (4H,m), 4.67 (2H,t), 5.34 (1H,s), 5.48 (2H,s), 6.70 (1H,s), 6.94 (1H,d), 7.22 (1H,m), 7.66 (1H,m), 8.59 (1H,d), 8.65 (1H,s), 8.82 (1H,s), 10.48 (1H,s). LRMS: m/z 572 ($\text{M}+2$)⁺.

20

PREPARATION 53

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

Obtained as a white foam (70%) from the title compounds of Preparation 25 29 and Preparation 41, using the procedure of Preparation 45A. δ (CDCl_3): 0.81 (3H,t), 1.02 (3H,t), 1.46 (2H,m), 2.39 (2H,q), 2.51 (4H,m), 2.82 (2H,t), 3.10 (4H,m), 3.39 (3H,s), 3.94 (2H,t), 4.85 (2H,t), 5.30 (1H,s), 5.46 (2H,s), 6.69 (1H,s), 6.90 (1H,d), 7.21 (1H,m), 7.65 (1H,m), 8.60 (1H,d), 8.65 (1H,s), 8.82 (1H,s), 10.46 (1H,s). LRMS: m/z 615 ($\text{M}+1$)⁺.

-141-

PREPARATION 54

4-[2-(2-Ethoxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

5 Obtained as a foam (69%) from the title compounds of Preparation 26 and Preparation 41, using the procedure of Preparation 52. Found: C, 55.13; H, 6.45; N, 17.27. $C_{29}H_{40}N_8O_6S$ requires C, 55.39; H, 6.41; N, 17.82%. δ ($CDCl_3$): 0.80 (3H,t), 1.02 (3H,t), 1.10 (3H,t), 1.45 (2H,m), 2.40 (2H,q), 2.50 (4H,m), 2.81 (2H,t), 3.09 (4H,m), 3.54 (2H,q), 3.98 (2H,t), 4.80 (2H,t), 5.30 (1H,s), 5.47 (2H,s), 6.70 (1H,s), 6.89 (1H,d), 7.22 (1H,m), 7.63 (1H,m), 8.59 (1H,d), 8.65 (1H,s), 8.82 (1H,s), 10.45 (1H,s). LRMS: m/z 629 (M+1)⁺.

10

PREPARATION 55

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(3-methoxyprop-1-oxy)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

15 Obtained as a foam (52%) from the title compounds of Preparation 27 and Preparation 41, using the procedure of Preparation 52. δ ($CDCl_3$): 0.82 (3H,t), 1.02 (3H,t), 1.44 (2H,m), 2.25 (2H,m), 2.40 (2H,q), 2.53 (4H,m), 2.84 (2H,t), 3.10 (4H,m), 3.29 (3H,s), 3.57 (2H,t), 4.79 (2H,t), 5.34 (1H,s), 5.47 (2H,s), 6.70 (1H,s), 6.92 (1H,d), 7.22 (1H,m), 7.66 (1H,m), 8.59 (1H,d), 8.65 (1H,s), 8.81 (1H,s), 10.45 (1H,s). LRMS: m/z 629 (M+1)⁺.

20

PREPARATION 56

3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(S)-yloxy)pyridin-3-ylcarboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

25 A solution of the title compound of Preparation 22 (330mg, 0.80mmol) and 1M aqueous sodium hydroxide solution (800 μ l, 0.80mmol) in ethanol (3ml) was stirred for 3 hours at room temperature, then evaporated under reduced pressure.

-142-

A mixture of the resulting solid, the title compound of Preparation 40 (196mg, 0.80mmol), 1-hydroxybenzotriazole hydrate (135mg, 0.88mmol), N-ethyldiisopropylamine (307µl, 1.76mmol), 1-(3-dimethylaminopropyl)-3-5 ethylcarbodiimide hydrochloride (169mg, 0.88mmol) and tetrahydrofuran (15ml) was stirred for 72 hours at room temperature, then evaporated under reduced pressure. The residue was partitioned between ethyl acetate (50ml) and water (15ml), the phases separated and the organic phase dried (Na_2SO_4) and evaporated under reduced pressure. The crude product was purified by 10 column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (95:5 to 90:10), to furnish the title compound (382mg, 78%) as a foam. δ (CDCl_3): 1.05 (6H,m), 2.40 (3H,m), 2.54 (5H,m), 2.85 (2H,q), 3.11 (4H,m), 3.54 (1H,m), 4.15 (3H,m), 5.31 (1H,s), 5.48 (2H,s), 5.90 (1H,m), 6.69 (1H,s), 6.94 (1H,d), 7.24 (1H,m), 7.67 (1H,m), 8.60 (1H,m), 15 8.66 (1H,s), 8.87 (1H,s), 10.27 (1H,s). LRMS: m/z 613 ($\text{M}+1$)⁺.

PREPARATION 57

4-(2-Ethoxy-5-nitropyridin-3-ylcarboxamido)-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

20 Oxalyl chloride (2.73ml, 31mmol) was added dropwise to a stirred suspension of the title compound of Preparation 8 (3.31g, 15.7mmol) in dichloromethane (50ml), followed by dimethylformamide (2 drops), and the reaction mixture stirred at room temperature for 3 hours. The resulting mixture was evaporated under reduced pressure and the residue azeotroped with 25 hexane to give a white solid.

A solution of the crude acid chloride in dichloromethane (20ml) was added dropwise to a stirred suspension of the title compound of Preparation 41 (4.06g, 15.7mmol), triethylamine (4.37ml, 31mmol) and dichloromethane (80ml) and the reaction mixture stirred at room temperature for 20 hours. The

-143-

resulting mixture was evaporated under reduced pressure and the residue partitioned between saturated aqueous sodium bicarbonate solution (200ml) and dichloromethane (300ml). The phases were separated, and the aqueous phase extracted with dichloromethane (2 x 300ml). The combined organic solutions were washed with brine, dried (Na_2SO_4) and evaporated under reduced pressure to give a purple solid. The crude product was triturated with ether and the resulting solid collected and dried under suction to afford the title compound (6.26g, 88%) as an off-white solid. Found: C, 55.42; H, 5.05; N, 10 21.49. $\text{C}_{21}\text{H}_{23}\text{N}_7\text{O}_5$ requires C, 55.62; H, 5.11; N, 21.62%. δ (CDCl_3): 0.83 (3H,t), 1.46 (2H,m), 1.60 (3H,t), 2.89 (2H,t), 4.85 (2H,q), 5.32 (1H,s), 5.48 (2H,s), 6.72 (1H,s), 6.95 (1H,d); 7.24 (1H,m), 7.67 (1H,m), 8.60 (1H,d), 9.16 (1H,s), 9.30 (1H,s), 10.59 (1H,s). LRMS: m/z 454 ($\text{M}+1$)⁺.

15

PREPARATION 58

3-Ethyl-4-[2-(2-methoxyethoxy)-5-nitropyridin-3-ylcarboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

1-Hydroxybenzotriazole hydrate (1.87g, 12.2mmol), N-ethyl diisopropyl amine (2.13ml, 12.2mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.34g, 12.2mmol) and the title compound of Preparation 40 (3.0g, 12.2mmol) were added, in turn, to a stirred, ice-cooled suspension of the title compound of Preparation 9 (2.96g, 12.2mmol) in dichloromethane (80ml) and the reaction mixture stirred for 18 hours at room temperature. The resulting mixture was washed consecutively with water (25ml), 2M hydrochloric acid (2 x 25ml), saturated aqueous sodium bicarbonate solution (25ml) and brine (25ml), then dried (MgSO_4) and evaporated under reduced pressure. The residual solid was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (99:1 to 97:3) to give the title compound (3.36, 58%) as a white solid. Found: C, 53.41; H, 4.90; N, 20.65. 25 $\text{C}_{21}\text{H}_{23}\text{N}_7\text{O}_6$ requires C, 53.72; H, 4.94; N, 20.89%. δ (CDCl_3): 1.08 (3H,t), 2.88 (2H,q), 3.40 (3H,s), 3.98 (2H,t), 4.90 (2H,t), 5.28 (1H,s), 5.48 (2H,s), 6.70 30

-144-

(1H,s), 6.92 (1H,d), 7.23 (1H,m), 7.66 (1H,m), 8.60 (1H,d), 9.15 (1H,s), 9.31 (1H,s), 10.50 (1H,s). LRMS: m/z 470 (M+1)⁺.

5

PREPARATION 59

4-(5-Amino-2-ethoxypyridin-3-ylcarboxamido)-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

A stirred mixture of the title compound of Preparation 57 (5g, 11mmol), Raney nickel (2.5g) and ethanol (150ml) was hydrogenated at 345kPa (50psi) and 40°C for 3 hours, then for a further 72 hours at room temperature. The resulting mixture was filtered and the filtrate evaporated under reduced pressure to give a pale yellow solid. The crude product was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (99:1 to 95:5), followed by trituration with ether, to yield the title compound (4.4g, 94%) as a beige solid. Found: C, 59.42; H, 5.96; N, 22.98. C₂₁H₂₅N₇O₃ requires C, 59.56; H, 5.95; N, 23.15%. δ (CDCl₃): 0.78 (3H,t); 1.43 (2H,m), 1.52 (3H,t), 2.82 (2H,t), 3.49 (2H,s), 4.59 (2H,q), 5.30 (1H,s), 5.46 (2H,s), 6.70 (1H,s), 6.93 (1H,d), 7.22 (1H,m), 7.65 (1H,m), 7.78 (1H,s), 7.94 (1H,s), 8.58 (1H,d), 10.53 (1H,s).

20

PREPARATION 60

4-[5-Amino-2-(2-methoxyethoxy)pyridin-3-ylcarboxamido]-3-ethyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

A stirred mixture of the title compound of Preparation 58 (3.3g, 7.0mmol), Raney nickel (2g) and ethanol (120ml) was hydrogenated at 345kPa (50psi) and 50°C for 18 hours. The resulting mixture was filtered and the

-145-

filtrate evaporated under reduced pressure to provide the title compound (3.01g, 98%) as a pale grey foam. Found: C, 56.47, H, 5.82; N, 21.40. $C_{21}H_{25}N_7O_4$; 0.40 H₂O requires C, 56.47; H, 5.82; N, 21.95%. δ (CDCl₃): 1.06 (3H,t), 2.81 (2H,q), 3.38 (3H,s), 3.50 (2H,s), 3.92 (2H,t), 4.65 (2H,t), 5.33 (1H,s), 5.46 (2H,s), 6.70 (1H,s), 6.92 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 7.76 (1H,s), 7.94 (1H,s), 8.60 (1H,d), 10.47 (1H,s). LRMS: m/z 440 (M+1)⁺.

PREPARATION 61

10 5-(5-Amino-2-ethoxypyridin-3-yl)-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Potassium t-butoxide (2.32g, 20mmol) was added carefully to a stirred suspension of the title compound of Preparation 59 (2.11g, 5mmol) and 4Å molecular sieves in ethanol (50ml) and the reaction mixture heated under reflux for 18 hours, allowed to cool and filtered. The filtrate was evaporated under reduced pressure and the residue partitioned between 1M hydrochloric acid (30ml) and ethyl acetate (30ml). The phases were separated, the aqueous phase extracted with ethyl acetate (2x30ml) and the combined organic solutions washed with brine, dried (Na₂SO₄) and evaporated under reduced pressure. 15 The residual brown oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4), to furnish the title compound (1.22g, 60%) as a pale yellow solid. Found: C, 61.92; H, 5.69; N, 23.95. $C_{21}H_{23}N_7O_2$ requires C, 62.21; H, 5.72; N, 24.18%. δ (CDCl₃): 0.94 (3H,t), 1.51 (3H,t), 1.62 (2H,m), 2.95 (2H,t), 3.57 (2H,s), 4.50 (2H,q), 5.68 (2H,s), 7.06 (1H,d), 7.21 (1H,m), 7.60 (1H,m), 7.78 (1H,s), 8.16 (1H,d), 8.57 (1H,s), 11.07 (1H,s).

-146-

PREPARATION 62

5-[5-Amino-2-(2-methoxyethoxy)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

5 Potassium bis(trimethylsilyl)amide (6.58g, 33.0mmol) was added to a stirred suspension of the title compound of Preparation 60 (2.90g, 6.60mmol) in 2-methoxyethanol (70ml) and the reaction mixture stirred under reflux for 18 hours. The resulting mixture was allowed to cool and then evaporated under reduced pressure to give a beige solid. The crude product was purified by 10 column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (98:2 to 95:5), to afford the title compound (2.21g, 79%) as a white solid. Found: C, 59.10; H, 5.44; N, 22.86. $C_{21}H_{23}N_7O_3$ requires C, 59.85, H, 5.50; N, 23.26%. δ ($CDCl_3$): 1.28 (3H,t), 3.01 (2H,q), 3.53 (3H,s), 3.58 (2H,s), 3.82 (2H,t), 4.62 (2H,t,), 5.66 (2H,s), 7.08 (1H,d), 7.20 (1H,m), 7.61 (1H,m), 7.75 (1H,s), 8.09 (1H,s), 8.57 (1H,d), 11.14 (1H,s).
15 LRMS: m/z 422 (M+1)⁺.

PREPARATION 63

5-(5-Chlorosulphonyl-2-ethoxypyridin-3-yl)-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3,d]pyrimidin-7-one

20 Sodium nitrite (295mg, 4.4mmol) was added portionwise to a stirred, ice-cooled solution of the title compound of Preparation 61 (900mg, 2.2mmol) in a mixture of glacial acetic acid (20ml) and concentrated hydrochloric acid (20ml) at such a rate as to maintain the temperature below -20°C. When the addition 25 was complete, the mixture was allowed to warm slowly to 0°C over 2 hours and then re-cooled to -15°C. Liquid sulphur dioxide (22ml) and a solution of copper(II) chloride (860mg, 6.6mmol) in a mixture of water (2ml) and glacial acetic acid (14ml) were then added and the reaction mixture stirred at 0°C for

-147-

30 minutes, followed by a further 2 hours at room temperature. The resulting mixture was carefully poured into stirred ice-water (300ml) and the suspension thus obtained was extracted with dichloromethane (3x100ml). The combined extracts were washed with brine, dried ($MgSO_4$) and evaporated under reduced pressure, then the residual oil triturated with ether to afford the title compound (720mg, 67%) as an off-white solid. δ ($CDCl_3$): 0.97 (3H,t), 1.60 (3H,t), 1.73 (2H,m), 3.01 (2H,t), 4.82 (2H,q), 5.70 (2H,s), 7.10 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.58 (1H,d), 8.90 (1H,s), 9.29 (1H,s), 10.55 (1H,s).

10

PREPARATION 64

5-[5-Chlorosulphonyl-2-(2-methoxyethoxy)pyridin-3-yl]-3-ethyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Obtained as a cream solid (84%) from the title compound of Preparation 15 62, using the procedure of Preparation 63. δ ($CDCl_3$): 1.32 (3H,t), 3.08 (2H,q), 3.58 (3H,s), 3.89 (2H,t), 4.85 (2H,t), 5.69 (2H,s), 7.12 (1H,d), 7.22 (1H,m), 7.64 (1H,m), 8.57 (1H,d), 8.89 (1H,s), 9.26 (1H,s), 10.75 (1H,s). LRMS: m/z 505 (M+1)⁺.

20

PREPARATION 65

3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarboxamido]-1-(pyridin-2-yl)methylpyrazolo-5-carboxamide

Obtained as a white crystalline solid (44%) from the title compounds of Preparation 19 and Preparation 42, using the procedure of Preparation 56. δ (25 $CDCl_3$): 1.02 (3H,t), 1.20 (3H,t), 2.40 (2H,q), 2.52 (4H,m), 2.66 (2H,q), 3.10 (4H,m), 3.39 (3H,s), 3.90 (2H,t), 4.81 (2H,t), 5.62 (2H,s), 5.70 (1H,s), 7.26 (2H,m), 7.71 (1H,m), 8.53 (1H,d), 8.66 (1H,s), 8.82 (1H,s), 9.04 (1H,s). LRMS: m/z 601 (M+1)⁺.

-148-

PREPARATION 66

3-Bromo-2-(1,3-dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine

60% Sodium hydride dispersion in mineral oil (133mg, 3.33mmol) was 5 added to a stirred, ice-cooled solution of 1,3-dimethoxypropan-2-ol (J. Amer. Chem. Soc., 1939, 61, 433; 400mg, 3.33mmol) in tetrahydrofuran (30ml) and the mixture stirred for 30 minutes. The title compound of Preparation 13 (500mg, 1.35mmol) was added and the reaction mixture stirred under reflux for 10 1 hour, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue partitioned between water (30ml) and ethyl acetate (30ml). The phases were separated and the aqueous phase extracted with ethyl acetate (2x30ml), then the combined extracts washed with brine (30ml), dried ($MgSO_4$) and evaporated under reduced pressure to give the title compound (566mg, 93%) as a yellow solid. δ ($CDCl_3$): 1.06 (3H,t), 2.43 (2H,q), 15 2.55 (4H,m), 3.08 (4H,m), 3.40 (6H,2xs), 3.70 (4H, 2xd), 5.60 (1H,m), 8.10 (1H,s), 8.44 (1H,s). LRMS: m/z 452.

PREPARATION 67

2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid ethyl ester

Obtained as a yellow solid (84%) from the title compound of Preparation 20 66, using the procedure of Preparation 19. δ ($CDCl_3$): 1.05 (3H,t), 1.40 (3H,t), 2.42 (2H,q), 2.55 (4H,m), 3.09 (4H,m), 3.40 (6H, 2xs), 3.70 (4H, 2xd), 4.37 (2H,q), 5.70 (1H,m), 8.40 (1H,s), 8.62 (1H,s). LRMS: m/z 446 ($M+1$)⁺.

25

PREPARATION 68

3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridine

Obtained as a clear oil (70%) from the title compound of Preparation 13

-149-

and 4-hydroxytetrahydropyran, following the procedure of Preparation 14, after purification by column chromatography on silica gel, using ethyl acetate as eluant. δ ($CDCl_3$): 1.05 (3H,t), 1.88 (2H,m), 2.08 (2H,m), 2.42 (2H,q), 2.54 (4H,m), 3.08 (4H,m), 3.66 (2H,m), 3.99 (2H,m) 5.40 (1H,m), 8.10 (1H,s), 8.42 (1H,s). LRMS: m/z 434 (M)⁺.

PREPARATION 69

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridine-3-carboxylic acid ethyl ester

Obtained as an oil (92%) from the title compound of Preparation 68, using the procedure of Preparation 19. δ ($CDCl_3$): 1.04 (3H,t), 1.40 (3H,t), 1.88 (2H,m), 2.08 (2H,m), 2.43 (2H,q), 2.55 (4H,m), 3.09 (4H,m), 3.66 (2H,m), 4.00 (2H,m), 4.40 (2H,q), 5.50 (1H,m), 8.40 (1H,s), 8.60 (1H,s). LRMS: m/z 427 (M)⁺.

PREPARATION 70

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridine-3-carboxylic acid sodium salt

A mixture of the title compound of Preparation 69 (611mg, 1.4mmol), 1M aqueous sodium hydroxide solution (1.6ml, 1.6mmol) and ethanol (6ml) was stirred at room temperature for 6 hours, then evaporated under reduced pressure. The residue was dissolved in water (16ml), then the solution washed with ethyl acetate (2x10ml) and evaporated under reduced pressure to provide the title compound (520mg, 93%) as a tan-coloured solid. δ ($DMSO_d_6$): 1.19 (3H,t), 1.70 (2H,m), 2.00 (2H,m), 2.80-3.88 (14H,m), 8.32 (1H,s), 8.73 (1H,s), 10.93 (1H,s). LRMS: m/z 400 (M+1)⁺.

-150-

PREPARATION 71

2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid sodium salt

5 Obtained as a solid (92%) from the title compound of Preparation 67, using the procedure of Preparation 70. LRMS: m/z 418 (M+1)⁺.

PREPARATION 72

4-[2-(1,3-Dimethoxyprop-2-oxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

10 A mixture of the title compounds of Preparation 71 (418mg, 0.95mmol) and Preparation 41 (250mg, 1.0mmol), 1-hydroxybenzotriazole hydrate (270mg, 2.0mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (380mg, 2.0mmol), triethylamine (280µl, 2.0mmol) and tetrahydrofuran (10ml) was stirred at room temperature for 36 hours, then evaporated under reduced pressure. The residue was partitioned between dichloromethane (10ml) and brine (10ml), the phases separated, the aqueous phase extracted with dichloromethane (2x10ml) and the combined organic solutions dried (MgSO₄) and evaporated under reduced pressure. The residual 15 yellow oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (98:2 to 96:4) to furnish the title compound (350mg, 56%) as an off-white solid. δ (CDCl₃): 0.81 (3H,t), 1.03 (3H,t), 1.44 (2H,m), 2.40 (2H,q), 2.52 (4H,m), 2.80 (2H,t), 3.10 (4H,m), 3.38 (6H,s), 3.78 (2H,dd), 3.92 (2H,dd), 5.31 (1H,s), 5.47 (2H,s), 5.93 (1H,m), 6.70 (1H,s), 6.92 (1H,d), 7.23 (1H,m), 7.65 (1H,m), 8.58 (1H,d), 8.65 (1H,s), 8.80 (1H,s), 10.26 (1H,s). LRMS: m/z 660 (M+2)⁺.

20

25

-151-

PREPARATION 73

3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-yloxy)pyridine

5 Obtained as an oil (89%) from the title compound of Preparation 13 and (R)-(-)-3-hydroxytetrahydrofuran, using the procedure of Preparation 17. δ ($CDCl_3$): 1.05 (3H,t), 2.20 (1H,m), 2.30 (1H,m), 2.42 (2H,q), 2.54 (4H,m), 3.07 (4H,m), 3.94 (2H,m), 4.02 (1H,m), 4.10 (1H,m), 5.63 (1H,m), 8.11 (1H,s), 8.43 (1H,s). LRMS: m/z 421 ($M+1$)⁺.

10

PREPARATION 74

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-yloxy)pyridine-3-carboxylic acid ethyl ester

15 Obtained as an oil (84%), from the title compound of Preparation 73, using the procedure of Preparation 19. δ ($CDCl_3$): 1.03 (3H,t), 1.40 (3H,t), 2.26 (2H,m), 2.42 (2H,q), 2.55 (4H,m), 3.10 (4H,m), 3.98 (3H,m), 4.12 (1H,m), 4.38 (2H,q), 5.70 (1H,m), 8.42 (1H,s), 8.62 (1H,s). LRMS: m/z 414 ($M+1$)⁺.

PREPARATION 75

3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(tetrahydrofuran-3(R)-yloxy)pyridin-3-ylcarboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

20 Obtained as a foam (78%) from the title compounds of Preparation 74 and Preparation 40, using the procedure of Preparation 56. δ ($CDCl_3$): 1.04 (6H,m), 2.40 (3H,m), 2.52 (5H,m), 2.84 (2H,q), 3.10 (4H,m), 3.94 (1H,m), 4.15 (3H,m), 5.28 (1H,s), 5.48 (2H,s), 5.90 (1H,m), 6.68 (1H,s), 6.92 (1H,d), 7.22 (1H,m), 7.67 (1H,m), 8.60 (1H,d), 8.64 (1H,s), 8.86 (1H,s), 10.28 (1H,s). LRMS: m/z 613 ($M+1$)⁺.

-152-

PREPARATION 76

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(tetrahydropyran-4-yloxy)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

5 A mixture of the title compounds of Preparation 70 (520mg, 1.3mmol) and Preparation 41 (285mg, 1.1mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (250mg, 1.3mmol), 1-hydroxybenzotriazole hydrate (199mg, 1.3mmol), N-ethyldiisopropylamine (226 μ l, 1.3mmol) and tetrahydrofuran (20ml) was stirred for 1 week at room temperature. Ethyl acetate (150ml) was then added and the resulting mixture washed with brine (2x50ml), dried ($MgSO_4$) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of ethyl acetate: dichloromethane:methanol (32:64:4 to 0:95:5), to afford the title compound (603mg, 86%) as a white foam. δ (DMSO- d_6): 0.74 (3H,t), 0.91 (3H,t), 1.39 (2H,m), 1.90 (2H,m), 2.05 (2H,m), 2.30 (2H,q), 2.42 (4H,m), 2.74 (2H,t), 2.95 (4H,m), 3.50 (2H,m), 3.85 (2H,m), 5.48 (2H,s), 5.52 (1H,m), 7.09 (1H,d), 7.35 (3H,m), 7.48 (1H,m), 8.39 (1H,s), 8.54 (1H,d), 8.65 (1H,s), 10.18 (1H,s). LRMS: m/z 641 (M+1)⁺.

20

PREPARATION 77

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

A stirred mixture of the title compounds of Preparation 28 (3.07g, 7.71mmol) and Preparation 41 (2.0g, 7.71mmol) in pyridine (50ml) was heated 25 at 50°C for 48 hours, then allowed to cool and evaporated under reduced pressure. The residue was partitioned between dichloromethane (100ml) and water (20ml), then the organic phase separated, dried ($MgSO_4$) and evaporated under reduced pressure. The residual brown foam was purified by column

-153-

chromatography on silica gel, using an elution gradient of ethyl acetate: methanol (100:0 to 90:10), to give the title compound (3.19g, 71%) as a white foam. Found: C, 54.66; H, 6.17; N, 18.38. $C_{27}H_{36}N_8O_5S$; 0.40 H₂O requires C, 5 54.79; H, 6.27; N, 18.93%. δ (CDCl₃): 0.82 (3H,t), 1.03 (3H,t), 1.45 (2H,m), 1.58 (3H,t); 2.40 (2H,q), 2.52 (4H,m), 2.86 (2H,t), 3.10 (4H,m), 4.79 (2H,q), 5.29 (1H,s), 5.46 (2H,s), 6.70 (1H,s), 6.93 (1H,d); 7.21 (1H,m), 7.64 (1H,m), 8.59 (1H,d), 8.64 (1H,s), 8.81 (1H,s), 10.56 (1H,s). LRMS: m/z 585 (M+1)⁺.

10

PREPARATION 78

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-propoxypyridine-3-carboxylic acid methyl ester

Obtained as an oil (53%) from the title compound of Preparation 49 and 1-ethylpiperazine, using the procedure of Preparation 18. δ (CDCl₃): 1.05 15 (6H,m), 1.86 (2H,m), 2.41 (2H,q), 2.54 (4H,m), 3.08 (4H,m), 3.92 (3H,s), 4.46 (2H,t), 8.40 (1H,s), 8.62 (1H,s). LRMS: m/z 372 (M+1)⁺.

PREPARATION 79

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propoxypyridine-3-carboxylic acid

20 A mixture of the title compound of Preparation 78 (370mg, 1.0mmol), 2M aqueous sodium hydroxide solution (1ml, 2mmol) and methanol (10ml) was stirred at room temperature for 2 hours. The resulting mixture was treated with solid carbon dioxide in order to adjust its pH to 7 and then evaporated under reduced pressure. The residue was triturated with dichloromethane (3x50ml) 25 and the combined organic solutions evaporated under reduced pressure to yield the title compound (340mg, 95%) as a white solid. LRMS: m/z 357 (M)⁺.

-154-

PREPARATION 80

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propoxypyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

5 Oxalyl chloride (122 μ l, 5.6mmol) was added dropwise to a stirred solution of the title compound of Preparation 79 (478mg, 1.4mmol) and dimethylformamide (3 drops) in dichloromethane (10ml) and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was azeotroped with dichloromethane (3x10ml), then added to a stirred, ice-cooled solution of the title compound of Preparation 41 (360mg, 1.4mmol) in pyridine (10ml) and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was partitioned between water (50ml) and dichloromethane (50ml), the phases separated and the aqueous phase 10 extracted with dichloromethane (2x50ml). The combined organic solutions were dried (Na_2SO_4) and evaporated under reduced pressure, then the crude product purified by column chromatography on silica gel, using ethyl acetate:methanol (80:20) as eluant, to provide the title compound (500mg, 37%) as a colourless glass. δ (CDCl_3): 0.81 (3H,t), 1.04 (3H,t), 1.27 (3H,t), 1.46 15 (2H,m), 2.00 (2H,m), 2.40 (2H,q), 2.53 (4H,m), 2.86 (2H,t), 3.09 (4H,m), 4.66 (2H,t), 5.27 (1H,s), 5.47 (2H,s), 6.68 (1H,s), 6.93 (1H,d), 7.21 (1H,m), 7.66 (1H,m), 8.59 (1H,d), 8.64 (1H,s), 8.80 (1H,s), 10.47 (1H,s). LRMS: m/z 599 (M+1)⁺.

25

PREPARATION 81

2-(2-Benzylxyethoxy)-3-bromo-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine

A mixture of a 2M solution of sodium bis(trimethylsilyl)amide in tetrahydrofuran (4.1ml, 8.2mmol), 2-benzylxyethanol (1.16ml, 8.2mmol) and tetrahydrofuran (5ml) was stirred at about 0°C for 1 hour. The title compound

-155-

of Preparation 13 (2.0g, 5.43mmol) was added and the reaction mixture stirred at room temperature for 5 hours, then evaporated under reduced pressure. The residue was suspended in ethyl acetate (10ml) and the suspension extracted with 2M hydrochloric acid (3x10ml). The combined extracts were basified with aqueous sodium bicarbonate solution and extracted with ethyl acetate (3x15ml). These combined extracts were dried (MgSO_4) and evaporated under reduced pressure, then the crude product purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5), to furnish the title compound (1.95g, 74%) as an oil.

10 δ (CDCl_3): 1.02 (3H,t), 2.40 (2H,q), 2.52 (4H,m), 3.07 (4H,m), 3.88 (2H,t), 4.62 (4H,m), 7.26 (1H,m), 7.34 (4H,m), 8.09 (1H,s), 8.42 (1H,s). LRMS: m/z 486 (M+2)⁺.

15

PREPARATION 82

2-(2-Benzylxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid ethyl ester

Obtained as an oil (42%) from the title compound of Preparation 81, using the procedure of Preparation 21. δ (CDCl_3): 1.04 (3H,t), 1.38 (3H,t), 2.42 (2H,q), 2.54 (4H,m), 3.08 (4H,m), 3.90 (2H,t), 4.38 (2H,q), 4.67 (4H,m), 7.28 (1H,m), 7.35 (4H,m), 8.41 (1H,s), 8.62 (1H,s). LRMS: m/z 478 (M+1)⁺.

PREPARATION 83

2-(2-Benzylxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid hydrochloride

Obtained as a pale yellow solid (88%) from the title compound of Preparation 82, using the procedure of Preparation 26. δ (CDCl_3): 1.45 (3H,t), 2.82 (2H,m), 3.09 (2H,q), 3.26 (2H,m), 3.64 (2H,m), 3.90 (4H,m), 4.64 (2H,s), 4.78 (2H,t), 7.33 (1H,m), 7.37 (4H,m), 8.58 (1H,s), 8.64 (1H,s), 12.17 (1H,s).

30 LRMS: m/z 450 (M+1)⁺.

-156-

PREPARATION 84

4-[2-(2-Benzylxyethoxy)-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

5 Obtained as an orange solid (80%), from the title compounds of Preparation 83 and Preparation 41, using the procedure of Preparation 52. δ (CDCl₃): 0.80 (3H,t), 1.02 (3H,t), 1.42 (2H,m), 2.40 (2H,q), 2.54 (4H,m), 2.81 (2H,t), 3.10 (4H,m), 4.06 (2H,t), 4.57 (2H,s), 4.86 (2H,t), 5.26 (1H,s), 5.45 (2H,s), 6.68 (1H,s), 6.90 (1H,d), 7.17-7.27 (5H,m), 7.34 (1H,m), 7.63 (1H,m),
10 8.59 (1H,d), 8.62 (1H,s), 8.82 (1H,s), 10.50 (1H,s). LRMS: m/z 692 (M+2)⁺.

PREPARATION 85

2-Benzyl-3-ethyl-4-nitropyrazole-5-carboxamide

15 Caesium carbonate (2.9g, 9.0mmol) was added to a stirred, ice-cooled solution of the title compound of Preparation 35 (1.7g, 8.8mmol) in dimethylformamide (20ml) and the suspension stirred for 30 minutes. Benzyl bromide (10.6ml, 9.0mmol) was added and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was partitioned between ethyl acetate (125ml) and brine (100ml), the 20 phases separated and the organic phase dried (MgSO₄) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using ethyl acetate as eluant, to afford the title compound (1.13g, 47%) as a white solid. δ (DMSO_d₆): 0.97 (3H,t), 2.96 (2H,q), 5.44 (2H,s), 7.24 (2H,m), 7.33 (3H,m), 7.68 (1H,s), 7.95 (1H,s). LRMS: m/z 274 (M+1)⁺.

25

PREPARATION 86

4-Amino-2-benzyl-3-ethylpyrazole-5-carboxamide

Obtained as a pale pink solid (90%) from the title compound of Preparation 85, using the procedure of Preparation 40. δ (DMSO_d₆): 0.87 (3H,t), 2.49 (2H,q), 4.46 (2H,s), 5.22 (2H,s), 6.85 (1H,s), 7.09 (3H,m), 7.25 (1H,m), 7.31 (2H,m). LRMS: m/z 245 (M+1)⁺.

-157-

PREPARATION 87

2-Benzyl-4-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-ethylpyrazole-5-carboxamide

5 Obtained as a white crystalline foam (46%) from the title compounds of Preparation 18 and Preparation 86, using the procedure of Preparation 56. δ (DMSO d_6): 0.92 (6H,m), 1.44 (3H,t), 2.30 (2H,q), 2.41 (4H,m), 2.74 (2H,q), 2.95 (4H,m), 4.62 (2H,q), 5.40 (2H,s), 7.17 (2H,m), 7.31 (4H,m), 7.50 (1H,s), 8.39 (1H,s), 8.65 (1H,s), 10.38 (1H,s). LRMS: m/z 571 (M+2)⁺.

10

PREPARATION 88a

3-Ethyl-1-(1-methylimidazol-2-yl)methyl-4-nitropyrazole-5-carboxamide

and

15

PREPARATION 88b

3-Ethyl-2-(1-methylimidazol-2-yl)methyl-4-nitropyrazole-5-carboxamide

A mixture of the title compound of Preparation 35 (2.2g, 11.95mmol), 2-chloromethyl-1-methylimidazole hydrochloride (J. Chem. Soc., 1957, 3305; 20 2.0g, 11.95mmol), caesium carbonate (8.5g, 26.3mmol) and dimethylformamide (100ml) was stirred at room temperature for 6 hours, then evaporated under reduced pressure. The residue was partitioned between water (150ml) and dichloromethane (150ml), the phases separated and the aqueous phase extracted with dichloromethane (2x150ml). The combined 25 extracts were dried ($MgSO_4$) and evaporated under reduced pressure, then the residue triturated with dichloromethane: methanol (90:10) and the resulting solid collected and dried under suction to give the first title compound (1-isomer; 305mg, 9%) as a cream solid. δ (DMSO d_6): 1.16 (3H,t), 2.82 (2H,q), 3.69 (3H,s), 5.40 (2H,s), 6.81 (1H,s), 7.13 (1H,s), 8.20 (1H,s), 8.50 (1H,s). 30 LRMS: m/z 279 (M+1)⁺.

-158-

The filtrate was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using dichloromethane:methanol:0.88 aqueous ammonia (90:10:1) as eluant, to yield 5 the second title compound (2-isomer; 480mg, 14%) as a solid. δ (CDCl_3): 1.16 (3H,t), 3.20 (2H,q), 3.77 (3H,s), 5.48 (2H,s), 6.22 (1H,s), 6.68 (1H,s), 7.00 (1H,s), 7.25 (1H,s). LRMS: m/z 279 ($\text{M}+1$)⁺.

PREPARATION 89

10 4-Amino-3-ethyl-2-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide

Obtained as a pink solid (92%) from the title compound of Preparation 88b, using the procedure of Preparation 40. δ (CDCl_3): 1.00 (3H,t), 2.68 (2H,q), 3.60 (3H,s), 5.34 (2H,s), 5.40 (1H,s), 6.55 (1H,s), 6.82 (1H,s), 6.98 (1H,s). LRMS: m/z 249 ($\text{M}+1$)⁺.

15

PREPARATION 90

20 3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarboxamido]-2-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide

Obtained as a solid (48%) from the title compounds of Preparation 29 and Preparation 89, using the procedure of Preparation 45A. δ (CDCl_3): 1.01 (3H,t), 1.10 (3H,t), 2.40 (2H,q), 2.52 (4H,m), 2.98 (2H,q), 3.08 (4H,m), 3.36 (3H,s), 3.66 (3H,s), 3.92 (2H,t), 4.82 (2H,t), 5.35 (1H,s), 5.42 (2H,s), 6.61 (1H,s), 6.86 (1H,s), 7.00 (1H,s), 8.64 (1H,s), 8.81 (1H,s), 10.33 (1H,s). LRMS: m/z 604 ($\text{M}+1$)⁺.

25

-159-

PREPARATION 91a

1-(1-Methylimidazol-2-yl)methyl-4-nitro-3-n-propylpyrazole-5-carboxamide

5

and

PREPARATION 91b

2-(1-Methylimidazol-2-yl)methyl-4-nitro-3-n-propylpyrazole-5-carboxamide

A stirred mixture of the title compound of Preparation 34 (5.0g, 10 25.3mmol), 2-chloromethyl-1-methylimidazole hydrochloride (J. Chem. Soc., 1957, 3305; 4.6g, 27.7mmol), caesium carbonate (18.1g, 55.6mmol) and acetonitrile (100ml) was heated at 50°C for 5 hours, then allowed to cool. Ethyl acetate (300ml) was added and the mixture washed with water (2x400ml), dried (MgSO₄) and concentrated under reduced pressure to a volume of about 15 200ml. The resulting precipitate was collected and combined with the material produced by crystallisation from ethyl acetate of the residue obtained by evaporation under reduced pressure of the filtrate, to provide, after drying, the first title compound (1-isomer; 1.0g, 13%) as white crystals. δ (DMSO_d₆): 0.89 (3H,t), 1.60 (2H,m), 2.76 (2H,t), 3.66 (3H,s), 5.39 (2H,s), 6.80 (1H,s), 7.12 (1H,s), 8.20 (1H,s), 8.48 (1H,s). LRMS: m/z 293 (M+1)⁺.

20

The crystallisation mother liquor was evaporated under reduced pressure and the residue recrystallised from ethyl acetate to furnish the second title compound (2-isomer; 700mg, 9%) as a solid. δ (DMSO_d₆): 0.92 (3H,t), 1.52 (2H,m), 3.04 (2H,t), 3.68 (3H,s), 5.49 (2H,s), 6.82 (1H,s), 7.14 (1H,s), 7.66 (1H,s), 7.93 (1H,s). LRMS: m/z 293 (M+1)⁺.

25

PREPARATION 92

4-Amino-2-(1-methylimidazol-2-yl)methyl-3-n-propylpyrazole-5-carboxamide

A stirred mixture of the title compound of Preparation 91b (500mg, 30 1.71mmol), 10% palladium on charcoal (150mg) and ethanol (20ml) was

-160-

hydrogenated for 4 hours at 345kPa (50psi), then filtered. The filtrate was combined with a dichloromethane: methanol (80:20) wash (50ml) of the filter pad, evaporated under reduced pressure and the residue crystallised from ethyl acetate to afford the title compound (320mg, 71%) as a pale pink solid. δ (CDCl₃): 0.90 (3H,t), 1.40 (2H,m), 2.60 (2H,t), 3.58 (3H,s), 3.94 (2H,s), 5.32 (3H,m), 6.54 (1H,s), 6.82 (1H,s), 6.98 (1H,s).

PREPARATION 93

10 3-(2-Phenylethenyl)pyridazine

Zinc chloride (820mg, 6mmol) was added to a stirred mixture of benzaldehyde (6.11ml, 60mmol) and 3-methylpyridazine (2.83g, 30mmol) and the resulting mixture heated for 20 hours at 150°C. The cool reaction mixture was partitioned between dichloromethane (40ml) and 2M aqueous sodium hydroxide solution (20ml), then the organic phase separated, combined with a dichloromethane extract (80ml) of the aqueous phase, dried (Na₂SO₄) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using dichloromethane: methanol (99:1) as eluant, to give the title compound (59%) as a solid. δ (CDCl₃): 7.12 (1H,d), 7.34 (3H,m), 7.56 (2H,d), 7.72 (1H,d), 8.37 (1H,s), 8.50 (1H,s), 8.60 (1H,s). LRMS: m/z 183 (M+1)⁺.

PREPARATION 94

25 3-Hydroxymethylpyridazine

Ozone was bubbled through a stirred solution of the title compound of Preparation 93 (3.60g, 0.02mol) in methanol (150ml) at -10°C. After 30 minutes the mixture was purged with nitrogen, sodium borohydride (750mg, 0.02mol) added portionwise and the resulting solution stirred for 2 hours at room temperature. The reaction mixture was acidified with 2M hydrochloric

-161-

acid, then basified with 0.880 aqueous ammonia solution and evaporated under reduced pressure. Purification of the residue by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (98:2 to 96:4), 5 provided the title compound (76%) as a solid. δ (CDCl₃): 3.66 (1H,s), 4.92 (2H,s), 7.48 (2H,m), 9.06 (1H,d).

PREPARATION 95

3-Chloromethylpyridazine hydrochloride

10 Thionyl chloride (3.05ml, 42mmol) was added to an ice-cooled flask containing the title compound of Preparation 94 (920mg, 8mmol) and the reaction mixture stirred for 45 minutes at room temperature, then evaporated under reduced pressure. The residue was azeotroped with toluene (40ml) to furnish the crude title compound (1.4g) as a brown solid. δ (DMSO_d₆): 4.98
15 (2H,s), 7.80 (1H,m), 7.90 (1H,d), 8.19 (1H,s), 9.22 (1H,d).

PREPARATION 96

4-Nitro-3-n-propyl-2-(pyridazin-3-yl)methylpyrazole-5-carboxamide

A mixture of the title compounds of Preparation 95 (700mg, 4.24mmol) 20 and Preparation 34 (840mg, 4.24mmol), caesium carbonate (3.45g, 10.6mmol) and acetonitrile (30ml) was stirred at 80°C for 2 hours, then allowed to cool. Brine (30ml) was added, the mixture extracted with dichloromethane (2x80ml) and the combined extracts dried (Na₂SO₄) and evaporated under reduced pressure. The residual brown oil was purified by column chromatography on 25 silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 90:10) to afford the title compound (480mg, 39%) as a yellow solid. δ (CDCl₃): 1.02 (3H,t), 1.60 (2H,m), 3.06 (2H,t), 5.72 (2H,s), 5.87 (1H,s), 7.25 (1H,s), 7.54 (2H,m), 9.20 (1H,s).

-162-

PREPARATION 97

4-Amino-3-n-propyl-2-(pyridazin-3-yl)methylpyrazole-5-carboxamide

Obtained as a pink gum (97%) from the title compound of Preparation 96, using the procedure of Preparation 40. δ (CDCl₃): 0.90 (3H,t), 1.47 (2H,m), 2.51 (2H,t), 5.25 (1H,s), 5.58 (2H,s), 6.58 (1H,s), 7.09 (1H,d), 7.43 (1H,m), 9.14 (1H,d). LRMS: m/z 261 (M+1)⁺.

PREPARATION 98

10 4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridazin-3-yl)methylpyrazole-5-carboxamide

Obtained as an orange gum (42%) from the title compounds of Preparation 28 and Preparation 97, using the procedure of Preparation 45A. δ (CDCl₃): 0.81 (3H,t), 1.01 (3H,t), 1.47 (2H,m), 1.55 (3H,t), 2.39 (2H,q), 2.50 (4H,m), 2.87 (2H,t), 3.07 (4H,m), 4.77 (2H,q), 5.58 (1H,s), 5.69 (2H,s), 6.71 (1H,s), 7.18 (1H,d), 7.45 (1H,m), 8.63 (1H,s), 8.79 (1H,s), 9.15 (1H,s), 10.52 (1H,s). LRMS: m/z 586 (M+1)⁺.

PREPARATION 99

20 2-Methylpyrimidine-1-oxide

A freshly prepared solution of sodium metal (11.5g, 0.50mol) in ethanol (170ml) was added dropwise over 1 hour to a stirred suspension of hydroxylamine hydrochloride (34.75g, 0.50mol) and phenolphthalein (50mg) in ethanol (200ml) so as to maintain a colourless solution and the mixture stirred at room temperature for 3 hours. Acetonitrile (26ml, 0.50mol) was added and this mixture stirred for a further 2 hours at room temperature, then at 45°C for 48 hours. The resulting mixture was filtered and the filtrate concentrated under reduced pressure to a volume of ca. 100ml, then cooled to 0°C. The resulting

precipitate was collected and dried under suction to give the intermediate acetamidoxime (9.9g, 27%) as white crystals.

5 Boron trifluoride diethyl ether complex (9.5ml, 75mmol), followed by 1,1,3,3-tetramethoxypropane (11.5ml, 70mmol), were added to a stirred mixture of dimethylformamide (100ml) and toluene (100ml). The acetamidoxime (5.0g, 67.5mmol) was then added and the reaction mixture heated under reflux for 45 minutes, then allowed to cool. The resulting mixture was evaporated under 10 reduced pressure and the residual brown oil partitioned between dichloromethane: methanol (80:20) (100ml) and aqueous sodium carbonate solution (100ml). The phases were separated, the aqueous phase extracted with dichloromethane: methanol (80:20) (10x50ml) and the combined organic solutions dried ($MgSO_4$) and evaporated under reduced pressure. The residue 15 was purified by column chromatography on silica gel, using dichloromethane: methanol (98:2) as eluant, to yield the title compound (2.5g, 34%) as an orange solid. δ ($CDCl_3$): 2.74 (3H,s), 7.19 (1H,m), 8.16 (1H,d), 8.39 (1H,d).

PREPARATION 100

2-Chloromethylpyrimidine

20 A stirred mixture of the title compound of Preparation 99 (2.5g, 22.7mmol) and phosphorous oxychloride (18ml, 193mmol) was heated under reflux for 2 hours, then allowed to cool. The resulting mixture was poured onto stirred ice and neutralised using solid sodium carbonate over 3 hours. The 25 aqueous solution thus obtained was extracted with dichloromethane (3x100ml), then the combined extracts dried ($MgSO_4$) and evaporated under reduced pressure. The residual brown oil was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to

-164-

97:3), to provide the title compound (510mg, 17%). δ (CDCl₃): 4.72 (2H,s), 7.22 (1H,m), 8.75 (2H,d). LRMS: m/z 129 (M+1)⁺.

5

PREPARATION 101a

4-Amino-3-n-propyl-1-(pyrimidin-2-yl)methylpyrazole-5-carboxamide

and

10

PREPARATION 101b

4-Amino-3-n-propyl-2-(pyrimidin-2-yl)methylpyrazole-5-carboxamide

Potassium hydroxide (393mg, 7mmol) was added to a stirred, ice-cooled solution of the title compound of Preparation 36 (1.2g, 6mmol) in dimethylformamide (10ml) and the mixture stirred for 1 hour at room temperature. The title compound of Preparation 100 (900mg, 7mmol) was then added and the reaction mixture stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was partitioned between water (10ml) and dichloromethane (15ml), the phases separated and the aqueous phase extracted with dichloromethane (2x15ml). The combined organic solutions were dried (MgSO₄) and evaporated under reduced pressure, then the residue purified by column chromatography on silica gel, using dichloromethane: methanol (95:5) as eluant, to furnish a mixture of the title compounds (not separated) (1.06g, 67%) as a pale pink solid. Analysis of the ¹H nmr spectrum indicated a N1:N2 ratio (i.e. 1-isomer:2-isomer) of 22:78. δ (DMSO_d₆): 0.81 (3H,t), 0.88 (3H,t), 1.38 (2H,m), 1.52 (2H,m), 2.48 (2H,t), 4.10 (2H,s), 4.44 (2H, s), 5.41 (2H,s), 5.73 (2H,s), 6.90 (1H,s), 7.06 (1H,s), 7.35 (1H,m), 7.42 (1H,m), 7.50 (2H,s), 8.68 (2H,d), 8.77 (2H,d). LRMS: m/z 261 (M+1)⁺.

-165-

PREPARATION 102a

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
ylcarboxamido]-3-n-propyl-1-(pyrimidin-2-yl)methylpyrazole-5-carboxamide

5

and

PREPARATION 102b

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-
ylcarboxamido]-3-n-propyl-2-(pyrimidin-2-yl)methylpyrazole-5-carboxamide

10 Triethylamine (1.12ml, 8.0mmol) was added to a stirred, ice-cooled suspension of the title compounds of Preparation 29 (680mg, 1.6mmol) and Preparations 101a/101b (417mg, 1.6mmol) in dichloromethane (20ml), then the reaction mixture stirred at room temperature for 18 hours, washed with water (10ml), dried ($MgSO_4$) and evaporated under reduced pressure. The residual brown foam was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (98:2 to 95:5), to afford the first title compound (1-isomer; 56mg, 6%) as an orange gum. δ ($CDCl_3$): 0.96 (3H,t), 1.04 (3H,t), 1.76 (2H,m), 2.42 (2H,q), 2.54 (4H,m), 3.38 (3H,s), 3.86 (2H,t), 4.76 (2H,t), 6.13 (2H,s), 7.11 (1H,m), 8.44 (1H,s), 8.62 (2H,d), 8.78 (1H,s), 10.17 (1H,s). LRMS: m/z 616 ($M+1$)⁺;

15 followed by the second title compound (2-isomer; 460mg, 47%) as an orange foam. δ ($CDCl_3$): 0.84 (3H,t), 1.03 (3H,t), 1.50 (2H,m), 2.40 (2H,q), 2.53 (4H,m), 2.88 (2H,t), 3.11 (4H,m), 3.39 (3H,s), 3.96 (2H,t), 4.85 (2H,q), 5.23 (1H,s), 5.58 (2H,s), 6.70 (1H,s), 7.25 (1H,m), 8.63 (1H,s), 8.74 (2H,d), 8.84 (1H,s), 10.52 (1H,s). LRMS: m/z 616 ($M+1$)⁺.

-166-

PREPARATION 103a

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-propyl-1-(pyrimidin-2-yl)methylpyrazole-5-carboxamide

5

and

PREPARATION 103b

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyrimidin-2-yl)methylpyrazole-5-carboxamide

10 Obtained as a mixture of isomers (88%) from the title compounds of Preparation 28 and Preparations 101a/101b using the procedure of Preparation 45A. LRMS: m/z 586 (M+1)⁺.

15

PREPARATION 104

4-Amino-3-n-propyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

20 Obtained as a solid (92%) from the title compound of Preparation 39a, using the procedure of Preparation 41. δ (DMSO₆): 0.88 (3H,t), 1.55 (2H,m), 2.43 (2H,t), 4.18 (2H,s), 5.59 (2H,s), 6.73 (1H,d), 7.22 (1H,m), 7.57 (2H,s), 7.69 (1H,m), 8.47 (1H,d). LRMS: m/z 260 (M+1)⁺.

PREPARATION 105

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-n-propyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

25 Obtained as a brown foam (74%) from the title compounds of Preparation 28 and Preparation 104, using the procedure of Preparation 45A. δ (CDCl₃): 0.94 (3H,t), 1.02 (3H,t), 1.62 (5H,m), 2.40 (2H,q), 2.52 (4H,m), 2.64 (2H,t), 3.09 (4H,m), 4.77 (2H,q), 5.58 (2H,s), 5.71 (1H,s), 7.26 (1H,m), 7.40 (1H,d), 7.74 (1H,m), 8.52 (1H,d), 8.67 (1H,s), 8.82 (1H,s), 9.60 (1H,s), 9.96 (1H,s). LRMS: m/z 585 (M+1)⁺.

-167-

PREPARATION 106

4-Amino-3-ethyl-1-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide

Obtained as a pink foam (95%) from the title compound of Preparation 88a, using the procedure of Preparation 40. δ (DMSO d_6): 1.09 (3H,t), 2.43 (2H,q), 3.72 (3H,s), 4.37 (2H,s), 5.44 (2H,s), 6.79 (1H,s), 7.08 (1H,s). LRMS: m/z 249 (M+1) $^+$.

PREPARATION 107

10 4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-ethyl-1-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide

Obtained as a solid (78%) from the title compounds of Preparation 28 and Preparation 106, using the procedure of Preparation 45A. δ (CDCl $_3$): 1.01 (3H,t), 1.21 (3H,t), 1.60 (3H,t), 2.40 (2H,q), 2.53 (4H,m), 2.72 (2H,q), 3.08 (4H,m), 3.94 (3H,s), 4.76 (2H,q), 5.54 (2H,s), 5.93 (1H,s), 6.83 (1H,s), 6.92 (1H,s), 8.65 (1H,s), 8.82 (1H,s), 9.95 (1H,s), 10.27 (1H,s). LRMS: m/z 575 (M+2) $^+$.

PREPARATION 108

20 4-Amino-1-(1-methylimidazol-2-yl)methyl-3-n-propylpyrazole-5-carboxamide

Obtained as a cream solid (78%) from the title compound of Preparation 91a, using the procedure of Preparation 40. δ (DMSO d_6): 0.87 (3H,t), 1.52 (2H,m), 2.38 (2H,t), 3.70 (3H,s), 4.35 (2H,s), 5.44 (2H,s), 6.78 (1H,s), 7.08 (1H,s). LRMS: m/z 263 (M+1) $^+$.

25

PREPARATION 109

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-ylcarboxamido]-1-(1-methylimidazol-2-yl)methyl-3-n-propylpyrazole-5-carboxamide

30 Obtained (67%) from the title compounds of Preparation 25 and

-168-

Preparation 108, using the procedure of Preparation 52. δ (CDCl_3): 0.95 (3H,t), 1.02 (3H,t), 1.66 (2H,m), 2.40 (2H,q), 2.51 (4H,m), 2.63 (2H,t), 3.09 (4H,m), 3.39 (3H,s), 3.88 (3H,s), 3.93 (2H,t), 4.80 (2H,t), 5.56 (2H,s), 5.81 (1H,s), 6.83 (1H,s), 6.92 (1H,s), 8.65 (1H,s), 8.82 (1H,s), 9.60 (1H,s), 10.08 (1H,s).

PREPARATION 110

3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridine

A mixture of 4-hydroxy-1-methylpiperidine (560mg, 4.89mmol), 60% sodium hydride dispersion in mineral oil (200mg, 4.89mmol) and tetrahydrofuran (30ml) was stirred at about 0°C for 30 minutes. The title compound of Preparation 13 (600mg, 1.63mmol) was added and the reaction mixture heated under reflux for 90 minutes, then allowed to cool. The resulting mixture was evaporated under reduced pressure, the residue suspended in ethyl acetate (50ml) and the suspension washed consecutively with 2M aqueous sodium hydroxide solution (2x20ml), water (20ml) and brine (20ml). The resulting solution was dried (MgSO_4) and evaporated under reduced pressure to give the title compound (660mg, 70%) as a yellow oil. δ (CDCl_3): 1.05 (3H,t), 1.92 (2H,m), 2.04 (2H,m), 2.33 (3H,s), 2.42 (4H,m), 2.55 (4H,m), 2.66 (2H,m), 3.08 (4H,m), 5.24 (1H,m), 8.09 (1H,s), 8.42 (1H,s). LRMS: m/z 447 (M)⁺.

PREPARATION 111

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridine-3-carboxylic acid ethyl ester

Triethylamine (2ml, 1.43mmol) and tetrakis(triphenylphosphine)-palladium(0) (200mg, 0.173mmol) were added to a stirred solution of the title compound of Preparation 110 (640mg, 1.43mmol) in ethanol (20ml) and the reaction mixture heated under carbon monoxide at 100°C and 1034kPa

-169-

(150psi) in a sealed vessel for 18 hours, then allowed to cool. The resulting mixture was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using dichloromethane: methanol (96.5:3.5) as eluant, to yield the title compound (550mg, 87%) as an orange solid. δ (CDCl₃): 1.02 (3H,t), 1.40 (3H,t), 2.16 (2H,m), 2.41 (2H,q), 2.56 (6H,m), 2.72 (3H,s), 3.08 (4H,m), 3.19 (4H,m), 4.38 (2H,q), 5.60 (1H,m), 8.42 (1H,s), 8.62 (1H,s). LRMS: m/z 441 (M+1).

10

PREPARATION 112

5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridine-3-carboxylic acid sodium salt

A mixture of the title compound of Preparation 111 (550mg, 1.25mmol), 1M aqueous sodium hydroxide solution (2.4ml, 2.40mmol) and ethanol (5ml) 15 was stirred at room temperature for 18 hours, then evaporated under reduced pressure. The residue was partitioned between water (15ml) and ethyl acetate (15ml), the phases separated and the aqueous phase evaporated under reduced pressure to provide the title compound (510mg, 94%) as a white solid. δ (DMSO-d₆): 0.93 (3H,t), 1.94 (2H,m), 2.10 (2H,m), 2.16 (3H,s), 2.29 (2H,q), 2.40 (4H,m), 2.68 (4H,m), 2.88 (4H,m), 5.08 (1H,m), 7.75 (1H,s), 8.28 (1H,s).

PREPARATION 113a

4-Amino-1-(2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide

25

and

PREPARATION 113b

4-Amino-2-(2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide

4-(2-Chloroethyl)morpholine (obtained by basification of the 30 hydrochloride salt (2.67g, 14.35mmol)) was added to a stirred solution of the

-170-

title compound of Preparation 36 (2.0g, 11.96mmol) and potassium hydroxide (800mg, 14.35mmol) in dimethylformamide (20ml) and the reaction mixture heated under reflux for 18 hours, then allowed to cool. The resulting mixture 5 was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using dichloromethane: methanol: glacial acetic acid (95:5:1) as eluant, to furnish the second title compound (2-isomer; 480mg, 14%). δ (CDCl₃): 0.98 (3H,t), 1.60 (2H,m), 2.48 (4H,m), 2.55 (2H,t), 2.76 (2H,t), 10 3.69 (4H,m), 3.94 (2H,s), 4.08 (2H,t), 5.19 (1H,s), 6.55 (1H,s). LRMS: m/z 282 (M+1)⁺;
followed by the first title compound (1-isomer; 350mg, 10%). δ (CDCl₃): 0.97 (3H,t), 1.64 (2H,m), 2.50 (6H,m), 2.81 (2H,t), 3.48 (2H,s), 3.64 (4H,m), 4.50 (2H,t).

15

PREPARATION 114

3-t-Butyl-1H-pyrazole-5-carboxylic acid hydrochloride

Hydrazine hydrate (1.7ml, 35mmol) was added dropwise to a stirred solution of 5,5-dimethyl-2,4-dioxohexanoic acid ethylester (J. Org. Chem., 1997, 62, 5908; 6.1g, 30.5mmol) in ethanol (20ml) and the reaction mixture 20 stirred at room temperature for 4 hours, then evaporated under reduced pressure. The residue was partitioned between dichloromethane (20ml) and water (20ml), the phases separated and the aqueous phase extracted with dichloromethane (2x20ml). The combined organic solutions were dried (MgSO₄) and evaporated under reduced pressure to give the crude ester as a 25 yellow solid.

A mixture of this product, 1,4-dioxan (100ml) and 2M aqueous sodium hydroxide solution (25.5ml, 51mmol) was stirred at room temperature for 72 hours, then the pH of the reaction mixture adjusted to 2 with hydrochloric acid. The resulting mixture was evaporated under reduced pressure and the residue

-171-

triturated with hot ethanol. This mixture was filtered and the filtrate evaporated under reduced pressure to afford the title compound (5.06g, 81%) as an orange solid. δ (DMSO d_6): 1.26 (9H,s), 6.46 (1H,s).

5

PREPARATION 115

3-t-Butyl-4-nitro-1H-pyrazole-5-carboxylic acid

The title compound of Preparation 114 (1.5g, 7.3mmol) was added portionwise to stirred, ice-cooled concentrated sulphuric acid (7.5ml), the 10 mixture warmed to 40°C and fuming nitric acid (1.13ml) then added dropwise, so as to maintain the internal temperature below 50°C. The reaction mixture was stirred at 50°C for 7 hours, allowed to cool and poured carefully onto ice/water (100g). The resulting suspension was stirred for 2 hours and filtered, then the collected solid washed with water and dried under suction to give the 15 title compound (975mg, 63%) as a white solid. δ (DMSO d_6): 1.33 (9H,s). LRMS: m/z 231 (M+18) $^+$.

PREPARATION 116

3-t-Butyl-4-nitro-1H-pyrazole-5-carboxamide

20 Oxalyl chloride (1.59ml, 18.2mmol) was added dropwise to a stirred, ice-cooled solution of the title compound of Preparation 115 (970mg, 4.55mmol) and dimethylformamide (1 drop) in dichloromethane (20ml) and the reaction mixture stirred at room temperature for 3 hours, then evaporated under reduced pressure. The residue was azeotroped firstly with dichloromethane and then 25 with 0.88 aqueous ammonia solution. The resulting material was triturated with hot ethanol, then acetonitrile, the mixture filtered and the filtrate evaporated under reduced pressure to yield the title compound (955mg, 99%) as a white solid. δ (DMSO d_6): 1.36 (9H,s), 7.60 (1H,s), 7.88 (1H,s). LRMS: m/z 230 (M+18) $^+$.

-172-

PREPARATION 117

3-t-Butyl-4-nitro-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

A mixture of the title compound of Preparation 116 (960mg, 4.55mmol), 5 caesium carbonate (3.7g, 11.36mmol) and 2-(chloromethyl)pyridine hydrochloride (821mg, 5.00mmol) in acetonitrile (20ml) was stirred at 70°C for 20 hours, then allowed to cool and filtered. The filtrate was evaporated under reduced pressure, then the residue purified by column chromatography on silica gel, using an elution gradient of ethyl acetate: methanol (100:0 to 10 95:5), to provide the title compound (300mg, 22%) as a yellow solid. δ (DMSO_d₆): 1.35 (9H,s), 5.40 (2H,s), 7.18 (1H,d), 7.32 (1H,m), 7.80 (1H,m), 8.10 (1H,s), 8.46 (1H,s), 8.51 (1H,d). LRMS: m/z 304 (M+1)⁺.

PREPARATION 118

4-Amino-3-t-butyl-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

A stirred mixture of the title compound of Preparation 117 (290mg, 0.96mmol) and 10% palladium on charcoal (29mg) in ethanol (20ml) was hydrogenated at 345kPa (50psi) and room temperature for 7 hours, then filtered. The filter pad was washed with ethanol and the combined washings 20 and filtrate evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of ethyl acetate: methanol (100:0 to 95:5), to furnish the title compound (220mg, 84%) as an orange solid. δ (CDCl₃): 1.36 (9H,s), 4.00 (2H,s), 5.50 (2H,s), 7.23 (1H,m), 7.38 (1H,d), 7.71 (1H,m), 8.50 (1H,d). LRMS: m/z 274 (M+1)⁺.

25

PREPARATION 119

4-[5-(4-Ethylpiperazin-1-ylsulphonyl)-2-(1-methylpiperidin-4-yloxy)pyridin-3-ylcarboxamido]-3-n-propyl-2-(pyridin-2-yl)methylpyrazole-5-carboxamide

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (350mg, 30 1.8mmol) was added to a stirred solution of 1-hydroxybenzotriazole hydrate

-173-

(250mg, 1.8mmol), triethylamine (350µl, 2.5mmol) and the title compounds of Preparation 112 (510mg, 1.18mmol) and Preparation 41 (330mg, 1.25mmol) in tetrahydrofuran (20ml) and the reaction mixture stirred at room temperature for 5 72 hours, then evaporated under reduced pressure. The residue was triturated several times with ethyl acetate to afford the title compound (175mg, 21%) as a white solid. δ (CDCl₃): 0.81 (3H,t), 1.04 (3H,t), 1.47 (2H,m), 2.17 (4H,m), 2.32 (5H,m), 2.40 (2H,q), 2.53 (4H,m), 2.76 (2H,m), 2.84 (2H,t), 3.10 (4H,m), 5.49 (3H,m), 5.64 (1H,s), 6.90 (2H,m), 7.22 (1H,m), 7.68 (1H,m), 8.60 (1H,d), 8.64 (1H,s), 8.82 (1H,s), 10.35 (1H,s). LRMS: m/z 654 (M+1)⁺.

PREPARATION 120

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2-(2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide

15 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (280mg, 1.5mmol) was added to a stirred solution of 1-hydroxybenzotriazole hydrate (200mg, 1.5mmol), triethylamine (278µl, 2.0mmol) and the title compounds of Preparation 23 (371mg, 1.0mmol) and Preparation 113b (250mg, 0.9mmol) in dichloromethane (20ml) and the reaction mixture stirred at room temperature for 20 18 hours. The resulting mixture was washed with water (10ml), dried (MgSO₄) and evaporated under reduced pressure, then the residue purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (97:3 to 95:5), to give the title compound (430mg, 68%) as a white solid. δ (CDCl₃): 0.93 (3H,t), 1.02 (3H,t), 1.58 (5H,m), 2.40 (2H,q), 2.52 (8H,m), 2.82 (2H,t), 2.90 (2H,t), 3.12 (4H,m), 3.72 (4H,m), 4.20 (2H,t), 4.79 (2H,q), 5.28 (1H,s), 6.63 (1H,s), 8.64 (1H,s), 8.82 (1H,s), 10.50 (1H,s).

PREPARATION 121

3-t-Butyl-4-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-1-(pyridin-2-yl)methylpyrazole-5-carboxamide

30 The title compound of Preparation 28 (384mg, 0.967mmol) was added dropwise to a stirred, ice-cooled solution of the title compound of Preparation

118 (220mg, 0.805mmol) and triethylamine (330 μ l, 2.42mmol) in dichloromethane (10ml) and the reaction mixture stirred at room temperature for 14 hours. The resulting mixture was washed with aqueous sodium bicarbonate solution (5ml) and brine (5ml), dried (Na_2SO_4) and evaporated under reduced pressure. The residue was purified by two column chromatography operations on silica gel, using an elution gradient of ethyl acetate: methanol (100:0 to 90:10) and then of dichloromethane: methanol (100:0 to 95:5), to yield the title compound (156mg, 32%) as a white solid. δ (CDCl_3): 1.02 (3H,t), 1.36 (9H,s), 1.55 (3H,t), 2.42 (2H,q), 2.55 (4H,m), 3.10 (4H,m), 4.77 (2H,q), 5.68 (3H,m), 7.02 (1H,d), 7.19 (1H,m), 7.65 (1H,m), 7.98 (1H,s), 8.56 (1H,d), 8.70 (1H,s), 8.87 (1H,s), 9.35 (1H,s). LRMS: m/z 599 ($\text{M}+1$)⁺.

PREPARATION 122

15 4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-1-(2-morpholin-4-yl)ethyl-3-n-propylpyrazole-5-carboxamide

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.34g, 7.0mmol) was added to a stirred solution of 1-hydroxybenzotriazole hydrate (945mg, 7.0mmol), N-ethyldiisopropylamine (1.22ml, 7.0mmol) and the title 20 compounds of Preparation 113a (1.82g, 6.5mmol) and Preparation 23 (428mg, 1.25mmol) in tetrahydrofuran (120ml) and the reaction mixture stirred at room temperature for 72 hours. The resulting mixture was evaporated under reduced pressure and the residue partitioned between aqueous sodium carbonate solution (50ml) and dichloromethane (100ml). The phases were separated, the 25 aqueous phase extracted with dichloromethane (2x100ml) and the combined organic solutions washed with brine (3x50ml), dried (Na_2SO_4) and evaporated under reduced pressure. The residue was triturated with ether, then crystallised from ethyl acetate-methanol, to provide the title compound (310mg, 42%) as a white solid. δ (CDCl_3): 0.92 (3H,t), 1.01 (3H,t), 1.54 (3H,t), 1.62 (2H,m), 2.36-2.60 (12H,m), 2.80 (2H,t), 3.08 (4H,m), 3.64 (4H,m), 4.49 (2H,t), 30 4.72 (2H,q), 5.78 (1H,s), 8.30 (1H,s), 8.66 (1H,s), 8.80 (1H,s), 9.49 (1H,s). LRMS: m/z 607 ($\text{M}+1$)⁺.

-175-

PREPARATION 123

3-Ethyl-1-methyl-4-nitropyrazole-5-carboxamide

and

PREPARATION 124

3-Ethyl-2-methyl-4-nitropyrazole-5-carboxamide



A mixture of the title compound of Preparation 35 (100g, 0.54mol), and caesium carbonate (194g, 0.60mol) in N,N-dimethylformamide (1000ml) was stirred at 10 room temperature for 45 minutes, then cooled in an ice-bath. Methyl iodide (37.2ml, 0.60mol) was added dropwise and once the addition was complete, the reaction was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate (500ml) and water (300ml). The layers were separated, the aqueous phase extracted with ethyl acetate (4x500ml) and the combined organic solutions dried (MgSO_4) and evaporated under reduced pressure. The crude product was recrystallised from dichloromethane/ethyl acetate to give some of the N1 isomer (17.0g, 16%).

The filtrate was evaporated under reduced pressure and the residue was 20 purified by column chromatography on silica gel, using ethyl acetate: pentane (80:20) as eluant to afford the title compound of Preparation 123 (25.0g, 23%) as a white solid.


25 δ (CDCl_3) : 1.27 (3H, t), 2.94 (2H, q), 4.06 (3H, s), 6.00 (1H, br s), 7.56 (1H, br s).

LRMS : m/z 216 ($\text{M}+18$)⁺

and the title compound of Preparation 124 (28.4g, 27%) as a white solid.


30 δ (CDCl_3) : 1.29 (3H, t), 3.00 (2H, q), 3.92 (3H, s), 5.98 (1H, s), 7.32 (1H, s).

-176-

PREPARATION 1252-Methyl-3-n-propyl-pyrazole-5-carboxylic acid ethyl ester

5 A solution of diethyloxalate (27.2ml, 0.2mol) in 2-pentanone (21.2ml, 0.2mol) was added dropwise to a solution of sodium (4.83g, 0.21mol) in ethanol (200ml), and the reaction stirred at 60°C for 5 hours, then cooled in an ice-bath. The solution was neutralised using acetic acid (11.5ml, 0.2mol) and N-methyl hydrazine (10.6ml, 0.2mol) then added dropwise. The mixture was
 10 stirred for a further 4 hours at room temperature and concentrated under reduced pressure. The residue was partitioned between dichloromethane (300ml) and water (200ml), and the phases separated. The aqueous layer was extracted with dichloromethane (3x100ml), the combined organic solutions were dried ($MgSO_4$) and evaporated under reduced pressure. The crude
 15 product was purified by column chromatography on silica gel, using ethyl acetate: hexane (25:75) as eluant to give ethyl 1-methyl-3-n-propyl-pyrazole-5-carboxylate (6.1g) and the title compound (22.1g, 56%).
 δ ($CDCl_3$) : 1.00 (3H, t), 1.40 (3H, t), 1.70 (2H, m), 2.60 (2H, t), 3.87 (3H, s), 4.40 (2H, q), 6.60 (1H, s).

20

PREPARATION 1262-Methyl-3-n-propylpyrazole-5-carboxylic acid

A mixture of the title compound of Preparation 125 (21.5g, 0.11mol) in aqueous
 25 sodium hydroxide solution (50ml, 6N, 0.3mol) was heated under reflux for 3 hours. The cooled mixture was diluted with water (50ml) and acidified using

-177-


concentrated hydrochloric acid (25ml) and the resulting precipitate was filtered and dried to give the title compound (17.3g, 94%) as a pale yellow solid.

A portion (1g) of this solid, was recrystallised from water/ethanol.

5 m.p. 120-122°C. δ (DMSO-d₆) : 0.95 (3H, t), 1.59 (2H, m), 2.60 (2H, t), 3.78 (3H, s), 6.48 (1H, s), 12.45 (1H, s).

PREPARATION 127


2-Methyl-4-nitro-3-n-propylpyrazole-5-carboxylic acid



10 Obtained as a solid (89%) from the title compound of Preparation 126, using a similar procedure to that described in Preparation 32. δ (DMSO-d₆) : 0.95 (3H, t), 1.60 (2H, m), 2.96 (2H, t), 3.88 (3H, s), 13.75 (1H, s).

PREPARATION 128


2-Methyl-4-nitro-3-n-propylpyrazole-5-carboxamide



A mixture of the title compound of Preparation 127 (18.6g, 87.3mmol) in thionyl chloride (75ml), was heated under reflux for 2 hours. The cooled reaction mixture was concentrated under reduced pressure and the residue poured into 20 an ice/ammonium hydroxide mixture. This was extracted with dichloromethane (4x100ml) and the combined organic extracts dried (MgSO₄) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel, using dichloromethane:methanol:0.88 ammonia (95:5:1) as eluant to afford the title compound (6.8g, 37%) as a solid.

25 δ (CDCl₃) : 1.07 (3H, t), 1.72 (2H, m), 3.00 (2H, t), 3.97 (3H, s), 6.14 (1H, s), 7.40 (1H, s).

-178-

PREPARATION 1292. 3-Diethyl-4-nitro-pyrazole-5-carboxamide


5 Ethyl iodide (7.2ml, 90.0mmol) was added to a suspension of the title compound of Preparation 35 (15.0g, 81.0mmol), and cesium carbonate (29.3g, 90.0mmol) in N,N-dimethylformamide (100ml) and the reaction stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure and the residue triturated with water (100ml), and the resulting solid 10 filtered and dried. A suspension of this solid in ether (250ml) was heated at 35°C for an hour, and the precipitate filtered and dried. This was recrystallised from ethyl acetate to afford the title compound as a crystalline solid (5.8g, 34%).

15 δ (CDCl₃) : 1.30 (3H, t), 1.54 (3H, t), 3.00 (2H, q), 4.20 (2H, q), 5.92 (1H, s), 7.27 (1H, s).

LRMS : m/z 212 (M)⁺

PREPARATION 1303-Ethyl-4-nitro-2-(pyridazin-3-yl)methyl-pyrazole-5-carboxamide

20



25 A mixture of the title compounds of Preparation 35 (2.66g, 14.5mmol), and 95 (2.65g, 16.1mmol) and caesium carbonate (13.1g, 40.2mmol) in acetonitrile (100ml) was stirred under reflux for 18 hours. The cooled reaction was concentrated under reduced pressure, the residue suspended in water and extracted with dichloromethane (5x100ml). The combined organic extracts were dried (Na₂SO₄), adsorbed onto silica gel and the product isolated by column

-179-

chromatography on silica gel, using an elution gradient of methanol: dichloromethane (5:95 to 10:90) to give 3-ethyl-4-nitro-1-(pyridazin-3-yl)methyl-pyrazole-5-carboxamide (1.31g), and the title compound (1.81g, 45%) as a pale yellow solid.


δ (CDCl₃) : 1.20 (3H, t), 3.11 (2H, q), 5.72 (2H, s), 5.89 (1H, s), 7.29 (1H, s), 7.55 (2H, m), 9.20 (1H, d).

LRMS : m/z 277 (M+1)⁺

10

PREPARATION 131

3-Ethyl-4-nitro-2-[1-(pyridin-2-yl)ethyl]-pyrazole-5-carboxamide



15

A mixture of 2-ethylpyridine (20.0g, 187mmol), N-bromosuccinimide (38.0g, 213mmol), and benzoyl peroxide (1.0g, 75% in water) in 1,1,1-trichloroethane (200ml), was heated under reflux for 3 hours. The cooled mixture was filtered, and the filtrate washed with water (2x100ml), aqueous sodium thiosulphate solution (100ml), and brine (100ml). The solution was dried (MgSO₄), filtered through charcoal, and then hydrobromic acid (25ml, 62%) added. This solution was concentrated under reduced pressure and azeotroped with toluene to give 2-(1-bromoethyl)pyridine hydrochloride as a dark oil (66.0g).

A mixture of the title compound of Preparation 35 (8.0g, 43.4mmol), caesium carbonate (35.0g, 107.4mmol) and the crude 2-(1-bromoethyl)pyridine hydrochloride (13.6g, 52.0mmol) in N,N-dimethylformamide (80ml) was stirred at room temperature for 20 hours. The mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate (150ml) and water (50ml). The layers were separated and the organic phase washed

-180-

with more water (3x50ml), brine (50ml), then dried (MgSO_4) and evaporated under reduced pressure. The residual oil was purified by column chromatography on silica gel, using an elution gradient of pentane: ethyl acetate: methanol (90:10:0 to 0:100:0 to 0:90:10) to afford the N1 isomer (4.3g), and the title compound (5.7g, 45%).


δ (CDCl_3) : 1.14 (3H, t), 2.01 (3H, d), 3.00 (2H, q), 5.66 (2H, q), 5.88 (1H, s), 6.98 (1H, s), 7.18 (1H, d), 7.25 (1H, m), 7.68 (1H, m), 8.56 (1H, d).

LRMS : m/z 290 ($\text{M}+1$)⁺

10

PREPARATION 132

3-Ethyl-2-(6-methylpyridin-2-yl)methyl-4-nitropyrazole-5-carboxamide




15 A mixture of the title compound of Preparation 35 (4.32g, 23.5mmol) and 6-methyl-2-picolyll chloride hydrochloride (5.0g, 23.4mmol) in N,N-dimethylformamide (50ml) was stirred at room temperature for 20 hours. The reaction mixture was concentrated under reduced pressure and the residue partitioned between water (50ml) and dichloromethane (50ml). The layers were 20 separated and the aqueous phase extracted with dichloromethane (3x50ml), the combined organic solutions washed with brine (50ml), dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, twice, using dichloromethane: methanol (95:5) as eluant and repeated using an elution gradient of pentane: ethyl acetate (50:50 to 0:100) to give the N1 isomer (1.0g) and the title compound (2.47g, 36%) as a white solid.

25 δ (CDCl_3) : 1.18 (3H, t), 2.53 (3H, s), 3.06 (2H, q), 5.42 (2H, s), 5.97 (1H, s), 6.90 (1H, d), 7.12 (1H, d), 7.22 (1H, s), 7.58 (1H, m).

LRMS : m/z 312 ($\text{M}+23$)⁺


30

-181-

PREPARATION 1332-Methoxy-6-methylpyridine

5 Trimethyloxonium tetrafluoroborate (10.0g, 67.6mmol) was added portionwise to a suspension of 6-methylpyridin-2-one (7.3g, 67.0mmol) in dichloromethane (100ml), and once addition was complete, the reaction was stirred at room temperature for 24 hours. Dichloromethane (50ml) and aqueous sodium hydroxide solution (50ml, 2N) were added and the layers separated. The 10 aqueous phase was extracted with dichloromethane (2x50ml), the combined organic solutions washed with brine (50ml), dried ($MgSO_4$) and evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel, using an elution gradient of pentane: dichloromethane (66:34 to 0:100) to afford the title compound (2.25g, 27%) as 15 a colourless oil.

δ ($CDCl_3$) : 2.49 (3H, s), 3.90 (3H, s), 6.38-6.73 (2H, m), 7.23-7.40 (1H, br d).


PREPARATION 1346-Bromomethyl-2-methoxypyridine

20 A mixture of the title compound of Preparation 133 (2.5g, 20.3mmol), N-bromosuccinamide (3.7g, 20.8mmol) and benzoyl peroxide (100mg, 0.41mmol) in 1,1,1-trichloroethane (50ml) was stirred under reflux for 3 hours, and a further 16 hours at room temperature. The reaction was washed with water (2x25ml), aqueous sodium thiosulphate solution (25ml), brine (25ml) and dried ($MgSO_4$) and evaporated under reduced pressure. The residue was shaken well with hydrobromic acid (62%, 2.4ml), and the suspension concentrated under reduced pressure, and azeotroped twice with toluene, to give the title compound as a yellow solid. δ ($CDCl_3$) : 3.95 (3H, s), 4.46 (2H, s), 6.63 (1H, d), 25 6.98 (1H, d); 7.53 (1H, m). LRMS : m/z 202/204 (M+1)⁺

25 6.98 (1H, d); 7.53 (1H, m). LRMS : m/z 202/204 (M+1)⁺

30 6.98 (1H, d); 7.53 (1H, m). LRMS : m/z 202/204 (M+1)⁺

-182-

PREPARATION 1353-Ethyl-2-(6-methoxypyridin-2-yl)methyl-4-nitro-pyrazole-5-carboxamide

5

A mixture of the title compound of Preparation 134 (5.2g, 18.4mmol), caesium carbonate (6.58g, 32.5mmol) and the title compound of Preparation 35 (3.4g, 18.4mmol) in N,N-dimethylformamide (30ml) was stirred at room temperature for 18 hours. The reaction was concentrated under reduced pressure, the residue partitioned between ether (100ml) and water (50ml), and the phases separated. The organic layer was washed with brine (20ml), dried (MgSO_4) and evaporated under reduced pressure. The residual gum was triturated with ether, to give the title compound (640mg, 11%) as a white solid.


10 The filtrate was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using pentane: ethyl acetate (66:34) as eluant to give a further (280mg, 5%) of the title compound.

15

δ (DMSO- d_6) : 1.18 (3H, t), 2.84 (2H, q), 3.68 (3H, s), 5.34 (2H, s), 6.73 (2H, m), 7.66 (1H, m), 8.17 (1H, s), 8.39 (1H, s).

LRMS : m/z 306 ($M+1$)⁺

20

PREPARATION 1364-Amino-2-methyl-3-n-propylpyrazole-5-carboxamide

25 A mixture of the title compound of Preparation 128 (6.17g, 29.0mmol) and tin (II) chloride dihydrate (32.8g, 145mmol) in industrial methylated spirits (IMS) (100ml) was heated under reflux for 2 hours. The cooled mixture was

-183-

concentrated under reduced pressure to approximately half it's volume, basified to pH 9 using aqueous 2N sodium hydroxide solution, and extracted with dichloromethane (3x300ml). The combined organic extracts were dried 5 ($MgSO_4$) and evaporated under reduced pressure and the crude product recrystallised from ethyl acetate/methanol to afford the title compound (4.86g, 92%).


m.p.170-174°C

10 δ (DMSO- d_6) : 0.90 (3H, t), 1.47 (2H, m), 2.50 (2H, t), 3.68 (3H, s), 4.43 (2H, s), 6.92 (1H, s), 7.04 (1H, s).

PREPARATION 137

4-Amino-2,3-diethyl-pyrazole-5-carboxamide

15




A mixture of the title compound of Preparation 129 (5.7g, 26.9mmol) and tin (II) chloride dihydrate (29.0g, 128mmol) in ethanol (200ml) was heated under reflux 20 for 45 minutes. The cooled reaction mixture was evaporated under reduced pressure and re-dissolved in ethyl acetate (200ml). This solution was poured into a 10% aqueous solution of sodium carbonate (400ml), and the mixture stirred vigorously for an hour. The layers were separated and the aqueous phase was extracted with ethyl acetate (2x100ml). The combined organic 25 solutions were dried (Na_2SO_4) and concentrated under reduced pressure to a volume of 50 ml, and the resulting crystals filtered off and dried, to afford the title compound (3.3g, 67%).

30 δ (CDCl₃) : 1.19 (3H, t), 1.40 (3H, t), 2.59 (2H, q), 3.94 (2H, s), 4.02 (2H, q), 5.20 (1H, s), 6.57 (1H, s).

LRMS : m/z 183 (M+1)⁺

-184-

PREPARATION 1384-Amino-3-ethyl-2-methylpyrazole-5-carboxamide

5

A mixture of the title compound of Preparation 124 (5.8g, 29.3mmol) and 10% palladium on charcoal (650mg) in ethanol (100ml) was hydrogenated at 60psi and room temperature for 20 hours. The reaction was filtered through Arbocel® and the filter pad washed well with hot ethanol (200ml). The combined filtrate 10 was evaporated under reduced pressure to afford the title compound as a solid (4.7g, 95%).


δ (CDCl₃) : 1.20 (3H, t), 2.59 (2H, q), 3.77 (3H, s), 3.95 (2H, s), 5.21 (1H, s), 6.54 (1H, s).

15

PREPARATIONS 139 TO 142

The compounds of the following tabulated Preparations of general formula:

20



were prepared from the corresponding nitropyrazoles, using a similar procedure 25 to that described in Preparation 138.


Preparation	R	LRMS: m/z	¹ H nmr
139			δ (CDCl ₃) : 0.98 (3H, t), 1.93 (3H, d), 2.50 (2H, q), 3.98 (2H, s), 5.23 (1H, s), 5.50 (1H, q), 6.68 (1H, s), 6.80 (1H, d), 7.17 (1H, m), 7.59 (1H, m), 8.54 (1H, d).
140		282 (M+23) ⁺	δ (CDCl ₃) : 1.04 (3H, t), 2.55 (5H, m), 4.00 (2H, s), 5.19 (1H, s), 5.30 (2H, s), 6.52 (1H, d), 6.60 (1H, s), 7.03 (1H, d), 7.48 (1H, m).
141 ¹		298 (M+23) ⁺	δ (CDCl ₃) : 1.22 (3H, t), 2.57 (2H, q), 3.78 (2H, s), 3.84 (3H, s), 5.45 (2H, s), 6.68 (1H, d), 6.90 (1H, d), 7.58 (1H, m).
142		247 (M+1) ⁺	δ (CDCl ₃) : 1.05 (3H, t), 2.58 (2H, q), 4.01 (2H, s), 5.28 (1H, br s), 5.59 (2H, s), 6.60 (1H, br s), 7.11 (1H, d), 7.42 (1H, m), 9.15 (1H, d).

1 = purified by column chromatography using ethyl acetate as eluant

5

PREPARATION 143

4-Amino-3-ethyl-1-methyl-pyrazole-5-carboxamide



10

A mixture of the title compound of Preparation 123 (940mg, 4.75mmol), and 10% palladium on charcoal (200mg) in ethanol (100ml) was hydrogenated at 50°C and 50psi for 18 hours. The cooled mixture was filtered through Arbocel®, and the filtrate evaporated under reduced pressure to afford the title compound 15 (786mg, 98%) as a clear oil.


δ (CDCl₃) : 1.23 (3H, t), 2.59 (2H, q), 2.82 (2H, s), 4.12 (3H, s).

LRMS : m/z 169 (M+1)⁺

-186-

PREPARATION 1443-Bromo-2-chloro-5-(4-methylpiperazin-1-ylsulphonyl)pyridine

5




N-Methylpiperazine (7.65ml, 69.0mmol) was added dropwise to a solution of the title compound of Preparation 12 (10.0g, 34.5mmol) in ethanol (200ml), and 10 the reaction stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and the residue partitioned between dichloromethane (200ml) and water (100ml) and the layers separated. The organic phase was dried (Na_2SO_4), and evaporated under reduced pressure to afford the title compound (10.53g, 87%) as a yellow solid.

15 δ (CDCl_3) : 2.28 (3H, s), 2.51 (4H, m); 3.14 (4H, m), 8.24 (1H, s), 8.67 (1H, s).

PREPARATION 1453-Bromo-2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridine

20



-187-


A mixture of the title compound of Preparation 144 (10.0g, 39.1mmol), potassium bis(trimethylsilyl)amide (5.92g, 29.7mmol) and ethanol (3.5ml) in tetrahydrofuran (150ml) was stirred at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate (150ml) and brine (50ml). The layers were separated, and the organic phase dried (Na_2SO_4), filtered and evaporated under reduced pressure, to afford the title compound, (9.1g, 88%).

δ (CDCl_3) : 1.44 (3H, t), 2.29 (3H, s), 2.51 (4H, m), 3.08 (4H, m), 4.54 (2H, q),
10 8.10 (1H, s), 8.44 (1H, s).
LRMS : m/z 365 ($\text{M}+1$)⁺

PREPARATION 146

3-Bromo-5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridine


15



A mixture of the title compound of Preparation 13 (1.11g, 3.0mmol) and n-propylamine (590mg, 10.0mmol) in toluene (20ml) was stirred under reflux for 90 minutes. The cooled mixture was partitioned between ethyl acetate (50ml) and water (20ml), and the layers separated. The organic phase was washed with brine (20ml), dried (Na_2SO_4) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4) to afford the title compound (1.15g, 98%) as a yellow crystalline solid.

20 δ (CDCl_3) : 1.02 (6H, m), 1.68 (2H, m), 2.41 (2H, q), 2.54 (4H, m), 3.06 (4H, m),
3.47 (2H, q), 5.57 (1H, m), 7.86 (1H, s), 8.40 (1H, s).
LRMS : m/z 393 ($\text{M}+2$)⁺

-188-


PREPARATION 1472-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid ethyl ester

5

Obtained (85%) as an orange solid, from the title compound of Preparation 145 using a similar procedure to that described in Preparation 21.

δ (CDCl₃) : 1.40 (3H, t), 1.46 (3H, t), 2.28 (3H, s), 2.50 (4H, m), 3.09 (4H, m), 4.40 (2H, q), 4.57 (2H, q), 8.40 (1H, s), 8.63 (1H, s). LRMS : m/z 358 (M+1)⁺

10

PREPARATION 1485-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridine-3-carboxylic acid ethyl ester

15 A mixture of the title compound of Preparation 146 (1.10g, 2.81mmol), triethylamine (5ml), and tetrakis(triphenylphosphine)palladium (0) (250mg, 0.216mmol) in ethanol (25ml) was stirred under an atmosphere of carbon monoxide at 100°C and 100psi for 16 hours. The cooled solution was evaporated under reduced pressure and the residue purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4) to afford the title compound (1.07g, 99%) as a yellow oil.

20

-189-

δ (CDCl₃) : 1.02 (6H, t), 1.40 (3H, t), 1.69 (2H, m), 2.40 (2H, q), 2.55 (4H, m), 3.05 (4H, m), 3.54 (2H, q), 4.37 (2H, q), 8.37 (1H, s), 8.57 (2H, m).


LRMS : m/z 385 (M+1)⁺

5

PREPARATION 149

2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic acid hydrochloride

10




Sodium hydroxide solution (21ml, 2M, 42.0mmol) was added to a solution of the title compound of Preparation 147 (7.57g, 21.0mmol) in dioxan (150ml) and 15 the reaction stirred at room temperature for 18 hours. The mixture was neutralised using hydrochloric acid, the dioxan removed under reduced pressure and the remaining aqueous solution acidified to pH 2, using hydrochloric acid. The solution was evaporated under reduced pressure, the residue re-suspended in hot ethanol, filtered, and the filtrate re-evaporated to 20 afford the title compound (5.46g, 71%).

δ (DMSO-d₆) : 1.37 (3H, t), 2.50 (4H, m), 2.72 (3H, s), 3.13-3.39 (4H, m), 4.53 (2H, q), 8.30 (1H, s), 8.75 (1H, s).

LRMS : m/z 330 (M+1)⁺

25


-190-

PREPARATION 1505-(4-Ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridine-3-carboxylic acid sodium salt

A mixture of the title compound of Preparation 148 (1.06g, 2.76mmol) in sodium hydroxide solution (1.5ml, 2N, 3.0mmol) and ethanol (10ml) was stirred at room temperature for 4 hours. The reaction was evaporated under reduced pressure, 10 the solid triturated with ether, and the suspension filtered and dried to afford the title compound (950mg).

δ (DMSO- d_6) : 0.87 (6H, t), 1.50 (2H, m), 2.43 (2H, q), 2.56 (4H, m), 2.78 (4H, m), 3.34 (2H, t), 8.08 (1H, s), 8.16 (1H, s).

15

PREPARATION 1514-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2-methyl-3-n-propylpyrazole-5-carboxamide

20

The title compound of Preparation 136 (525mg, 2.88mmol) was added to a mixture of the title compound of Preparation 149 (1.04g, 3.2mmol), 1-

-191-

hydroxybenzotriazole hydrate (470mg, 3.5mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (670mg, 3.5mmol) and N-ethylidiisopropylamine (2.4ml, 14.0mmol) in tetrahydrofuran (50ml), and the reaction stirred at room temperature for 36 hours. The reaction mixture was concentrated under reduced pressure and the residue suspended in sodium carbonate solution (20ml) and extracted with dichloromethane (3x20ml). The combined organic extracts were washed with brine (3x20ml), dried (Na_2SO_4) and evaporated under reduced pressure. The crude product was triturated with ether to give a yellow solid which was then purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 96:4) to give the title compound (720mg, 51%) as a white solid.


A sample (50mg) of this product was recrystallised from ethyl acetate to give colourless crystals (32mg) of the title compound.

m.p. 242-244°C
 δ (CDCl_3) : 0.95 (3H, t), 1.59 (5H, m), 2.27 (3H, s), 2.48 (4H, m), 2.89 (2H, t), 3.10 (4H, m), 3.86 (3H, s), 4.79 (2H, q), 5.27 (1H, s), 6.63 (1H, s), 8.65 (1H, s), 8.84 (1H, s), 10.53 (1H, s).

LRMS : m/z 494 ($\text{M}+1$)⁺

PREPARATION 152

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-ethyl-2-methylpyrazole-5-carboxamide



-192-

Obtained as a solid (65%) from the title compounds of Preparations 23 and 138, following the procedure described in Preparation 151.


5 δ (CDCl₃) : 1.02 (3H, t), 1.21 (3H, t), 1.58 (3H, t), 2.39 (2H, q), 2.54 (4H, m), 2.90 (2H, q), 3.10 (4H, m), 3.84 (3H, s), 4.78 (2H, q), 5.30 (1H, s), 6.63 (1H, s), 8.64 (1H, s), 8.83 (1H, s), 10.54 (1H, s).

LRMS : m/z 494 (M+1)⁺

10

PREPARATION 153

4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2-methyl-3-n-propylpyrazole-5-carboxamide



15

Obtained as a solid (64%) from the title compounds of Preparations 23 and 136, following a similar procedure to that described in Preparation 151, except an elution gradient of methanol: ethyl acetate (7:93 to 10:90) was used as the chromatographic eluant.

20 δ (CDCl₃) : 0.94 (3H, t), 1.02 (3H, t), 1.60 (5H, m), 2.40 (2H, q), 2.54 (4H, m), 2.89 (2H, t), 3.10 (4H, m), 3.84 (3H, s), 4.78 (2H, q), 5.25 (1H, s), 6.63 (1H, s), 8.65 (1H, s), 8.83 (1H, s), 10.52 (1H, s).


LRMS : m/z 508 (M+1)⁺

25

-193-

PREPARATION 1544-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-2,3-diethylpyrazole-5-carboxamide

5



The title compound of Preparation 137 (3.3g, 16.8mmol) and triethylamine (7.5ml, 54.0mmol) were added to an ice-cooled solution of the title compound of Preparation 28 (6.51g, 18.0mmol) in dichloromethane (100ml), and the reaction was stirred at room temperature for 18 hours. The mixture was washed consecutively with brine (50ml), aqueous sodium bicarbonate solution (2x50ml), then dried (Na_2SO_4) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 90:10) to afford the title compound as a solid.

δ (CDCl_3) : 1.04 (3H, t), 1.22 (3H, t), 1.50 (3H, t), 1.59 (3H, t), 2.40 (2H, q), 2.54 (4H, m), 2.91 (2H, q), 3.10 (4H, m), 4.16 (2H, q), 4.78 (2H, q), 5.30 (1H, s), 6.68 (1H, s), 8.65 (1H, s), 8.84 (1H, s), 10.55 (1H, s).


LRMS : m/z 508 ($\text{M}+1$)⁺

20

PREPARATIONS 155 TO 157

The compounds of the following tabulated Preparations of the general formula:

-194-



were prepared, from the title compound of Preparation 28 and the appropriate amines, following similar procedures to that described in Preparation 154.


5

Prep.	R1	Data
155 ¹		δ (CDCl ₃) : 1.02 (6H, m), 1.59 (3H, t), 1.98 (3H, d), 2.40 (2H, q), 2.54 (4H, m), 2.86 (2H, q), 3.09 (4H, m), 4.79 (2H, q), 5.32 (1H, s), 5.67 (1H, q), 6.77 (1H, s), 6.94 (1H, d), 7.20 (1H, m), 7.63 (1H, m), 8.58 (1H, d), 8.65 (1H, s), 8.82 (1H, s), 10.55 (1H, s). LRMS : m/z 585 (M+1) ⁺
156 ²		δ (CDCl ₃) : 1.04 (6H, m), 1.59 (3H, t), 2.40 (2H, q), 2.52 (4H, m), 2.59 (3H, s), 2.89 (2H, q), 3.09 (4H, m), 4.80 (2H, q), 5.30 (1H, s), 5.42 (2H, s), 6.62 (1H, d), 6.70 (1H, s), 7.08 (1H, d), 7.54 (1H, m), 8.64 (1H, s), 8.82 (1H, s), 10.61 (1H, s).
157 ²		δ (CDCl ₃) : 1.04 (3H, t), 1.23 (3H, t), 1.59 (3H, t), 2.41 (2H, q), 2.54 (4H, m), 2.70 (2H, q), 3.10 (4H, m), 3.86 (3H, s), 4.78 (2H, q), 5.52 (2H, s), 5.66 (1H, s), 6.70 (1H, d), 6.93 (1H, d), 7.59 (1H, m), 8.68 (1H, s), 8.83 (1H, s), 9.02 (1H, s), 9.90 (1H, s). LRMS : m/z 601 (M+1) ⁺

1 = the title compound was isolated by trituration with ether.

2 = ethyl acetate: methanol (94:6) was used as the chromatographic eluant.

-195-


PREPARATION 1584-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-ethyl-1-methylpyrazole-5-carboxamide

5

Obtained (51%) as a white solid from the title compounds of Preparations 23 and 143, using a similar procedure to that described in Preparation 151.

δ (CDCl₃) : 1.03 (3H, t), 1.25 (3H, t), 1.57 (3H, t), 2.42 (2H, q), 2.58 (6H, m), 3.10 (4H, m), 4.06 (3H, s), 4.76 (2H, q), 5.57 (1H, br s), 7.55 (1H, br s), 8.70 (1H, s), 8.83 (1H, s); 9.24 (1H, s).

LRMS : m/z 494 (M+1)⁺

PREPARATION 15915 4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-1-methyl-3-n-propylpyrazole-5-carboxamide

A mixture of the title compounds of Preparation 24 (2.0g, 5.48mmol), the hydrochloride salt of 4-amino-1-methyl-3-n-propylpyrazole-5-carboxamide, EP-A-0463756; (1.08g, 4.94mmol), 1-hydroxybenzotriazole hydrate (920mg, 6.87mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.15g, 6.0mmol) and N-ethyldiisopropylamine (2.86ml, 16.5mmol) in tetrahydrofuran (20ml) was stirred at room temperature for 18 hours. The

-196-

reaction mixture was concentrated under reduced pressure and the residue partitioned between ethyl acetate (100ml) and water (50ml). The layers were separated and the organic phase was dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using dichloromethane: methanol (95:5) as eluant to afford the title compound (940mg, 38%), as a white solid.


δ (CDCl_3) : 0.95 (3H, t), 1.02 (3H, t), 1.52 (3H, t), 1.63 (2H, m), 2.40 (2H, q), 2.54 (6H, m), 3.09 (4H, m), 4.05 (3H, s), 4.75 (2H, q), 5.81 (1H, s), 7.58 (1H, s), 8.67 (1H, s), 8.80 (1H, s), 9.25 (1H, s).

LRMS : m/z 509 ($\text{M}+2$)⁺

PREPARATION 160

3-Ethyl-4-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propylaminopyridin-3-

ylcarboxamido]-2-(pyridin-2-yl)methylpyrazole-5-carboxamide



1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (250mg, 1.3mmol) was added to a solution of the title compounds of Preparations 40 (245mg, 1.0mmol) and 150 (456mg, 1.2mmol), N-ethyldiisopropylamine (194mg, 1.5mmol) and 1-hydroxybenzotriazole hydrate (203mg, 1.5mmol) in dichloromethane (10ml), and the reaction stirred at room temperature for 16 hours. The reaction was poured into ethyl acetate (30ml), washed with water (10ml) and brine (10ml), dried (MgSO_4) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using an elution gradient of dichloromethane: methanol (100:0 to 94:6), and triturated with ether, to afford the title compound (242mg, 41%) as a white solid.


-197-

5 δ (CDCl₃) : 0.95 (3H, t), 1.01 (6H, m), 1.62 (2H, m), 2.39 (2H, q), 2.52 (4H, m),
 2.86 (2H, q), 3.09 (4H, m), 3.46 (2H, q), 5.39 (1H, s), 5.43 (2H, s), 6.64 (1H, s),
 6.87 (1H, d), 7.20 (1H, m), 7.63 (1H, m), 8.17 (1H, s), 8.53 (1H, s), 8.58 (1H, d),
 8.64 (1H, m), 9.58 (1H, s).

LRMS : m/z 584 (M+1)⁺

PREPARATION 161

10 4-(2-Ethoxy-5-nitropyridin-3-ylcarboxamido)-3-ethyl-2-methylpyrazole-5-
carboxamide



15 Oxalyl chloride (2.6ml, 30.2mmol) was added dropwise to an ice-cooled solution of the title compound of Preparation 8 (1.6g, 7.55mmol) and N,N-dimethylformamide (1 drop) in dichloromethane (40ml), and the reaction stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and azeotroped with dichloromethane several times.

20 This intermediate acid chloride was added to an ice-cooled solution of the title compound of Preparation 138 (960mg, 5.74mmol) and triethylamine (2.6ml, 18.7mmol) in dichloromethane (40ml), and the reaction stirred at room temperature for 2 hours. The mixture was washed with water (20ml), brine (20ml), dried (Na₂SO₄) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient 25 of dichloromethane: methanol (100:0 to 90:10) to afford the title compound (2.06g, 99%).


25 δ (CDCl₃) : 1.24 (3H, t), 1.61 (3H, t), 2.92 (2H, q), 3.88 (3H, s), 4.84 (2H, q),
 5.27 (1H, s), 6.66 (1H, s), 9.17 (1H, s), 9.33 (1H, s), 10.57 (1H, s).

LRMS : m/z 363 (M+1)⁺

-198-

PREPARATION 1624-(5-Amino-2-ethoxypyridin-3-ylcarboxamido)-3-ethyl-2-methylpyrazole-5-carboxamide

5




A mixture of the title compound of Preparation 161 (2.06g, 5.7mmol) and 10% palladium on charcoal (200mg) in ethanol (70ml) was hydrogenated at room temperature and 50psi, for 6 hours. The reaction mixture was filtered through

10 Arbocel®, the filter pad washed with further ethanol, and the combined filtrates evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5) to afford the title compound (760mg, 40%) as a solid.

15 δ (CDCl₃) : 1.23 (3H, t), 1.54 (3H, t), 2.87 (2H, q), 3.50 (2H, s), 3.87 (3H, s), 4.60 (2H, q), 5.24 (1H, s), 6.62 (1H, s), 7.78 (1H, s), 7.96 (1H, s), 10.54 (1H, s).

LRMS : m/z 333 (M+1)⁺

PREPARATION 1635-(5-Amino-2-ethoxypyridin-3-yl)-3-ethyl-2-methylpyrazole-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

A mixture of the title compound of Preparation 162 (760mg, 2.29mmol) and potassium bis(trimethylsilyl)amide (685mg, 3.43mmol) in ethanol (50ml) was

25 heated at 100°C in a sealed vessel for 20 hours. The cooled mixture was

-199-


evaporated under reduced pressure. The residue was purified by column chromatography on silica gel, using an elution gradient of dichloromethane: methanol (100:0 to 95:5) to afford the title compound (550mg, 76%) as a solid.

5 δ (CDCl₃) : 1.41 (3H, t), 1.53 (3H, t), 3.03 (2H, q), 3.58 (2H, s), 4.09 (3H, s), 4.58 (2H, q), 4.78 (1H, s), 8.20 (1H, s), 11.17 (1H, s).

LRMS : m/z 315 (M+1)

PREPARATION 164

10 5-(5-Chlorosulphonyl-2-ethoxypyridin-3-yl)-3-ethyl-2-methylpyrazole-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one




15 Obtained (72%) from the title compound of Preparation 163 following a similar procedure to that described in Preparation 63.

18 δ (CDCl₃) : 1.42 (3H, t), 1.60 (3H, t), 3.07 (2H, q), 4.14 (3H, s), 4.82 (2H, q), 8.92 (1H, s), 9.36 (1H, s), 10.58 (1H, s).

PREPARATION 165

20 (R)-1-Methoxy-2-propanol



25 Sodium methoxide (54g, 1.0mol) was added portionwise to ice-cooled methanol (1000ml), and the resulting solution stirred for 20 minutes in an ice-bath. (R)-Propylene oxide (58g, 1mol) was added dropwise over 30 minutes, and once addition was complete, the reaction was stirred at room temperature for 18

-200-

hours. The mixture was concentrated under reduced pressure, and acidified, with ice-cooling, using (1M) ethereal hydrochloric acid, and the resulting mixture stirred for an hour, then filtered. The filtrate was dried (K_2CO_3), filtered and 5 evaporated under reduced pressure. The residue was heated to 70°C over dried calcium oxide for 30 minutes, then distilled at atmospheric pressure to afford the title compound (25.4g, 28%) as an oil.

b.p. 118-120°C


10 δ ($CDCl_3$) : 1.16 (3H, d), 2.28 (1H, d), 3.20 (1H, m), 3.36 (1H, m), 3.40 (3H, s), 3.97 (1H, m).

$[\alpha]_D$ -20.83° (c=1.02, dichloromethane)

PREPARATION 166

4-Methoxy-2-butanol

15




Lithium aluminium hydride (220ml, 1.0M solution in tetrahydrofuran, 220mmol) was added dropwise over 15 minutes, to an ice-cooled solution of 4-methoxybut-3-en-2-one (20.0g, 200mmol) in tetrahydrofuran (200ml), and the 20 reaction stirred at room temperature for 16 hours. The solution was re-cooled in an ice-bath, water (8ml) was added dropwise, followed by 15% aqueous sodium hydroxide solution (8ml), and after a further 10 minutes, additional water (24ml). The mixture was stirred for 20 minutes, filtered, and the filtrate concentrated under reduced pressure to a volume of 100ml. 10% Palladium on 25 charcoal (500mg) was added and the mixture hydrogenated at 60 psi for 16 hours. The reaction was filtered through Arbocel®, and the filtrate evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using an elution gradient of dichloromethane: ether (99:1 to 50:50) to afford the title compound (4.0g, 19%).

30 δ ($CDCl_3$) : 1.20 (3H, d), 1.67-1.78 (2H, m), 2.80 (1H, s), 3.38 (3H, s), 3.55-3.65 (2H, m), 4.00 (1H, m).

PREPARATION 167N-Methylcyclopropylcarboxamide

5




Cyclopropane carboxylic acid (15.83ml, 200mmol) was added dropwise to a warm (40°C) solution of thionyl chloride (16.71ml, 213mmol) in toluene (80ml), 10 and once addition was complete, the reaction was stirred at 80°C for 2 hours. The mixture was cooled in an ice-bath, a solution of methylamine in tetrahydrofuran (300ml, 2M, 600mmol) was added, the mixture allowed to warm to room temperature and concentrated under reduced pressure. The residue was suspended in dichloromethane (200ml), washed with saturated aqueous 15 sodium bicarbonate solution (200ml), brine (200ml), dried (MgSO_4) and evaporated under reduced pressure. The residual white solid was recrystallised from hexane/ether, to afford the title compound (11.3g, 57%) as a white crystalline solid.

Found : C, 58.73; H, 9.30; N, 13.70. $\text{C}_5\text{H}_9\text{NO} \cdot 0.2\text{H}_2\text{O}$ requires C, 58.46; H, 20 9.22; N, 13.63%
 δ (CDCl_3) : 0.70 (2H, m), 0.95 (2H, m), 1.32 (1H, m), 2.81 (3H, d), 5.73 (1H, s).
 LRMS : m/z 199 ($\text{M}+1$)⁺

PREPARATION 168N-Cyclopropylmethyl-N-methylamine hydrochloride

25



A solution of the title compound of Preparation 167 (7.90g, 79.7mmol) in ether 30 (75ml) was added dropwise over 5 minutes to a suspension of lithium


-202-

aluminium hydride (3.03g, 96.0mmol) in ether (100ml), and the reaction stirred under reflux for 4 hours. The cooled mixture was quenched by the consecutive addition of water (3ml), 10% aqueous sodium hydroxide solution (9ml) and water (3ml). The resulting suspension was stirred for 5 minutes, filtered and the solids washed well with ether (100ml). The combined filtrate was dried (MgSO_4), cooled in an ice-bath, and saturated with hydrochloric acid. This solution was evaporated under reduced pressure to afford the title compound (8.7g, 90%) as a gum.

10 δ (CDCl_3) : 0.45 (2H, m), 0.72 (2H, m), 1.24 (1H, m), 2.70 (3H, t), 2.88 (3H, t), 2.88 (2H, m), 9.48 (2H, br s).

Preparation 169

15 4-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-ylcarboxamido]-3-ethyl-2-(1-methylimidazol-2-yl)methylpyrazole-5-carboxamide



1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.2g, 6.25 mmol) was added to a solution of the preparations of 23 (1.6g, 4.66mmol) and 89 (1.2g, 4.84mmol), hydroxybenzotriazole hydrate (960mg, 6.2mmol) and N-ethyldiisopropylamine (2.5ml, 14.5mmol) in tetrahydrofuran (15ml), and N,N-dimethylformamide (3ml), and the reaction stirred at room temperature for 18 hours. The mixture was diluted with water (100ml), and extracted with dichloromethane (3x150ml). The combined organic extracts were dried (Na₂SO₄) and evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using dichloromethane:methanol (95:5) as eluant to afford the title compound (1.42g, 2.55mmol).

-203-


δ (CDCl₃) : 0.98-1.16 (6H, m), 1.52-1.70 (6H, m), 2.40 (2H, q), 2.55 (4H, m), 2.99-3.16 (6H, m), 3.72 (3H, s), 4.78 (2H, q), 5.30 (1H, br s), 5.44 (2H, s), 6.60 (1H, br s), 6.86 (1H, s), 7.00 (1H, s), 8.65 (1H, s), 8.82 (1H, s), 10.48 (1H, s).

5 LRMS : m/z 574 (M+18)⁺

Preparation 170

5-[2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(1-methylimidazol-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

10



Obtained as a cream foam (62%) from the title compound of Preparation 169 following a similar procedure to that described in Example 78.

δ (CDCl₃) : 1.00 (3H, t), 1.30 (3H, t), 1.57 (3H, t), 2.40 (2H, q), 2.54 (4H, m), 3.06-3.20 (6H, m), 3.78 (3H, s), 4.75 (2H, q), 5.64 (2H, s), 6.84 (1H, s), 6.99 (1H, s), 8.61 (1H, s), 8.99 (1H, s), 10.66 (1H, s).

15 LRMS : m/z 556 (M+1)⁺

-204-

Biological Activity

The following Table illustrates the in vitro activities for a range of the
5 compounds of the invention as inhibitors of cGMP PDE5.

TABLE

EXAMPLE	IC ₅₀ (nm)
10	10.1
11	10.0
18	8.9
43b	3.6
46	8.1
48	6.9
98	7.0
99	5.7
127	7.3
153	7.2


Safety Profile

10


Several compounds of the invention have been tested at doses of up to 3mg/kg i.v. in mouse and at 0.5mg/kg p.o. in dog, with no untoward effects being observed.

CLAIMS

1. A compound of the formula (IA) or (IB):



(IA)



(IB)

5 or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, wherein R¹ is C₁ to C₃ alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substituents selected from C₁ to C₄ alkoxy; halo; CN; CF₃; OCF₃ or C₁ to C₄ alkyl wherein said C₁ to C₄ alkyl group is optionally substituted by C₁ to C₄ haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms;

10 R² is C₁ to C₆ alkyl;

15 R¹³ is OR³ or NR⁵R⁶;

20 R³ is C₁ to C₆ alkyl optionally substituted with one or two substituents selected from C₃ to C₅ cycloalkyl, OH, C₁ to C₄ alkoxy, benzyloxy, NR⁵R⁶, phenyl, furanyl and pyridinyl; C₃ to C₆ cycloalkyl; 1-(C₁ to C₄ alkyl) piperidinyl; tetrahydrofuranyl or tetrahydropyranyl; and wherein said C₁ to C₆ alkyl or said C₁ to C₄ alkoxy groups are optionally terminated by haloalkyl;

25 R⁴ is SO₂NR⁷R⁸;

R⁵ and R⁶ are each independently selected from H and C₁ to C₄ alkyl optionally substituted with C₃ to C₅ cycloalkyl or C₁ to C₄ alkoxy, or, together with the nitrogen atom to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl group;

R⁷ and R⁸, together with the nitrogen atom to which they are attached,

form a 4-R¹⁰-piperazinyl group optionally substituted with one or two C₁ to C₄ alkyl groups and optionally in the form of its 4-N-oxide; R¹⁰ is H; C₁ to C₄ alkyl optionally substituted with one or two substituents selected from OH, NR⁵R⁶, CONR⁵R⁶, phenyl optionally substituted with C₁ to C₄ alkoxy, benzodioxolyl and benzodioxanyl; C₃ to C₆ alkenyl; pyridinyl or pyrimidinyl; and

Het is a C-linked 6-membered heterocyclic group containing one or two nitrogen atoms, optionally in the form of its mono-N-oxide, or a C-linked 5-membered heterocyclic group containing two or three nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkoxy or NHR¹⁵ wherein R¹⁵ is H, C₁ to C₄ alkyl or C₁ to C₄ alkanoyl and halo is Br, Cl, F or I.

15 2. A compound according to claim 1 wherein R¹ is C₁ to C₂ alkyl optionally substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R² is C₂ to C₄ alkyl; R¹³ is OR³ or NR⁵R⁶; R³ is C₁ to C₄ alkyl optionally substituted with one or two substituents selected from cyclopropyl, cyclobutyl, OH, methoxy, ethoxy, benzyloxy, NR⁵R⁶, phenyl, furan-3-yl, pyridin-2-yl and pyridin-3-yl; cyclobutyl; 1-methylpiperidin-4-yl; tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R⁵ and R⁶ are each independently selected from H and C₁ to C₂ alkyl optionally substituted with cyclopropyl or methoxy, or, together with the nitrogen atom to which they are attached, form a azetidinyl, pyrrolidinyl or morpholinyl group; R⁷ and R⁸, together with the nitrogen atom to which they are attached, form a 4-R¹⁰-piperazinyl group optionally substituted with one or two methyl groups and optionally in the form of its 4-N-oxide; R¹⁰ is H, C₁ to C₃ alkyl optionally substituted with one or two substituents selected from OH, NR⁵R⁶, CONR⁵R⁶, phenyl optionally substituted with methoxy, benzodioxol-5-yl and benzodioxan-2-yl; allyl; pyridin-2-yl; pyridin-4-yl or pyrimidin-2-yl; and Het is selected from pyridin-2-yl; 1-oxidopyridin-2-yl; 6-methylpyridin-2-yl; 6-methoxypyridin-2-yl; pyridazin-3-yl; pyrimidin-2-yl and 1-methylimidazol-2-yl.

-207-

3. A compound according to claim 2 wherein R¹ is C₁ to C₂ alkyl optionally substituted with Het; 2-(morpholin-4-yl)ethyl or benzyl; R² is C₂ to C₄ alkyl; R¹³ is OR³; R³ is C₁ to C₄ alkyl optionally monosubstituted with cyclopropyl, cyclobutyl, OH, methoxy, ethoxy, phenyl, furan-3-yl or pyridin-2-yl; cyclobutyl; tetrahydrofuran-3-yl or tetrahydropyran-4-yl; R⁷ and R⁸, together with the nitrogen atom to which they are attached, form a 4-R¹⁰-piperazinyl group optionally in the form of its 4-N-oxide; R¹⁰ is C₁ to C₃ alkyl optionally monosubstituted with OH; and Het is selected from pyridin-2-yl; 1-oxidopyridin-2-yl; 6-methylpyridin-2-yl; 6-methoxypyridin-2-yl; pyridazin-3-yl; pyrimidin-2-yl and 1-methylimidazol-2-yl.

4. A compound according to any of claims 1 to 3 selected from:
3-ethyl-5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
3-ethyl-5-[5-(4-ethyl-4-oxidopiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
5-[2-(2-methoxyethoxy)-5-(4-methylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-3-n-propyl-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;
30 (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

-208-

3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-(6-methylpyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

5 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(6-methoxypyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one;

10 5-[2-i-butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-2,3-diethyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one; and

15 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[1-(pyridin-2-yl)ethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one.

5. A pharmaceutical composition comprising a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, together with a pharmaceutically acceptable diluent or carrier.

15

6. A veterinary formulation comprising a compound of formula (IA) or (IB), or a veterinarilly acceptable salt thereof, or a veterinarilly acceptable solvate of either entity, together with a veterinarilly acceptable diluent or carrier.

20

7. A compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing, for use as a human medicament.

25

8. A compound of formula (IA) or (IB), or a veterinarilly acceptable salt thereof, or a veterinarilly acceptable solvate of either entity, or a veterinary formulation containing any of the foregoing, for use as an animal medicament.

30

9. The use of a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, for the manufacture of a human medicament for the curative or prophylactic treatment of a medical condition for which a cGMP PDE5 inhibitor is indicated.
10. The use of a compound of formula (IA) or (IB), or a veterinarilly acceptable salt thereof, or a veterinarilly acceptable solvate of either entity, for the manufacture of an animal medicament for the curative or prophylactic treatment of a medical condition for which a cGMP PDE5 inhibitor is indicated.
15. 11. The use of a compound of formula (IA) or (IB), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate containing either entity, for the manufacture of a human medicament for the curative or prophylactic treatment of male erectile dysfunction (MED), female sexual dysfunction (FSD), premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility.
20. 25. 12. The use of a compound of formula (IA) or (IB), or a veterinarilly acceptable salt thereof, or a veterinarilly acceptable solvate containing either entity, for the manufacture of an animal medicament for the curative or prophylactic treatment of male erectile dysfunction (MED), female sexual dysfunction (FSD), premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction,

5 incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility;


10 13. A method of treating or preventing a medical condition for which a cGMP PDE5 inhibitor is indicated, in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (IA) or (IB), or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, or a pharmaceutical composition or veterinary formulation containing any of the foregoing.

15 20 14. A method of treating or preventing male erectile dysfunction (MED), female sexual dysfunction (FSD), premature labour, dysmenorrhoea, benign prostatic hyperplasia (BPH), bladder outlet obstruction, incontinence, stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, stroke, peripheral vascular disease, conditions of reduced blood vessel patency, chronic asthma, bronchitis, allergic asthma, allergic rhinitis, glaucoma or diseases characterised by disorders of gut motility in a mammal (including a human being), which comprises administering to said mammal a therapeutically effective amount of a compound of formula (IA) or (IB), or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity, or a pharmaceutical composition or veterinary formulation containing any of the foregoing.


25 30

-211-

15. A compound of formula (IIA) or (IIB):



(IIA)




(IIB)

5


wherein Y is halo, and R^1 , R^2 and R^{13} are as defined in claim 1.

16. A compound according to claim 16 wherein Y is chloro.

10 17. A compound of formula (IVA) or (IVB):



(IVA)





(IVB)

wherein R^1 , R^2 and R^{13} are as defined in claim 1.

-212-



18. A compound of formula (VA) or (VB):



5

wherein R¹, R² and R¹³ are as previously defined in claim 1.

19. A compound of the formula (IXA) or (IXB):




10

wherein R¹, R², R⁴ and R¹³ are as previously defined in claim 1.


15

20

20. A process for the preparation of a compound of formula (IA) or (IB):



(IA)



(IB)

5

wherein R¹ is C₁ to C₃ alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substituents selected from C₁ to C₄ alkoxy, halo; CN; CF₃; OCF₃ or C₁ to C₄ alkyl wherein said C₁ to C₄ alkyl group is optionally substituted by C₁ to C₄ haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms;

10 R² is C₁ to C₆ alkyl;
 R¹³ is OR³ or NR⁵R⁶;
 R³ is C₁ to C₆ alkyl optionally substituted with one or two substituents selected from C₃ to C₅ cycloalkyl, OH, C₁ to C₄ alkoxy, benzyloxy, NR⁵R⁶, phenyl, furanyl and pyridinyl; C₃ to C₆ cycloalkyl; 1-(C₁ to C₄ alkyl) piperidinyl; tetrahydrofuranyl or tetrahydropyranyl; and wherein said C₁ to C₆ alkyl or said C₁ to C₄ alkoxy groups are optionally terminated by haloalkyl;

15 R⁴ is SO₂NR⁷R⁸;
 R⁵ and R⁶ are each independently selected from H and C₁ to C₄ alkyl optionally substituted with C₃ to C₅ cycloalkyl or C₁ to C₄ alkoxy, or, together with the nitrogen atom to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl or morpholinyl group;
 20 R⁷ and R⁸, together with the nitrogen atom to which they are attached,


25

-214-


form a 4-R¹⁰-piperazinyl group optionally substituted with one or two C₁ to C₄ alkyl groups and optionally in the form of its 4-N-oxide; R¹⁰ is H; C₁ to C₄ alkyl optionally substituted with one or two substituents selected from OH, NR⁵R⁶, CONR⁵R⁶, phenyl optionally substituted with C₁ to C₄ alkoxy, benzodioxolyl and benzodioxanyl; C₃ to C₆ alkenyl; pyridinyl or pyrimidinyl; and

5 Het is a C-linked 6-membered heterocyclic group containing one or two nitrogen atoms, optionally in the form of its mono-N-oxide, or a C-linked 5-membered heterocyclic group containing two or three nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C₁ to C₄ alkyl, C₁ to C₄ alkoxy or NHR¹⁵ wherein R¹⁵ is H, C₁ to C₄ alkyl or C₁ to C₄ alkanoyl and halo is Br, Cl, F or I.

10 which process comprises reacting a compound of formula (IIA) or (IIB), respectively:




(IIA)



(IIB)

wherein Y is halo, and R¹, R² and R¹³ are as previously defined in this claim, with a compound of formula (III):

20



wherein R⁷ and R⁸ are as previously defined in this claim, optionally followed by formation of a pharmaceutically or veterinarily acceptable salt



25

of the required product or a pharmaceutically or veterinarly acceptable solvate of either entity.

5



21. A process for the preparation of a compound of formula (IA) or (IB) as defined in claim 20, or a pharmaceutically or veterinarly acceptable salt thereof, or a pharmaceutically or veterinarly acceptable solvate of either entity, which comprises cyclisation of a compound of formula (VA) or (VB) respectively:

10



wherein R¹, R² and R¹³ are as previously defined for formulae (IA) and (IB) in claim 20 to form a compound of formula (IVA) or (IVB):

15



20



which can be converted to a compound of formula (IIA) or (IIB), by reaction with a compound of formula (III) R⁷R⁸NH wherein R⁷ and R⁸ are as defined in claim 20, said compound of formula (IIA) or (IIB) may in turn be converted by the process according to claim 20 to

-216-

form a compound of formula (IA) or (IB) which is optionally followed by formation of a pharmaceutically or veterinarily acceptable salt of the required product or a pharmaceutically or veterinarily acceptable solvate of either entity.

5

22. A process for the preparation of a compound of formula (IA) or (IB) as defined in claim 20, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity which comprises cyclisation of a compound of formula 10 (IXA) or (IXB) respectively:



15

wherein R¹, R², R⁴ and R¹³ are as defined in claim 20.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/00519

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07D487/04 A61K31/505 C07D401/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation or document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 28902 A (PFIZER LTD ;PFIZER (US); PFIZER RES & DEV (IE); ELLIS PETER (GB);) 22 December 1994 see the whole document ---	1-22
Y	WO 96 16644 A (PFIZER LTD ;PFIZER RES & DEV (IE); PFIZER (US); CAMPBELL SIMON FRA) 6 June 1996 *see the whole document; in particular page 3, lines 1-6 and page 4, lines 10-11* ---	1-22
Y	EP 0 201 188 A (WARNER LAMBERT CO) 17 December 1986 see the whole document ---	1-22
Y	US 5 294 612 A (BACON EDWARD R ET AL) 15 March 1994 see the whole document ---	1-22
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 May 1999

Date of mailing of the international search report

07/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

Intern. Appl. Application No.

PCT/IB 99/00519

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 98 49166 A (BUNNAGE MARK EDWARD MATHIAS JOHN PAUL (GB); STREET STEPHEN DEREK) 5 November 1998 see the whole document	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. No

PCT/IB 99/00519

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9428902	A 22-12-1994	AT 163852	T	15-03-1998
		AU 676571	B	13-03-1997
		AU 6797394	A	03-01-1995
		CA 2163446	A, C	22-12-1994
		CN 1124926	A	19-06-1996
		CZ 9503242	A	17-07-1996
		DE 69408981	D	16-04-1998
		DE 69408981	T	02-07-1998
		DK 702555	T	06-04-1998
		EP 0702555	A	27-03-1996
		ES 2113656	T	01-05-1998
		FI 955911	A	08-12-1995
		GR 3026520	T	31-07-1998
		IL 109873	A	27-12-1998
		IL 121836	A	27-12-1998
		JP 9503996	T	22-04-1997
		NO 954757	A	24-11-1995
		NZ 266463	A	24-03-1997
		PL 311948	A	18-03-1996
		ZA 9404018	A	08-12-1995
WO 9616644	A 06-06-1996	EP 0793486	A	10-09-1997
		FI 972205	A	23-05-1997
		JP 9512834	T	22-12-1997
EP 0201188	A 17-12-1986	US 4666908	A	19-05-1987
		JP 61236778	A	22-10-1986
US 5294612	A 15-03-1994	US 5541187	A	30-07-1996
WO 9849166	A 05-11-1998	AU 7644598	A	24-11-1998
		HR 980222	A	28-02-1999

THIS PAGE BLANK (USPTO)